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Abstract 
Autism is one of the leading causes of human intellectual disability (ID).  
More than 1% of the human population has autism spectrum disorders (ASDs), and it 
has been estimated that over 50% of those with ASDs also have ID.  Fragile X 
syndrome (FXS) is the most common inherited form of mental retardation and is the 
leading known genetic cause of autism, affecting approximately 1 in 4000 males and 
1 in 8000 females.  Approximately 30% of boys with FXS will be diagnosed with 
autism in their later lives. 
The cause of FXS is through an over-expansion of the CGG trinucleotide 
repeat located at the 5’ untranslated region of the FMR1 gene, leading to 
hypermethylation of the surrounding sequence and eventually partially or fully 
silencing of the gene.  Therefore, the protein product of the gene, fragile X mental 
retardation protein (FMRP), is reduced or missing. 
As a single-gene disorder, FXS offers a scientifically tractable way to 
examine the underlying mechanism of the disease and also shed some light on 
understanding ASD and ID.  The mouse model of FXS (Fmr1−/y mice) is widely 
accepted and used as a good model, offering good structural and face validity.  Since 
a primary deficit of FXS is believed to be altered neuronal communication, in this 
thesis I examined white matter tract and dendritic spine abnormalities in the mouse 
model of FXS.  Loss of FMRP does not alter the gross morphology of the white 
matter.  However, recent brain imaging studies indicated that loss of FMRP could 
lead to some minute abnormalities in different major white matter tracts in the human 
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brain.  The gross white matter morphology and myelination was unaltered in the 
Fmr1−/y mice, however, a small but significant increase of axon diameter in the 
corpus callosum (CC) was found compared to wild-type (WT) controls.  Our 
computation model suggested that the increase of axon diameter in the Fmr1−/y mice 
could lead to an increase of conduction velocity in these animals. 
One of the key phenotypes reported previously in the loss of FMRP is the 
increase of “immature” dendritic spines.  The increase of long and thin spines was 
reported in several brain regions including the somatosensory cortex and visual 
cortex in both FXS patients and the mouse model of FXS.  Although recent studies 
which employed state-of-the-art microscopy techniques suggested that only minute 
differences were noticed between the WT and Fmr1−/y mice.  In agreement with 
previous findings, I found an increase of dendritic spine density in the visual cortex 
in the Fmr1−/y mice, and spine morphology was also different between the two 
genotypes.  We found that the spine head diameter is significantly increased in the 
CA1 area of the apical dendrites of the Fmr1−/y mice compared to WT controls.  
Dendritic spine length is also significantly increased in the same region of the 
Fmr1−/y mice.  However, apical spine head size does not alter between the two 
genotypes in the V1 region of the visual cortex, and spine length is significantly 
decreased in the Fmr1−/y mice compared to WT animals in this region. 
Lovastatin, a drug known as one of the 3-hydroxy-3-methyl-glutaryl-CoA 
(HMG-CoA) reductase inhibitors, functions as a modulator of the mitogen-activated 
protein kinases (MAPK) pathway through inhibiting Ras farnesylation, was used in 
an attempt to rescue the dendritic spine abnormalities in the Fmr1−/y mice.  Mice 
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lacking FMRP are susceptible to audiogenic seizure (AGS).  Previous work has 
shown that 48 hr of lovastatin treatment reduced the incidence of AGS in the Fmr1−/y 
mice.  However, chronic lovastatin treatment failed to rescue the spine density and 
morphology abnormalities in the Fmr1−/y mice. 
Mouse models are invaluable tools for modelling human diseases.  However 
inter-strain differences have often confounded results between laboratories.  In my 
final Chapter of this thesis, I compared two commonly used C57BL/6 substrains of 
mice by recording their electrophysiological responses to visual stimuli in vivo.  I 
found a significant increase of high-frequency gamma power in adult C57BL/6JOla 
mice, and this phenomenon was reduced during the critical period.  My results 
suggested that the C57BL/6JOla substrain has a significant stronger overall 
inhibitory network activity in the visual cortex than the C57BL/6J substrain.  This is 
in good agreement with previous findings showing a lack of open-eye potentiation to 
monocular deprivation in the C57BL/6JOla substrain, and highlights the need for 
appropriate choice of mouse strain when studying neurodevelopmental models.  
They also give valuable insights into the genetic mechanisms that permit experience-
dependent developmental plasticity. 
In summary, these findings give us a better understanding of the fine structure 
abnormalities of the Fmr1−/y mice, which in turn can benefit future discoveries of the 
underlying mechanisms of neurodevelopmental disorders such as ID and ASDs. 
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Lay summary 
Intellectual disability (ID) and autism spectrum disorders (ASDs) are co-
occurring developmental disorders.  More than 1% of the human population have 
ASDs and approximately 2 – 3% have ID.  Furthermore, it is estimated that over 
50% of individuals with ASDs also have intellectual disability and 25 – 30% of 
people with ID have ASDs.  ASDs are mainly diagnosed via three distinct 
behavioural deficits (namely the “triad” deficits), including impaired social 
interaction, impaired communication, and restrict interest or repetitive behaviours. 
To date, the underlying developmental aetiology of most ASDs/ID remains 
unknown.  However, studying other single-gene disorders that have high co-
occurrence of ID and ASDs may offer a strategy to unravel the mystery of autism.  
Fragile X syndrome (FXS) is one of the single-gene disorders that among 30% of 
FXS patients will meet the diagnosis criteria for autism in their later lives and almost 
all boys presenting with ASDs.  FXS also shares several behavioural phenotypes 
such as learning disability and impaired social interaction with autism.  Because FXS 
is caused by the silencing of a single gene, it is relatively straightforward to study in 
animal models.  In this thesis I therefore used a specific mouse line that modelled 
FXS.  This model is widely used and accepted for studying key symptoms observed 
both in FXS patients and animal models. 
The brain comprises two parts, so called white matter and grey matter.  The 
white matter is mainly composed of nerve fibres known as “axons” that connect 
nearby and distal parts of the brain so they can effectively communicate.  The grey 
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matter, on the other hand, is mainly composed of the brain cells known as “neurons” 
and “glia”.  Furthermore, each one of the hundreds of billions neurons sends out 
axons that make thousands of contacts with other neurons.  These contacts occur on 
tree-like extensions from the cell called “dendrites”.  Alterations in these connections 
are believed to underlie many forms of ASDs/ID.  To gain insights of the underlying 
mechanisms of FXS, I examined the white matter and grey matter abnormalities in 
the mouse model of FXS.  My results indicated that no gross abnormalities of both 
the white matter and grey matter were noticed in the mouse model of FXS.  An 
increase of axon diameter was found in the mouse model of FXS, suggesting that the 
conduction velocity might increase in these animals. 
In good agreement with previous findings, I noticed an increase of dendritic 
spine density and altered spine morphology in two brain regions of the mouse model 
of FXS.  Lovastatin, a well-known blood cholesterol lowering drug, was reported 
previously that it was effective in rescuing certain key phenotypes in the mouse 
model of FXS.  However, chronic lovastatin treatment did not rescue the dendritic 
spine abnormalities in these animals. 
Since ASDs/ID are developmental disorders that result from both genetic and 
environmental influences, I next studied the mechanism by which genetic 
predisposition affects experience-dependent brain development.  Two distinct 
substrains of mice show very different responses to early visual deprivation.  I found 
that mice that lack a particular response to visual deprivation show very different 
brain rhythms to those that have this response.  This finding gives a vital glimpse 
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into the cellular mechanism that underlies this form of experience-dependent 
development in the cerebral cortex. 
In summary, these findings regarding those fine structure abnormalities in the 
mouse model of FXS can provide some valuable insights to the underlying 
mechanisms of FXS, and therefore benefit the further understanding of ID and 
ASDs. 
 













“The worst thing about a disability is that people see it before they see you.” 
—Easter Seals 
 




Chapter 1: General Introduction 
1.1 Intellectual disability (ID) 
Intellectual disability or mental retardation is defined as “a condition of 
arrested or incomplete development of the mind, which is especially characterised by 
impairment of skills manifested during the developmental period, which contribute to 
the overall level of intelligence, i.e., cognitive, language, motor, and social abilities” 
(World Health Organization, 1993).  The prevalence of ID is estimated around 1% of 
the entire human population (Harris, 2006; Maulik et al., 2011).  A strong sexual bias 
is noticed in the ID population.  Approximately 30% more males are diagnosed with 
ID or mental retardation than females (Leonard and Wen, 2002; McLaren and 
Bryson, 1987).  Among all the individuals with ID, different degrees of mental 
retardation ranging from mild, moderate, severe, and profound affects about 85%, 
10%, 4%, and 2% of this population, respectively (King et al., 2009; Maulik et al., 
2011). 
 
1.1.1 Symptoms of ID 
The core symptom of ID is a significant impairment in intellectual 
performance which is determined by scoring 70 or below in the intelligence quotient 
(IQ) test.  Patients with ID are often being identified in early childhood due to the 




neurodevelopmental disorders such as epilepsy, autism/autism spectrum disorders 
(ASDs) or fragile X syndrome (FXS). 
Comorbidity in ID patients is common.  For example, 40 – 55% of children 
with autism have ID in a various degrees (Newschaffer et al., 2007), and nearly all 
patients with FXS have moderate to severe ID (O’Donnell and Warren, 2002).  
Epilepsy, language disorders, sleep disturbances, and other mental disorders are all 
common comorbid disorders seen in ID patients (Di Nuovo and Buono, 2007; 
Einfeld et al., 2011; Emerson and Hatton, 2007; Matson and Cervantes, 2013). 
 
1.1.2 Diagnosis of ID 
The diagnosis criteria for ID consists of an IQ test score of 70 or below, and 
deficits in at least two behaviours related to adaptive functioning by the age of 18 
(American Psychiatric Association, 2000).  ID is therefore most likely to be 
diagnosed in late childhood or until early adulthood due to the use of IQ test as its 
diagnostic tool.  Based on the results of the IQ test, ID patients can further be divided 
into 4 groups: mild (IQ = 55 – 70), moderate (IQ = 40 – 55), severe (IQ = 25 – 40), 
and profound (IQ < 25) (American Psychiatric Association, 2013).  However, the use 
of IQ test as the main diagnostic tool has been criticised as this cannot assess the 
actual adaptive functioning of the patients, which is crucial for care givers and social 
workers to evaluate the level of support the patients need.  Moreover, IQ test 
becomes less valid toward the lower end of its range.  Hence, in the latest version of 




severity of ID is now based on adaptive functioning rather than the IQ score, and is 
assessed in three domains including conceptual, social, and practical skills 
(American Psychiatric Association, 2013).  Based on the DSM-V, ID is only 
diagnosed when all three of the following criteria are met: 
1.) Deficit in intellectual functions (assessed through the IQ test). 
2.) Deficit in adaptive functioning (assessed the patient’s ability for daily 
living, e.g., communication, independent living, participation in social 
activities). 
3.) Onset of both 1 and 2 during the developmental period. 
 
1.1.3 Genetics of ID 
Both environmental and genetic factors account for about 40% of all the 
currently known causes of ID, which leaves 60% of the ID population with unknown 
causes (Rauch et al., 2006).  Maternal malnutrition, maternal psychiatric disorders, 
maternal alcohol abuse during pregnancy, and certain birth complications can all lead 
to ID in the new-borns (Morgan et al., 2012; Vissers et al., 2015).  Moreover, ID is 
more likely to occur in patients with mental disorders such as schizophrenia, bipolar 
disorder, and major depression; patients with ID also have a higher risk (about 30%, 
which is 3 – 4 fold higher than healthy individuals) of developing mental disorders 




Genetic causes of ID are extensively studied.  Chromosomal abnormalities 
(Lubs et al., 2012), rare copy number variants (Girirajan et al., 2012), and de novo 
mutations (Hamdan et al., 2011b; The Deciphering Developmental Disorders Study, 
2015; Vissers et al., 2010) have all been reported as a cause of ID.  ID can be further 
subdivided into syndromic ID and non-syndromic ID; syndromic ID patients present 
at least one or more clinical features of other developmental disorders, whereas in 
non-syndromic ID patients intellectual disability is their sole clinical feature.  Single-
gene neurodevelopmental disorders such as FXS, neurofibromatosis type 1 (NF1), 
and tuberous sclerosis complex (TSC) are all examples of the coexistence between 
ID and other neurodevelopmental disorders.  De novo mutations (e.g., SYNGAP1 
haploinsufficiency, STXBP1) have been suggested as a major cause of non-
syndromic ID.  And with the advancement of techniques (e.g., next-generation 
sequencing, genomic microarrays), more understandings regarding the cause of non-
syndromic IDs would be expected. 
Finally, X-linked intellectual disability (XLID) have been thoroughly studied 
in the past 40 years and it is estimated to account for 5 – 10% of ID in males (Lubs et 
al., 2012).  In total, 102 genes has been described and are responsible for around 50% 
of the current known XLID syndromes (Lubs et al., 2012).  Details of these genes 





Figure 1-1.  A detailed map of genes with identified mutations that cause syndromal X-linked 
intellectual disability and their locations on the chromosomal band. 
Arrowhead indicates the location of the FMR1 gene on the X-chromosome, which is considered as the 
leading cause of X-linked intellectual disability.  Figure credit: (Lubs et al., 2012). 
 
1.2 Autism and autism spectrum disorders (ASDs) 
Autism is the most common ASD, and the latter has a prevalence of 1 in 68 
children among the population of the United States and 1 in 160 children among the 




World Health Organisation, 20161).  The prevalence of autism has increased 
dramatically since 1970, as children born before that with a prevalence rate of 2 – 5 
cases per 10000 children; and children born after 1970 with a rate around 1 in 1000 
(Gillberg and Wing, 1999).  Although there is no precise explanation for this increase, 
it is believed that the improve of diagnostic and the awareness of the disease are the 
two main reasons (Gillberg and Wing, 1999). 
Autism is first described by two psychiatrists, Dr. Leo Kanner and followed 
by Dr. Hans Asperger in the early 1940s (Asperger, 1944; Kanner, 1943).  At that 
time Kanner’s definition of autism was more “narrowed” compared to the current 
standards.  He described 11 children with “extreme autistic aloneness,” delayed 
echolalia, and an “anxiously obsessive desire for the maintenance of sameness”, and 
some of them may have extraordinary memory skills in his report published in 1943 
(Baker, 2013; Kanner, 1943).  This “strict” definition of autism provided by Kanner 
may count as one of the major factors that the prevalence of autism is far fewer of the 
children born before 1970, as most of the physicians use Kanner’s definition as the 
diagnostic standard of autism at that time before the third version of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-III) was introduced. 
ASDs are the leading cause of intellectual disability and affects around 1% of 
the entire human population (Baird et al., 2006; Chakrabarti and Fombonne, 2001; 
Elsabbagh et al., 2012; Kim et al., 2011; Levy et al., 2009; U.S. Centers for Disease 
Control and Prevention, 2014).  Traditionally, ASDs comprise three different 
                                                 




diagnoses: autism, Asperger’s disorder, and pervasive developmental disorder not 
otherwise specified (PDD-NOS).  All these three disorders overlap in a certain 
degree but meanwhile contain some distinct features.  For example, patients with 
Asperger’s disorder generally do not show signs of language delay in their early 
development, whereas most autistic patients would show different degrees of 
language delay and communication impairment.  But repetitive/stereotyped 
behaviours and social deficits are core features in both of them.  Details of each 
disorder will be discussed in the rest of this Chapter. 
 
1.2.1 Symptoms and comorbidity 
Autism stands for a disorder that covers a wide range of symptoms.  It is 
mainly diagnosed via three distinct behavioural deficits (namely the “triad” deficits), 
including impaired social interaction, impaired communication, and restrict interest 
or repetitive behaviours (Belmonte and Bourgeron, 2006; Newschaffer et al., 2007).  
However, the diagnosis of autism is reduced to two main categories according to the 
latest version of DSM (DSM-V); namely the deficits in social communications and 
restricted/repetitive behaviours in early childhood. 
From the developmental perspective, these symptoms mainly become 
obvious around 3 years of age.  High risk infants (whose older siblings are diagnosed 
with autism) can show certain deficits in either communication, ways of play, or 
responsiveness to outer stimuli as early as 6 – 12 months of age (Volkmar and 




such as touch, problems of sleep regulation, and less likely to engage in either motor 
or vocal imitations from these children have also been reported previously (Dawson 
et al., 2000; Maestro et al., 2002). 
Around 50% of autistic patients also have intellectual disability/mental 
retardation (Levy et al., 2009; Newschaffer et al., 2007; Yeargin-Allsopp et al., 
2003), but some patients tend to have normal or even above average IQ.  Beyond that, 
some other symptoms are often seen in patients with ASD, such as seizure (Matson 
and Neal, 2009; Tuchman and Rapin, 2002; Tuchman et al., 2010; Viscidi et al., 
2013), attention-deficit hyperactivity disorder (ADHD) (Levy et al., 2009), 
dysregulation of immune system (Warren et al., 1996), problems relating to 
gastrointestinal systems (Kuddo and Nelson, 2003), difficulties with feeding (Volkert 
and Vaz, 2010), and sleep disruption (Polimeni et al., 2005). 
Comorbid psychiatric disorders in patients with autism are also mentioned in 
previous studies (Leyfer et al., 2006; Matson and Nebel-Schwalm, 2007; Simonoff et 
al., 2008).  Among all of the comorbid psychiatric disorders, 44% of the children 
with autism meet the diagnostic criteria for specific phobias.  Interestingly, children 
with autism tend to have uncommon phobias when comparing with normal 
developing children.  For example, certain types of specific phobias are common in 
the normal children population, such as fears of tunnels and bridges; but for the 
children with autism, they rarely develop phobias to these.  Instead, they tend to 
develop phobias to more than one object or situation, which normal children would 





Obsessive compulsive disorder, or OCD, is another psychiatric disorder that 
patients with autism have high comorbidity with.  Around 37% of children with 
autism were also diagnosed to have OCD (Levy et al., 2009; Leyfer et al., 2006).  
Other comorbid psychiatric disorders common in patients with autism are ADHD (up 
to 31%), anxiety, and depression (Kim et al., 2000). 
 
1.2.2 Diagnosis of autism and ASDs 
In the new online app version (2016) of the 10th International Statistical 
Classification of Diseases and Related Health Problems (ICD-10) (World Health 
Organization, 1993), autism is categorized under “Pervasive Developmental 
Disorders (PDDs)” which is then specified as: 
“A group of disorders characterized by qualitative abnormalities in 
reciprocal social interactions and in patterns of communication, and by a restricted, 
stereotyped, repetitive repertoire of interests and activities.  These qualitative 
abnormalities are a pervasive feature of the individual’s functioning in all 
situations.” 
According to the previous edition of the DSM (DSM-IV), autism (autistic 
disorder is the term used in DSM-IV) is categorised as PDD along with other four 
disorders: Asperger’s disorder, childhood disintegrative disorder, PDD-NOS, and 
Rett syndrome (American Psychiatric Association, 2000).  However, in the latest 
version of the DSM (DSM-V), autism is no longer categorised under PDD but now it 




(American Psychiatric Association, 2013).  The introduction of ASD as an 
independent diagnosis in DSM-V is based on several considerations, one of them is 
the overlap between PDD-NOS and Asperger’s disorder which needs to be clarified.  
Beyond this, the arguments that Asperger’s disorder is just a group of “high-
functioning” autistic patients (i.e., IQ > 70) also urges a better and clearer definition 
of these PDDs (Carpenter et al., 2009; Howlin, 2003; Sharma et al., 2011). 
According to the definition of PDD-NOS in the DSM-IV, it has been 
described as the following: 
“This category should be used when there is a severe and pervasive 
impairment in the development of reciprocal social interaction or verbal and 
nonverbal communication skills, or when stereotyped behaviour, interests, and 
activities are present, but the criteria are not met for a specific pervasive 
developmental disorder, schizophrenia, schizotypal personality disorder, or avoidant 
personality disorder.  For example, this category includes “atypical autism”—
presentations that do not meet the criteria for autistic disorder because of late age of 
onset, atypical symptomatology, or subthreshold symptomatology, or all of these.” 
Meanwhile, Asperger’s disorder is only diagnosed when all six of the 
following criteria are met: 
1.) Qualitative impairment in social interaction. 





3.) The disturbance causes clinically significant impairment in social, 
occupational, or other important areas of functioning. 
4.) There is no clinically significant general delay in language (e.g., single 
words used by age 2 years, communicative phrases used by age 3 years). 
5.) There is no clinically significant delay in cognitive development or in the 
development of age-appropriate self-help skills, adaptive behaviour (other 
than in social interaction), and curiosity about the environment in 
childhood. 
6.) Criteria are not met for another specific pervasive developmental disorder 
or schizophrenia.  (American Psychiatric Association, 2000) 
Thus, if one does not show obvious cognitive impairment but show some 
repetitive/restricted behaviours during childhood development, then the presence of 
delayed language development would be the main factor to assign this patient into 
the PDD-NOS group rather than the Asperger’s disorder group.  And depending on 
the severity of cognitive or language impairment, PDD-NOS can then be subdivided 
to three subgroups: 1) a high-functioning group that resembles Asperger’s disorder 
but with mild cognitive impairment or language delay; 2) a subgroup that resembles 
autism but with either a relative late onset or too severe cognitive delays, or patients 
are too young to meet the full diagnostic criteria for autism; and 3) a subgroup that 
does not meet the full diagnostic criteria for autism due to having fewer 
repetitive/stereotyped behaviours (Walker et al., 2004).  And with the newly 




To be more precise, autistic disorder, Asperger’s disorder, and PDD-NOS are now 
collapsed into the “Autism Spectrum Disorder” described in the DSM-V (American 
Psychiatric Association, 2013). 
With the new DSM-V, now the diagnosis criteria for autism is reduced to two 
main categories with two restrictions, and all criteria need to be fulfilled to meet the 
diagnosis.  To summarise, patients show signs of  A) persistent deficits in social 
communication and B) restricted and repetitive patterns of behaviour, interests, or 
activities; and C) all these symptoms are present in early childhood and D) these 
symptoms together limit and impair their everyday functioning can then be 
diagnosed as ASD (American Psychiatric Association, 2013). 
 
1.2.2.1 Post-mortem diagnosis of autism. 
In Darby’s report dated back in 1976, he did not find any pathological 
evidence in two patients diagnosed with autism with mental retardation (Darby, 
1976).  One autistic patient was diagnosed with tuberous sclerosis after the autopsy 
(Darby, 1976).  Even to date, the post-mortem studies for autism are still very limited 
compared to other neurodevelopmental disorders, fewer than 100 cases and 
approximately 5 autism cases per study (Amaral et al., 2008).  Although no gross 
anatomical differences were reported, one most consistent finding among several 
previous studies suggested that an increase of head circumference was noticed in 
children with autism in their early lives, especially the 1st year after birth.  This rapid 




(Courchesne et al., 2003, 2001; Dawson et al., 2007; Dementieva et al., 2005; Hazlett 
et al., 2005; Sparks et al., 2002). 
 
1.2.3 Functional brain imaging findings in autism 
The increased head circumference in the early ages of patients with autism 
reveals that there might be some brain anatomical and structural deficits among them.  
With the improved brain imaging techniques, scientists and physicians now can 
gather more information regarding our brain in a more efficient way.  And more 
importantly, with the invention of magnetic resonance imaging (MRI) and positron 
emission tomography (PET), brain imaging can now not only give us detailed 
structural information about the brain but also evaluate its function.  The 
advancement of brain imaging techniques is crucial as functional brain imaging can 
detect the minute brain activities during the time when subjects are performing tasks 
that designed to stimulate or require the activation of certain specific brain regions.  
Thus functional brain imaging can provide some invaluable information that cannot 
be obtained via traditional brain imaging such as X-ray computed tomography (CT). 
To date, the primary use of PET is to detect the consumption of glucose in the 
blood flow.  As glucose is the main source of energy consumption for all the organs 
in the body, through measuring the rate and amount of glucose consumption can 
therefore indicate the activity of organs or regions during the imaging process.  To 




radioactive tracer isotope, the most common one is the [18F]-fluorodeoxyglucose2 
(FDG), which is an analogue of glucose (Boellaard et al., 2010).  With its fine tissue 
metabolic mapping, FDG-PET is now greatly used in the field of oncology as tumour 
tissues consume more energy than normal tissues (Boellaard et al., 2010).  
Combining with CT scan, the PET-CT scanner can provide a thorough examination 
of the subject with the 3-dimential structural reconstruction via CT and tissue activity 
measured by PET.  MRI, on the other hand, is mainly designed to detect the much 
smaller changes in the blood flow during energy consumption, which is the 
consumption of oxygen.  Similar to PET, MRI scanning is also a non-invasive 
procedure.  MRI can also be used to do functional mapping of the brain through its 
blood-oxygen-level dependent (BOLD) imaging, MRI can therefore measure brain 
activity and so called the functional MRI (fMRI) (Ogawa et al., 1992; Raichle, 2003). 
In Courchesne’s paper (Courchesne et al., 2001) dated back to 2001, using 
MRI to systematically analyse the brain structure abnormalities in 2 – 4-year-old 
children with autistic traits showed that over 90% of autistic boys had a significantly 
larger brain volume compared to normal controls.  Meanwhile, 37% of these boys 
met the diagnostic criteria for developmental macrencephaly, a clinical symptom 
used to described an abnormally large brain (Courchesne et al., 2001).  The increased 
overall cerebral volumes in children with ASDs were further confirmed in several 
other studies (Courchesne et al., 2003; Dawson et al., 2007; Dementieva et al., 2005; 
Hazlett et al., 2005; Sparks et al., 2002), the volume of amygdalae and hippocampi 
                                                 




were also significantly increased as indicated in some previous studies (Schumann et 
al., 2009, 2004; Sparks et al., 2002). 
Several detailed studies indicated that besides a general increased head 
circumference, some sub-regional and cell-specific abnormalities were also noticed 
in the patients of autism.  A case study composed of six autistic patients revealed an 
interesting results that all six patients showed increased cell packing density and 
reduced cell size in the hippocampus and amygdala regions, accompanying with 
reduced and limited dendritic arbors (Kemper and Bauman, 1993; Palman et al., 
2004).  A decreased Purkinje cell density in the cerebellum is also reported (Kemper 
and Bauman, 1993; Ritvo et al., 1986; Williams et al., 1980), which is surprisingly 
consistent among studies that it is observed in 12 out of 12 autistic patients examined 
by 4 different labs (Courchesne, 1997).  Besides, reduced volume of grey matter is 
also noticed in the autistic patients (Courchesne et al., 2001).  Abnormalities in the 
cerebral cortex is mostly sparse and not consistent between studies nor cases 
examined.  One area worth mentioning is the anterior cingulate cortex, which is 
consistently reported that it is unusually coarse and poorly laminated among all cases 
examined (Kemper and Bauman, 1993). 
A recent study examining the whole brain local network connectivity of 
autistic patients, unaffected siblings, and typically-developing controls showed that 
hypoconnectivity might be an endophenotype of autism (Moseley et al., 2015).  
Several diffusion tensor imaging (DTI) studies also suggested that the brain 
microstructures of autistic patients are affected such as the corpus callosum (CC) 




(Travers et al., 2015), bilateral anterior cingulate cortex (Barnea-Goraly et al., 2004), 
and the frontal lobe (Sundaram et al., 2008).  Although overall in general 
myelination in patients with autism appears to be normal (Courchesne, 1997). 
 
1.2.4 Underlying genetics of autism and ASDs 
Although the discovery and diagnosis of autism can be traced back to the 
1940s, its precise underlying mechanism remains unknown.  One thing to be noted is 
that autism is highly genetic, sibling studies showed that the second child’s chances 
of being diagnosed as autism or ASDs is up to 50 times higher than normal 
population if the first child is autistic (Levy et al., 2009; O’Roak and State, 2008; 
Rutter et al., 1999).  Sex differences are also noticed in autism, where males tend to 
be affected four times more than females (Kogan et al., 2009).  Further studies 
focusing on the monozygotic (MZ) and dizygotic (DZ) twin pairs yield some more 
intriguing results: the concordance in MZ ranges from 69% – 95% and in DZ is 0% 
in most cases reported, highlights the importance of genetic factors in autism but also 
raises the notion that other factors are involved in the cause of autism (Lauritsen and 
Ewald, 2001; Newschaffer et al., 2007; Ritvo et al., 1985; Steffenburg et al., 1989).  
Among 6 – 10% of children with autism, a medical disorder that might lead to autism 
is diagnosed (Fombonne, 2003; Fombonne et al., 1997).  However, this leaves 
approximately 90% of the rest of the children belonging to idiopathic autism, and 




Several genetic findings in the recent years shed a light on the underlying 
mechanisms of autism.  Certain single-gene disorders such as FXS (FMR1), Rett 
syndrome (MECP2), neurofibromatosis type 1 (NF1), tuberous sclerosis complex 
(TSC1/2), Angelman syndrome (UBE3A: ubiquitin-protein ligase E3A) , and 
Timothy syndrome (CACNA1C: calcium channel, voltage-dependent, L type, alpha 
1C subunit) are all known genetic risk factors for autism (Kelleher and Bear, 2008).  
FXS is the leading cause of human intellectual disability, up to 30% of patients with 
FXS would meet the diagnostic criteria for autism in their lives (Jacquemont et al., 
2007; Kelleher and Bear, 2008).3  Another X-linked single gene disorder, Rett 
syndrome, is almost exclusively occurs in females, with an incidence of 1 in 10000 – 
15000.  It is one of the most common causes of mental retardation in females, and it 
is caused via a loss-function mutation of the MECP2 gene which encodes the methyl-
CpG-binding protein 2 (MeCP2) (Amir et al., 1999).  Nearly 100% of patients with 
Rett syndrome will develop autism in their later lives (Kelleher and Bear, 2008).  
Patients with TSC also have a very high incidence rate of autism, up to 60% of 
patients with TSC may develop autism in their later lives (Kelleher and Bear, 2008; 
Miles, 2011).  NF1 is another common neurodevelopmental disorder which is caused 
by losing function of the neurofibromin 1 gene, or NF1.  Neurofibromin is a tumour 
suppressor protein and is mainly found within neurons and oligodendrocytes in the 
central nervous system (CNS) or Schwann cells in the peripheral nervous system 
(PNS) (Daston et al., 1992; Wallace et al., 1990; Zhu et al., 2002).  Patients with 
Angelman syndrome usually suffer from severe mental retardation, severe language 
                                                 




delay, and often show loud laughter or smiling, which is one of the characteristic of 
this disorder (Peters et al., 2004).  Although the precise underlying mechanism is 
unclear, a single mutation or a deletion on chromosome 15 of the region which 
contains the UBE3A gene, is recognised as the main cause of this disorder.  Up to 
40% of children with Angelman syndrome also meet the diagnostic criteria for 
autism (Kelleher and Bear, 2008; Peters et al., 2004).  A rarer disorder, Timothy 
syndrome, is also reported in several previous studies which suggest it might also 
lead to autism.  Timothy syndrome was first reported in 1992, that some patients 
showed a novel arrhythmia syndrome which associated with syndactyly (webbing of 
fingers and toes).  Beyond heart conditions, affected individuals also suffered from 
multiple organs/systems symptoms, including eyes, skin, gastrointestinal system, 
teeth, lungs, immune system, and the CNS (Splawski et al., 2004).  Due to its 
severity, the average age of death among affected individuals is 2.5 years.  Around 
60% of surviving individuals will meet the diagnostic criteria for autism owing to the 
severe language and cognitive impairment of the disorder (Kelleher and Bear, 2008; 
Splawski et al., 2004).  Besides these known single-gene disorders, novel de novo 
mutations that contribute to ASDs are also being noticed in recent years, since they 
offer more candidate genes that may have been neglected previously (Hamdan et al., 
2011a, 2009; Iossifov et al., 2012; O’Roak et al., 2012, 2011; Ronemus et al., 2014; 
Sanders et al., 2012). 
The intriguing fact that MZ twins do not have 100% concordance may 
suggest that other factors such as environmental factors would also contribute to 




such as the use of valproic acid, thalidomide and alcohol during maternity.  Other 
factors like maternal hypothyroidism, congenital cytomegalovirus infection, and 
congenital rubella infection (for a detailed review, see Folstein and Rosen-Sheidley, 
2001).  Among this, congenital rubella infection is the most compelling evidence that 
links to either typical or atypical autism, roughly 10% children with congenital 
rubella meet the diagnostic criteria for autism (Chess, 1971; Desmond et al., 1967). 
 
1.2.5 Current therapeutic strategies for autism and ASDs 
As described above, ASD is a heterogeneous syndrome that its aetiology 
includes comorbidity with other neurodevelopmental disorders, genetic mutations, 
exposure to certain substances during maternity, and environmental factors.  Thus, 
no cure has been found even to date, after the disorder has been identified 70 years 
ago. 
There are only two approved pharmacological therapies for ASD currently, 
risperidone and aripiprazole, and both are designed to alleviate the irritability which 
is caused by ASD rather than targeting the core symptoms (Ghanizadeh et al., 2014).  
Other atypical antipsychotics may be used, such as drugs that alleviate ADHD 
symptoms in patients with autism, antidepressants, and antiepileptic drugs.  
However, only methylphenidate (Ritalin) has shown to be effective in improving 
ADHD symptoms in patients with autism, but many other antipsychotic drugs either 
did not differ from placebo or cause more adverse effects than improving the 




Thus, behavioural training sessions and language therapies are essential to 
improve patients communicating skills and allow them to learn how to interact with 
other individuals.  Since most children are diagnosed at early childhood, parenting 
workshops and professional consultants also are key resources to help the whole 
family to understand and cope with autistic patients. 
 
1.3 Fragile X syndrome (FXS) 
FXS is the most common inherited form of human mental retardation and is 
the leading known genetic cause of autism, affecting approximately 1 in 4000 males 
and 1 in 8000 females (Crawford et al., 2001; O’Donnell and Warren, 2002; Turner 
et al., 1996).  Moreover, approximately 30% of boys with FXS will meet the 
diagnostic criteria for autism in their lives (Jacquemont et al., 2007).  The 
predominant cause of FXS is a trinucleotide (CGG) repeat expansion in the 5’ 
untranslated region (UTR) of the fragile X mental retardation 1 (FMR1) gene.  
Humans without FXS normally have 6 – 54 CGG repeats, however the repeat length 
is much longer in individuals with FXS and cytosines in the region become 
hypermethylated when the number of repeats exceeds 200.  This leads to silencing of 
FMR1 and loss of the protein it encodes, fragile X mental retardation protein 
(FMRP) (Kooy, 2003; Krueger and Bear, 2011; Penagarikano et al., 2007; Verkerk et 
al., 1991).  Whereas autism appears to involve multiple genetic factors, FXS is 




to offer insights into symptoms shared between these related disorders (The Dutch-
Belgian Fragile X Consortium, 1994). 
 
1.3.1 Symptoms of FXS 
The first FXS report was described by J. Purdon Martin and Julia Bell in 
1943, the same year when Leo Kanner published the first report of autism (Martin 
and Bell, 1943).  In this report, Martin and Bell examined a family in which 11 males 
within two generations showed abnormal signs including a severe degree of 
dementia, and their mental ages were between two to four years of age despite the 
fact that all of them were above age sixteen and some of them were in their fifties 
(Martin and Bell, 1943).  Beyond mental retardation, patients of FXS often have 
some other clinical signs such as spontaneous epilepsy, autistic behaviours, 
hyperactivity, and macroorchidism (Bowen et al., 1978; Hatton et al., 2006; Kooy, 
2003; Musumeci et al., 1991; Partington, 1984; Penagarikano et al., 2007; Turner et 
al., 1975).  Some distinct facial characteristics were also noticed, an elongated, 
narrow face and prominent ears were the most commonly accepted facial features of 
FXS (Heulens et al., 2013; Penagarikano et al., 2007).  A below-average IQ score is 
often noticed in affected individuals, in males IQ can range from 20 – 70 whereas in 







1.3.2 Diagnosis of FXS 
The term “fragile X syndrome” describes the nature of this disease; a fragile 
site on the X chromosome.  This phenomenon was first reported by Lubs in 1969, 
when he identified a constriction of the long arm of the X chromosome from several 
mentally retarded individuals in a single family (Lubs, 1969).  Years later 
Sutherland’s work first established the concept that specific culture conditions (i.e., 
types of the tissue culture medium) would affect the frequency of lesions at the 
fragile site (Sutherland, 1977).  And he concluded that the fragile site of FXS is 
likely located either in the Xq27 or Xq28 region (Sutherland, 1977).  The fragile site 
was then further confirmed that it is located specifically to band Xq27.3 through 
using an electron microscope (Harrison et al., 1983). 
Through years of research we now can conclude that the cause of FXS is 
through silencing of the FMR1 gene and eventually lead to the loss of FMRP.  The 
silencing process is called dynamic mutation (Richards and Sutherland, 1997), where 
the copy number of trinucleotide repeat exceeds to a certain degree that would lead 
to a disease and/or a fragile site of the gene.  In the case of FXS, the length of the 
CGG trinucleotide repeat which is located in the 5’ UTR is more than 200; whereas 
in unaffected individuals the length of the repeat is between 6 – 54.  The expansion 
of the CGG repeat lead to hypermethylation to the surrounding sequence and silence 
the gene entirely or partially, therefore contribute to the absence of the protein 
product FMRP (Penagarikano et al., 2007; Pieretti et al., 1991; Verkerk et al., 1991).  




however, about 1% of FXS patients are not caused by expansion of the CGG repeat 
but through rare single point mutations in the FMR1 gene (Collins et al., 2010). 
A diagnosis of FXS is often made in young children as some symptoms such 
as delayed or absent of language development are noticed around 3 years of age 
(Bailey et al., 2009).  At the early developmental stage, children with FXS can be 
misdiagnosed as ASD due to sharing some common traits (e.g., irritability, 
symptoms of ADHD, social and language deficits) (Sullivan et al., 2006).  Some 
facial characteristics like a narrow-long face, prominent ears, and highly arched 
palate combine with macroorchidism (can be noticed around 2 years of age) can 
assist physicians to better distinguish these children (Lachiewicz and Dawson, 1994).  
Beyond these behavioural traits and other symptoms, a genetic screening would be 
the most accurate way to confirm the diagnosis of FXS. 
 
1.3.3 Functional brain imaging findings in FXS 
A series of brain imaging studies reveal some minute differences between the 
FXS patients and healthy controls.  To summarise, increased fractional anisotropy 
(FA) values and decreased radial diffusivity are noticed in the inferior longitudinal, 
inferior fronto-occipital, and uncinated fasciculi from both male and female patients 
with FXS based on DTI findings (Green et al., 2015).  FA describes the degree of 
diffusivity and reports with a value between 0 and 1.  A value of 0 represents that 
diffusion is unrestricted thus it can happen in any directions; whereas a value of 1 




values can be used to measure brain white matter (WM) integrity, especially axon 
fibre density and myelination.  Thus, increased FA values in the FXS patients 
suggests increased fibre density and/or increased myelination in those areas.  Lower 
FA values is reported in the fronto-striatal pathways and parietal sensory-motor tracts 
from female FXS patients (Barnea-Goraly et al., 2003).  On the contrary, increased 
axon fibre density is reported in the left ventral fronto-striatal pathway from young 
boys with FXS (Haas et al., 2009). 
Findings in MRI studies also reveal some microstructural alterations in 
patients with FXS.  Functional connectivity and grey matter density are found 
decreased in the left insular cortex in both male and female patients compared to age-
matched healthy controls (Hall et al., 2013).  Enlarged grey matter volume (GMV) in 
the caudate, thalamus, and fusiform gyri is reported in young males with FXS (1 – 3 
years old), and reduced GMV is noticed in the cerebellar vermis.  Along with this, 
white matter volume (WMV) of the striatal-prefrontal regions was increased in FXS 
patients compared to controls (Hoeft et al., 2010).  The decrease of posterior vermis 
size is also reported in another independent study focusing on both male and female 
FXS patients (Mostofsky et al., 1998).  A summarised table is listed below. 
Table 1-1.  A brief summary of brain structural abnormalities in individuals with FXS. 
DTI 
Age ~20 y/o 
Gender Males and females 
Findings 
Increased FA and decreased radial diffusivity in the inferior 
longitudinal, inferior fronto-occipital, and uncinated fasciculi 





Age 13 – 22 y/o 
Gender Females 
Findings 
Lower FA values was reported in the fronto-striatal pathways and 
the parietal sensory-motor tracts 
Ref. (Barnea-Goraly et al., 2003) 
DTI 
Age 1 – 3 y/o 
Gender Males 
Findings Increased fibre density in the left ventral fronto-striatal pathway 
Ref. (Haas et al., 2009) 
DTI 
Age 7 – 14 y/o 
Gender Females 
Findings 
Higher diffusivity in the corpus callosum, parts of the internal and 
external capsules, occipital lobes, and central portions of the right 
thalamus 
Ref. (Villalon-Reina et al., 2013) 
MRI 
Age 10 – 23 y/o 
Gender Males and females 
Findings 
Decreased functional connectivity and grey matter density in the 
left insular cortex 
Ref. (Hall et al., 2013) 
MRI 
Age 1 – 3 y/o 
Gender Males 
Findings 
Enlarged GMV in the caudate, thalamus, and fusiform gyri; 
reduced GMV in the cerebellar vermis 
WMV of the striatal-prefrontal regions was greater over time 
Ref. (Hoeft et al., 2010) 




Gender Males and females 
Findings Decreased posterior vermis size in the FXS patients 
Ref. (Mostofsky et al., 1998) 
 
 
1.3.4 Animal models of FXS 
Animal models are essential for tackling the underlying mechanisms of 
human diseases.  In the case of FXS, several animal models across different species 
were made in this regard, including Drosophila (Lee et al., 2003; McBride et al., 
2005; Michel et al., 2004; Morales et al., 2002; Sekine et al., 2008), zebrafish (den 
Broeder et al., 2009; Tucker et al., 2006), mouse, and more recently rat (Hamilton et 
al., 2014; Till et al., 2015).   
Drosophila contains a single, functionally conserved member of the FMR1 
family, the dfmr1 gene (Wan et al., 2000).  Zhang et al. and Morales et al. referred to 
the dfmr1 gene as Drosophila fragile X related (dfxr) gene in their studies.  Similar 
to mammals, Drosophila dFXR is highly expressed in both pre- and postsynaptic 
neurons, and dfxr mutants showed defects in the larval neuromuscular junction 
(NMJ) synaptic terminals compared to WT flies (Zhang et al., 2001).  Further 
characterisation indicates that dFXR is ubiquitously expressed and cytoplasmically 
localised, and only exists in neurons but not in glia (Morales et al., 2002).  dFXR was 




(especially higher-order branches) was reported in the dfxr mutant larvae compared 
to the WT larvae (Lee et al., 2003). 
Morpholino antisense oligonucleotide repression of fmr1 mRNA translation 
(fmr1MO) was used to study the loss-of-function of fmr1 in the zebrafish.  The 
fmr1MO zebrafish showed a great reduction of protein levels of Fmr1, and a 
significant increase in neurite branching and an increase in neurite branch 
terminations in Rohon-Beard primary sensory neurons (Tucker et al., 2006).  These 
defects can then be rescued by treating fmr1MO-injected embryos with a selective 
mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP), indicating the 
branching defects caused by the loss of Fmr1 was mGluR-dependent.  One 
characteristic phenotype of human patients with FXS is mild craniofacial 
abnormalities such as elongated face, prominent ears, and high-arched palate 
(Heulens et al., 2013).  These facial features were not recapitulated in the mouse 
model of FXS as previously reported (Heulens et al., 2013).  However, craniofacial 
defects were noticed in the fmr1MO zebrafish (abnormalities of the Meckel’s 
cartilage) and can be rescued by MPEP treatment (Tucker et al., 2006). 
Instead of using the knock-down approach, den Broeder and colleagues used 
the fmr1 knock-out strategy to study the loss of Fmr1 in zebrafish (den Broeder et al., 
2009).  Strikingly, none of the previously characterised phenotypes (i.e., craniofacial 
defects and abnormal neurite branching) reported by using the fmr1MO zebrafish 
were found in the fmr1 knock-out zebrafish.  One possible explanation is that the 




morpholino oligonucleotides are known to cause phenotypes that are unrelated to the 
intended gene (Robu et al., 2007). 
The first genetic mouse model of FXS was engineered in 1994 (The Dutch-
Belgian Fragile X Consortium, 1994).  Taking advantage of the fact that the mouse 
Fmr1 gene has 98% homology with the human FMR1 gene, the mouse model was 
engineered by introducing a neomycin cassette into exon 5 of the mouse Fmr1 gene, 
to generate an Fmr1 knock-out mouse.  This mouse model of FXS successfully 
recapitulated some of the key phenotypes of the disease, including macroorchidism, 
learning deficits, and hyperactivity (The Dutch-Belgian Fragile X Consortium, 1994).  
Moreover, the brain of the Fmr1 knock-out mouse did not differ from the WT mice, 
with normal myelination and no gross alterations were noted (The Dutch-Belgian 
Fragile X Consortium, 1994).  And most importantly, no FMRP expression was 
found in the brains of the knock-out mice when examined with Western blotting (The 
Dutch-Belgian Fragile X Consortium, 1994). 
The Fmr1 knock-out mouse showed several behavioural phenotypes that can 
be related to FXS-like symptoms, including hyperactivity, seizures, cognitive 
impairments, increased anxiety/depression, and hyper-responsiveness to sensory 
stimulation (Bregman et al., 1988; Ding et al., 2014; Frankland et al., 2004; Kooy, 
2003; Musumeci et al., 2000, 1991; Spencer et al., 2005; The Dutch-Belgian Fragile 
X Consortium, 1994).  Some autistic-like phenotypes were also reported, such as 
repetitive/stereotypic behaviours and deficits in social interaction, which 




Hatton et al., 2006; Kerby and Dawson, 1994; Rogers et al., 2001; Spencer et al., 
2011). 
Intriguingly, the cause of FXS is an expansion of the CGG trinucleotide 
repeat located in the promotor region of the FMR1 gene, and eventually silence the 
gene through hypermethylation.  Thus, the Fmr1 knock-out mouse mentioned above 
only mimicked the result of losing FMRP, but did not completely reproduce the 
actual cause of FXS.  Several studies therefore began to create mouse models of FXS 
via expanding the CGG repeat, which should be a more causative and precise model 
than the knock-out model. 
The CGG repeat in the FMR1 gene is well-conserved in most of the mammals 
with a variation of the number of copies of the repeat between species (Deelen et al., 
1994).  To replicate the expansion of CGG repeat in mice, a “knock-in” mouse 
model was engineered by replacing the endogenous mouse CGG repeat (~8 – 11 
CGG) with a human CGG repeat which carried various numbers of CGG triplets 
varying from studies (Bontekoe et al., 2001; Lavedan et al., 1998, 1997; Ludwig et 
al., 2014; Van Dam et al., 2005).  When numbers of CGG triplets of the inserted 
human CGG repeat ranging from 50 – 200 (i.e., in the permutation range), the knock-
in mice recapitulated the fragile X-associated tremor/ataxia syndrome (FXTAS) and 
showed an elevation of Fmr1 mRNA level and a slightly reduced FMRP level as 
well as some neuromotor disturbances and cognitive decline shown in humans with 
FXTAS (Ludwig et al., 2014; Tassone et al., 2000; Van Dam et al., 2005).  Longer 




would be more promising than previous knock-out models as this approach 
mimicked the actual mechanism that caused FXS. 
However, a longer expansion of the CGG triplets did not silence the Fmr1 
gene in the knock-in mouse model and FMRP was still expressed, hence greatly 
reducing the possibility of using this knock-in model as a model of FXS (Brouwer et 
al., 2007).  Similar to those knock-in models previously described, the longer 
expansion model also showed elevated Fmr1 mRNA levels and reduced FMRP 
expression compared to the WT controls.  Immunocytochemistry also indicated a 
significant reduction of FMRP in these mice, however, FMRP was still detectable 
and with the highest expression in the CA2 and CA3 regions of the hippocampus. 
The absence of hypermethylation of the CpG island might be the explanation 
of why FMRP was still expressed in the knock-in mouse model.  One possibility is 
that certain methyl transferases that are essential for methylating the FMR1 promotor 
in humans might be missing in the mouse (Brouwer et al., 2007).  This finding 
suggested that the knock-in mouse model could serve as an animal model for 
studying FXTAS, but not ideal for FXS.  Thus, despite the fact that the knock-in 
model mimicked the causative mechanism of FXS in humans better than the knock-








1.3.5 Underlying mechanisms of FXS 
Silence of the FMR1 gene results in a partial or full reduction of its protein 
product FMRP.  Although the relationship/causality between CGG expansion and 
methylation remains unclear, evidence suggests that both events lead to the reduction 
of FMRP (Jin and Warren, 2000).  FMRP is expressed in most tissues, but most 
abundantly existed in neurons (particularly in the granular layers of hippocampus and 
cerebellum), and testes (Abitbol et al., 1993; Hinds et al., 1993).  In the cell, FMRP 
is predominantly localised in the cytoplasm, but generally about 5% of the total 
amounts of FMRPs are localised in the nucleus.  Evidence suggests that it can shuffle 
between the cytoplasm and nucleus owes to its nuclear localisation signal (NLS) and 
nuclear export signal (NES) (Eberhart et al., 1996; Fridell et al., 1996). 
FMRP is a ribonucleic acid (RNA) binding protein, more specifically, it 
assembles with messenger RNAs (mRNA) into ribonucleoprotein (RNP) particles by 
entering the nucleus and then exports into the cytoplasm.  Once in the cytoplasm, 
FMRP then associates with ribosomes and regulates downstream gene expression via 
posttranscriptional mechanisms (Eberhart et al., 1996; Schaeffer et al., 2003).  More 
than 800 FMRP target mRNAs have been reported previously (Darnell and Klann, 
2013).  Among these mRNAs, about 30% of them are enriched in the post-synaptic 
density (PSD), such as the N-Methyl-D-aspartate (NMDA) receptor subunits, 
mGluR5 receptor, and PSD-95; suggesting a regulatory role of FMRP in the PSD 
through coupling to different post-synaptic receptors.  It is not surprising that FMRP 
targets the post-synaptic proteins as previous electron microscopic studies already 




been found that it may regulate a great portion of pre-synaptic proteome (e.g., 
scaffolding proteins, synaptotagmins) (Darnell and Klann, 2013).  A recent study 
indicated that enhanced vesicle recycling and enlarged readily-releasable and 
reserved vesicle pools were found in Fmr1 knock-out mice further suggested the role 
of FMRP in repressing presynaptic protein synthesis (Deng et al., 2011). 
Additionally, FMRP is one of the proteins that are synthesised in response of 
the mGluR pathway which in turn negatively regulate its downstream protein 
translation (Weiler and Greenough, 1999); loss of FMRP would therefore lead to an 
exaggerated mGluR signalling and an elevated downstream basal protein synthesis 
and this is thought of as the main underlying mechanism of FXS. 
In 2004, the “mGluR theory” was proposed as one of the underlying 
mechanisms of FXS (Bear et al., 2004).  It is based on the findings that several 
symptoms of patients with FXS and mouse model of the disease can be speculated as 
a consequence of group 1 metabotropic glutamate receptor (mGluR) activation (Fig. 
1-2).  The initial hypothesis was established on the findings from both human post-
mortem results and mouse models of FXS that an immature dendritic spine 
phenotype stands as a hallmark of losing FMRP.4  This may indicate that the 
dynamic equilibrium between spine formation and elimination (i.e., spine pruning) is 
disrupted in the case of FXS (Cruz-Martín et al., 2010).  Notwithstanding the 
discrepancy in the literature concerning the spine data, long-term depression (LTD), 
a mechanism of spine pruning (Bian et al., 2015), is exaggerated in hippocampal 
                                                 




CA1 neuronal responses to group 1 mGluR stimulation (mGluR-LTD) in mouse and 
rat models of FXS (Huber et al., 2002; Till et al., 2015).  FMRP is then recognised as 
a translational repressor based on this phenomenon along with other studies 










Figure 1-2.  The mGluR signalling pathway. 
Activation of group 1 mGluRs engages the MAPK-ERK and PI3K-mTOR pathways that involves in 
mRNA translation and local protein synthesis.  MEK phosphorylates and activates ERK, and ERK 
activates and phosphorylates Mnk1 that phosphorylates eIF4E.  PI3K phosphorylates and activates 
Akt, which then phosphorylates and activates mTOR.  Both ERK and mTOR phosphorylate and 
activate S6 kinase 1, which in turn phosphorylate ribosomal protein S6 that enhance translation 
initiation.  mTOR also activates and phosphorylates the eIF4E binding proteins (4E-BPs).  
Phosphorylation of 4E-BPs induces the release of 4E-BPs from eIF4E and results in promoting cap-
dependent translation via the eIF4E complex.  MEK: mitogen-activated protein kinase kinase; Mnk1: 
MAPK-interacting serine/threonine kinase 1; PI3K: phosphatidylinositol 3-kinase; Akt (also known as 






A key reproducible hallmark of the Fmr1 knock-out deletion is elevated basal 
protein synthesis and an exaggerated, protein synthesis-independent mGluR-LTD in 
the hippocampal region (Huber et al., 2002; Nosyreva and Huber, 2006; Osterweil et 
al., 2010; Till et al., 2015).  There are two main signalling pathways downstream of 
mGluR that regulate protein synthesis, the mitogen-activated protein kinase kinase 
(MEK)-extracellular signal-regulated kinase (ERK) pathway and the 
phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) 
pathway (Banko et al., 2006; Gallagher et al., 2004).  Thus, the MEK-ERK pathway 
and/or the PI3K-mTOR pathway are very likely to be involved in these alterations 
under the loss of FMRP.  Genetically (Dölen et al., 2007) or pharmacologically 
(Gandhi et al., 2014; Michalon et al., 2012) reducing the activity of the mGluR 
pathway has rescued several key phenotypes in the mouse model of FXS.  
Meanwhile, reducing the activity of either the MEK-ERK pathway, the PI3K-mTOR 
pathway, or their shared downstream effector p70 ribosomal S6 kinase 1 (S6K1) 
have all been reported to reverse some key phenotypes in the mouse model of FXS 
(Auerbach et al., 2011; Bhattacharya et al., 2012; Osterweil et al., 2010). 
An increase of activity of the PI3K-mTOR pathway is reported in the case of 
FXS (Hoeffer et al., 2012; Sharma et al., 2010).  Similar findings focusing on the 
MEK-ERK pathway are also reported (Wang et al., 2012).  However, a paper 
published in 2010 by Osterweil et al. suggests that the basal activity of either the 
MEK-ERK pathway or the PI3K-mTOR pathway are not greatly altered in FXS, and 
the increased basal protein synthesis is most likely due to an increased sensitivity of 




Moreover, inhibiting the MEK-ERK pathway via its inhibitor U0126 (but not the 
mTOR pathway inhibitor rapamycin) corrects the increased basal protein synthesis in 
the mouse model of FXS (Osterweil et al., 2010). 
The mGluR theory of FXS led to the clinical trials for what would have been 
the first rational treatment for FXS, rather than symptom controls only.5  Other 
studies also offer some possibilities and new strategies to unravel the underlying 
mechanism of FXS.  Matrix metalloproteinase 9 (MMP-9) mRNA was recently 
identified as an FMRP target, it colocalised with FMRP in the dendrites and evidence 
suggests that MMP-9 mRNA translation is locally regulated by FMRP at synapses 
following neuronal stimulation (Janusz et al., 2013).  Genetically removal of MMP-9 
rescues several key phenotypes in the mouse model of FXS, including dendritic spine 
abnormalities, exaggerated mGluR-LTD, and non-neural features such as 
macroorchidism (Sidhu et al., 2014). 
The endocannabinoid signalling has also recently been implicated in FXS 
because of the ability of group 1 mGluR stimulation to generate the release of 
endogenous cannabinoids that subsequently regulate synaptic transmission.  Two 
types of cannabinoid receptors, CB1 and CB2, are predominantly expressed in the 
mammalian system; where CB1 mainly enriched in the CNS while CB2 in the PNS.  
However, recent studies also provide evidence that CB1 can be found in several 
peripheral organs and systems whereas CB2 can also be found in neurons and 
microglial cells (Svizenska et al., 2008).  Both CB1 and CB2 are G-protein coupled 
                                                 




receptors, more specifically, they both couple with the Gi/o subunit and therefore 
negatively regulate the activity of adenylyl cyclase, hence reduce the production of 
cyclic adenosine monophosphate (cAMP) (Svizenska et al., 2008).  The decrease of 
cAMP leads to the inactivation of protein kinase A (PKA) as PKA activation is 
cAMP-dependent.  Eventually, activation of presynaptic CB1 receptors leads to a 
reduction of PKA activity via a cAMP-dependent manner, and the reduction of PKA 
hence attenuates its downstream signalling such as the MEK-ERK pathway (Fig. 1-
3) (Davis et al., 2003).  Pharmacological and genetic blockade of CB1 but not CB2 
in the mouse model of FXS rescues cognitive deficit, dendritic spine abnormality, 





Figure 1-3.  The CB1-cAMP-ERK pathway. 
CB1 receptor activation inactivates cAMP, therefore negatively regulates the MAPK/ERK signalling 
pathway.  cAMP-dependent PKA indirectly activates Ras and its subsequent MAPK/ERK signal 
transduction pathway.  PKA also directly inactivates Raf-1, hence, depending on the expression of B-
Raf, cAMP can either activate or deactivate the MAPK/ERK pathway (i.e., the ability of cAMP to 
activate the MAPK/ERK pathway correlates with the expression of B-Raf).  Raf-1 and B-Raf are 
members of the Raf kinase family and they both can be activated and phosphorylated by Ras.  Raf-1 
knockout mice die in utero, however, Raf-1 knockout fibroblasts show no alterations in ERK 
activation and this is likely due to the compensation effect of B-Raf.  Ref: (Bos, 2003; Roberson et al., 





1.3.6 Current therapeutic strategies for FXS 
The mGluR-theory points out a possible route of targeting the core symptoms 
of FXS, hence several studies using different approaches to target the mGluR-
signalling flourished since then.  mGluR antagonists shows promising results in the 
mouse model of FXS, thus several large scale clinical trials have been initiated in 
different countries all over the world.  The first trial led by Berry-Kravis et al. in 
2009 using a highly selective mGluR antagonist fenobam in patients of FXS.  Their 
results suggests that a single dose of fenobam can improve the prepulse inhibition 
test and also rapidly reduce anxiety and hyperactivity in those patients, without any 
noticeable side effects (Berry-Kravis et al., 2009).  However, the lack of a proper 
placebo controlled group and fail to conduct a double-blind design made this result 
problematic.  Later, two new selective mGluR5 antagonists AFQ056 (Mavoglurant; 
Novartis pharmaceuticals) and RO491756 (Basimglurant; Hoffman-LaRoche 
pharmaceuticals) entered into phase II clinical trial, but both were stopped in 2014 as 
they failed to reach their efficacy criteria (Hagerman and Polussa, 2015). 
As previously discussed, genetic or pharmacological removal of MMP-9 
rescues some key phenotypes in the mouse model of FXS, suggesting that MMP-9 
might serve as an important role in the underlying mechanism of FXS (Bilousova et 
al., 2009; Sidhu et al., 2014).  A pilot study targeting young FXS patients (mean age: 
10 – 11 y/o) indicates that the MMP-9 inhibitor minocycline can improve their 
performance in a task using quantitative electroencephalography (EEG) and event-




Direct targeting of the mGluR-signalling pathway shows promising results in 
animal models of FXS, however, current clinical trials failed to reproduce the 
success in human patients.  Thus, some attempts have been made to target the 
upstream or downstream of the mGluR-signalling pathway.  The γ-aminobutyric acid 
(GABA) system is down-regulated in the case of FXS as noticed in many brain areas 
of the mouse model of FXS (D’Hulst and Kooy, 2007; Olmos-Serrano et al., 2010); 
thus agonists of the GABA receptors have been tested in both FXS patients and 
animal models of FXS to test if restoring the GABA-mediated inhibition can rescue 
FXS.  Follow by getting promising results from the animal model (Henderson et al., 
2012), a GABAB receptor agonist (STX209; arbaclofen) was then being used in a 
clinical trial that enrolled 63 FXS patients (Berry-Kravis et al., 2012).  The outcome 
is encouraging, an improvement in the social impairments domain was noticed in 
patients received STX209 but not the placebo-treated group (Berry-Kravis et al., 
2012).  A larger STX209 clinical trial initiated by Seaside Therapeutics was 
discontinued in 2013.  No official details have been released yet, but the company 
disclosed the closure was due to financial and resource limitations. 
Lastly, in the light of the promising findings from a previous study focusing 
on the effect of lovastatin treatment on a mouse model of NF1 (Li et al., 2005), a 
new approach of targeting FXS has emerged.  The underlying cause of NF1 is an 
exaggerated activity of p21Ras, thus inhibition of p21Ras activity would be 
beneficial and effective in treating NF1.  Lovastatin belongs to the statin family and 
serves as a 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor, 




hypercholesterolemia (i.e., high blood cholesterol), as HMG-CoA reductase serves as 
a rate-limiting enzyme in cholesterol synthesis (Goldstein and Brown, 1990).  
Lovastatin was then recognised as a potent Ras inhibitor via inhibiting Ras 
farnesylation, which in turn limits its ability to attach to the inner cell membrane to 
trigger downstream signalling cascades (Downward, 2003; Johnson et al., 2002).  
Acute administration of lovastatin rescues the audio-genic seizure phenotype in the 
mouse model of FXS, and biochemical assays confirmed its ability to restore the 
excessive protein synthesis downstream of the mGluR-MEK-ERK signalling 
pathway to the WT animals level (Osterweil et al., 2013).  This finding indicates the 
potential therapeutic effect of lovastatin in FXS.  The first clinical trial of lovastatin 
(LovaX) indicates that after 12 weeks of lovastatin treatment, significant 
improvement in aberrant behaviours, communication, and socialisation were noticed 
among 80% of the participants and the treatment was well-tolerated (Caku et al., 
2014).  Meanwhile, lovastatin has been approved by the United States Food and 
Drug Administration for the long-term treatment of familial hypercholesterolemia in 
young children, to prevent the development of cardiovascular diseases in these 
children in their later adulthood (Descamps et al., 2011).  The high tolerance and 
potential therapeutic effect hence makes lovastatin a valuable candidate in the 








1.4 Aims of the thesis 
Based on the clinical and animal models’ findings, loss of FMRP does not 
cause gross abnormalities in the brain.  However, fine structural abnormalities such 
as myelination and dendritic spine abnormalities are reported, but with some caveats.  
For example, no detailed EM data describing the axonal pathology in the mouse 
model of FXS has been published.  Nevertheless, a great deal of the previous reports 
addressing spine abnormalities in FXS used Golgi staining as the way of spine 
visualisation, which was not ideal especially for spine morphological analysis.  
Hence, in this thesis I first examined the axonal profile in the Fmr1−/y mice using 
electron microscopy (Chapter 3). 
Secondly, I used intracellular dye filling as the way of spine visualisation and 
examined the effect of lovastatin on dendritic spine abnormalities in the Fmr1−/y mice 
(Chapter 4).  Lovastatin has been previously reported to rescue some key phenotypes 
in the Fmr1−/y mice, but the effect of lovastatin treatment on spine abnormalities has 
not been addressed previously. 
Lastly, I examined the experience-dependent visual plasticity in two 
commonly used inbred mouse substrains (Chapter 5).  This project is a pilot study to 
identify the visual responses in two C57BL/6 substrains for two reasons: 1) we kept 
the Fmr1−/y mice on these two backgrounds; it is therefore important to characterise 
the visual plasticity of this two substrains, especially since a lack of homeostatic 
plasticity has previously been reported in the C57BL/6JOla substrain.  2) We plan to 




such as SYNGAP1 haploinsufficiency, but SynGAP−/− mice appeared to only breed on 




Chapter 2: Materials and Methods 
2.1 Animals 
All animals were obtained from the animal unit located in the Hugh Robson 
Building (BRR-HRB, The University of Edinburgh) in accordance with the United 
Kingdom Animals (Scientific Procedures) Act 1986 under the authority of Project 
Licences (PPL 60/3631 and PPL 60/4290).  Animals were housed under a 12 hr/12 hr 
light/dark cycle.  All mice had ad libitum access to food and water at all times 
through the experiment unless otherwise specified.  All experiments were performed 
blind to the genotype of the animal.  Only males were used and they were generally 
housed in a group of 4 – 6 mice per cage. 
 
2.2 Genotyping 
Genotyping of animals was obtained by using a thermal cycler (MJ MiniTM, 
Bio-Rad) for conducting polymerase chain reaction (PCR), specific custom-designed 
primers were purchased from MWG Operon (Eurofins, EU).6  For DNA digestion, 
ear notches from experimental animals were put into 1.5 ml Eppendorf tubes and 
digested with 500 µl “tail buffer”7 containing 20 mg/ml Proteinase K (10 µl per 1 ml 
tail buffer) overnight in a water bath with temperature set at 55°C. 
                                                 
6All primers are listed in the Appendix at the end of the thesis. 




Next day, digested tissues were pelleted at maximum speed in a microfuge 
for 10 – 15 min.  Supernatant of each sample (400 µl) was then transferred to a new 
set of Eppendorf tubes containing 400 µl isopropanol, and then DNA of each sample 
was pelleted at maximum speed in a microfuge for 10 min.  Supernatants were 
poured off in the sink, and tubes were then rinsed with 900 µl 70% ethanol.  After 
removing all ethanol in the tubes, 150 µl double distilled water (ddH2O) was added 
to each tube using filter tips.  The lids remained open and samples were resuspended 
at room temperature overnight. 
Next day, samples were then processed differently based on the targeted gene 
of interest.  In general, 1 µl DNA from each sample was mixed with custom-
designed oligonucleotide primers (1 µl of each primer), 6 µl of GoTaq® Green 
Master Mix (Promega, USA), and 2 µl of nuclease-free water, to make a 12 µl final 
product.  All procedures were done on ice and once finished the tubes were then 
transferred to a pre-heated (95°C) thermal cycler for PCR reaction.  For the Fmr1−/y 
mice four sets of primers were used to amplify both the WT allele and the neomycin 
cassette of the knock-out allele.  Specifically, primer pairs 2009/2010 (2009: 5’—
GTG GTT AGC TAA AGT GAG GAT GAT—3’; 2010: 5’—CAG GTT TGT TGG 
GAT TAA CAG ATC—3’, Eurofins MWG Operons) were used to amplify the WT 
allele and primer pairs 162/163 (162: 5’—CCG GTT CTT TTT GTC AAG ACC 
G—3’; 163: 5’—CGG CAG GAG CAA GGT GAG AT—3’, Eurofins MWG 
Operons) were used for the neomycin cassette of the knock-out allele.  Details of 
PCR reaction and cycling settings can be found in the Appendix section.  The final 




(bp) represented the Fmr1 knock-out allele with the neomycin cassette, the other 
band with a size around 500 bp indicated the WT allele.  The PCR products were 
separated on a 1.5% agarose gel containing 1 µl of SYBR® Safe DNA gel stain 
(Thermo Fisher Scientific #S33102) in 1X running buffer (TBE buffer, 50 – 60 ml) 
at 40 V for 35 – 40 min.  A 100 bp ladder was used to mark the size of bands on the 
gel (New England BioLabs # N3231S).  An ultraviolet-transilluminator was then 
used for visualisation of target DNAs. 
 
2.3 Immunohistochemistry 
Mice were anesthetized with sodium pentobarbital prior to transcardial 
perfusion with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde 
(PFA) in 0.1 M phosphate buffer.  Brains were removed and post-fixed in 4% PFA 
overnight at 4°C before being sectioned.  Coronal sections were sliced at 50 µm 
using a vibrating microtome (Leica #VT1000 S) and sections containing the regions 
of interest were first washed with ice-cold PBS several times then incubated with 
blocking buffer containing 5% cold water fish gelatin and 0.5% Triton X-100 in PBS 
for 2 hr at room temperature.  Sections were then washed several times with PBS and 
treated with primary antibodies in blocking buffer for the first day, and then reacted 
with secondary antibodies in blocking buffer on the second day.  Details of 
antibodies used are listed in the corresponding Chapters. 
After several washes with PBS containing 0.1% Triton X-100 (PBST), nuclei 




PBST.  Finally, sections were mounted and coverslipped in VECTASHIELD® 
HardSet (Vector #H-1400, CA, USA) before imaging.  For long-term storage and 
better reservation, sections can be incubated and stored in VECTASHIELD® (Vector 
#H-1000, CA, USA) prior and after confocal imaging. 
 
2.4 Electron microscopy 
Mice were anaesthetised with sodium pentobarbital prior to transcardial 
perfusion with ice-cold PBS followed by 2% PFA and 2.5% glutaraldehyde in 0.1 M 
PB.  Brains were removed and post-fixed in 4% PFA for 2 – 4 h before being 
sectioned in the coronal plane.  All sections were post-fixed in 1% osmium tetroxide 
in 0.1 M PB for 30 min, dehydrated in an ascending series of ethanol, followed by 
propylene oxide and embedded on glass slides in Durcupan resin.  Area of interest 
was cut off from each section and put on a pre-made resin block, secured with 
superglue and left in the hood for 24 – 48 hr before use.  Ultrathin sections (60 nm) 
were cut from regions of interest (1 × 1 mm2) and collected on Formvar-coated grids 
(Agar Scientific), stained with lead citrate in a LKB-Wallac Ultrostainer 






2.5 Stick and stain (intracellular dye filling) 
Mice were sacrificed through transcardial perfusion with ice-cold PBS then 
followed by 4% PFA.  The volume and concentration of PFA needed to be carefully 
monitored as this would affect the dye-filling process dramatically.  Brains were then 
rinsed with ice-cold PBS several times next morning, and quickly sliced into 200 µm 
coronal sections with a vibratome.  Sections containing the region of interest were 
collected into a 24-well plate pre-filled with ice-cold PBS. 
Coronal sections containing the region of interest were placed in a chamber 
on a membranous filter (Millipore #HAWG04700, MA, USA), a “C” shaped weight 
was then put on top to ensure the section remained in position during dye-filling.  
The chamber was filled with ice-cold PBS and was put into a holding stage of the 
upright microscope.  The section was imaged using a 20X water immersion objective 
in PBS.  Microinjection pipettes were pulled from thin walled glass capillaries (1.5 
mm O.D. × 1.17 mm I.D., Harvard Apparatus, MA, USA) and filled with fluorescent 
dyes (Alexa Fluor® 568 Hydrazide, 10 mM made up in ddH2O, Life Technologies 
#A-10437).  They were subsequently backfilled with a conducting solution (0.1 M 
KCl, pH 7.4).  An AgCl2 wire which connected to a pulse generator (Isolated Pulse 
Stimulator, A-M Systems Model 2100, WA, USA) was inserted in the electrode.  An 
earth wire connecting the solution and the pulse generator was used to close the 
circuit.  The electrode was checked to see if regular puffs of dye were emitted under 
fluorescence, then inserted carefully into a cell body without penetrating it.  A given 
cell might require 15 – 20 min to fill depending on its size and fixation using a 




from a single animal.  Cells after filling were post-fixed with 4% PFA for 1 hr then 
rinsed with PBS and stored in mounting medium (VECTASHIELD® antifade 
mounting medium, Vector # H-1000, CA, USA) at 4°C before imaging. 
Sections were rinsed with PBS and nuclei were counterstained with TO-
PRO®-3 iodide (1:1000, Life Technologies #T3605) before mounting with 
VECTASHIELD® HardSet (Vector # H-1400, CA, USA).  An inverted laser-
scanning confocal microscope (Zeiss Axiovert LSM510, Germany) was used to 
acquire images of filled cells.   
 
2.6 Image acquisition and analysis of filled cells 
All confocal images in this thesis were acquired by Nyquist sampling.  
Undersampling often fails to reconstruct the true information of the image.  Although 
theoretically oversampling would have a better resolution to reconstruct the image, 
some obvious drawbacks such as the increase amounts of acquisition time and 
storage space are reported.  Most importantly, oversampling often causes 
photobleaching and ultimately destroys the image.  I used the commonly known 
Nyquist sampling (i.e., the sampling frequency is greater than twice the band width 
of the signal) method to acquire my confocal images in order to reconstruct all the 





Confocal image Z-stacks (0.14 µm per stack) were first deconvolved by using 
the deconvolution software (Huygens Essential, The Netherlands) prior image 
analysis.  NIH ImageJ was used to analyse dendritic spine density and characterise 
spine morphology.  For more detailed spine measurement such as spine head 
diameter and spine length, a commercial image analysis software IMARIS® with 
FilamentTracer plugin (Bitplane, Zurich, Switzerland) was used in order to perform a 
more detailed dendritic structure analysis. 
 
2.7 Western blotting 
Animals were sacrificed via neck dislocation, brains were then quickly 
removed and the region of interest were dissected out from both hemispheres.  All 
procedures were performed in a dissecting dish on ice and filled with ice-cold PBS 
with 10% sucrose.  Dissected tissues were quickly put into 1.5 ml Eppendorf tubes 
which were pre-cooled with dry ice to “snap-freeze” before being stored in a −80°C 
freezer. 
Tissues were homogenised with lysis buffer containing protease and 
phosphatase inhibitors (RIPA buffer: 50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-
100, 0.5% sodium deoxylcholate, 0.1% SDS, 1 mM EDTA, pH 7.4; protease 
inhibitor (EDTA free), Roche #11836170001; phosphatase inhibitor cocktail, 
Calbiochem #524625 (II) and #524628 (IV)).  Protein concentration of homogenised 
tissues were checked by using a protein assay kit (PierceTM BCA Protein Assay Kit, 




(96 wells), pipette 10 µl of each standard or unknown sample replicate into each 
well, and then add 200 µl of the BCA working reagent into each well.  The 
microplate was then put on a plate shaker to mix thoroughly for 30 seconds.  The 
plate was then covered with tin foil and left in 37°C for 30 min for incubation.  
Finally, the microplate was allowed to cool to room temperature prior plate reading.  
Several loading stocks were made based on the plate reading results of protein 
concentration of each sample.  A 50 µl loading stock with a protein concentration of 
0.5 µg/µl (containing 25 µl of 2X Laemmli buffer) was made for each sample and all 
loading stocks were stored in a −80°C freezer prior gel running.  Details of buffers 
used and buffers recipes can be found in the Appendix section (Chapter 8) at the end 
of the thesis. 
Pre-cast gels (Mini-PROTEAN® TGX gels, Bio-Rad #456-1046; 12%) were 
used for all Western blotting experiments in this thesis.  Those pre-made loading 
stocks were heated to 95°C on a heat plate for 5 min prior to gel running.  The first 
and last lane of each gel were loaded with 5 µl of 2X Laemmli buffer only, and one 
lane was loaded with 5 µl of protein ladder (PageRuler® Plus Prestained Protein 
Ladder, 10 to 250 kDa, Thermo #26619) of each gel.  The remaining lanes were then 
loaded with 10 µl loading stock to make the final protein concentration of each lane 
equal to 5 µg.  Gels were running for about 100 min with 100 V before transferring 
to nitrocellulose membranes.  All components were equilibrated in transfer buffer to 
reduce the risk of air bubbles which would impede protein transfer.  The gels were 
transferred to nitrocellulose membranes for 1 hr with 100 mA, then membranes were 




(Odyssey® blocking buffer, Li-COR #927-40000, Cambridge, UK) for 45 min at 
room temperature.  Primary antibodies against the proteins of interest were then 
added into the blocking buffer (with 0.1% Tween-20) at the desired concentration 
and gels were incubated at 4°C overnight.  Membranes were washed thoroughly with 
PBS the next day and incubated with secondary antibodies for 1 hr at room 
temperature in a light-tight box to prevent fading.  Membranes were then washed 
again with PBS for several times and were imaged with an Odyssey Infrared Imaging 
System (Li-COR Odyssey 9120, Cambridge, UK) which equipped with two infrared 
channels (700 nm and 800 nm).  Images of Western blots were then quantified with a 
freeware provided by Li-COR (Image StudioTM Lite, Li-COR). 
Some membranes were blotted several times with different antibodies, in this 
case membranes were incubated in 1X stripping buffer (ReBlot Plus stripping 
solution (10X), Millipore #2504) for 10 – 15 min at room temperature and rinsed 
thoroughly with PBS.  After incubating in blocking buffer for 1 hr, a new primary 
antibody can then be introduced to the membrane following the above process. 
For Western blot results, images gathered via Li-COR Odyssey were 
processed and quantified by using their own software Image StudioTM Lite.  Two 
channels were analysed separately.  For each channel, multiple size-fixed user-
defined region of interests (ROIs) were put on top of each individual lane where 
proteins were shown.  Along that, a small area surrounding each ROI was used as the 
background value for further readout adjustment.  An absolute value was then shown 




was used as a loading control and all values presented were shown as a ratio of 
protein : β-actin. 
 
2.8 Visual evoked potential (VEP) recording in the 
mouse visual cortex 
2.8.1 Electrode implantation 
Mice were anesthetized by inhalation of isoflurane (1.5 – 2% in pure O2).  
Depth of anaesthesia was carefully monitored throughout the whole surgery 
procedure via monitoring the respiration rate and hind-limb pinch withdrawal.  A 
heating plate connected to a thermometer was used at all times during surgery to 
maintain the animal’s body temperature.  A subcutaneous injection of Buprenorphine 
(Vetergesic®; 0.05 mg/kg) was given prior to surgery.  Surgical area was first cleaned 
with iodine and 70% ethanol, then the skull was exposed by removing the hair and 
skin above.  For future head restraint purpose, a steel headpost was affixed to the 
skull at a position anterior to bregma with cyanoacrylate glue.  Two small burr holes 
were drilled in the skull just anterior to bregma and overlaying the prefrontal cortex, 
and another two burr holes were drilled overlaying the binocular visual cortex (3.2 
mm lateral of lambda; 3 mm was used for animals at P28).  Two reference electrodes 
were implanted into the two burr holes anterior to bregma.  Each one of the reference 
electrodes was custom made by soldering a silver wire with a gold wire contact (FST 
#19003-00).  Two tungsten recording electrodes (FHC Tungsten Microelectrode, 




within 0.4 – 0.5 MΩ) were implanted into the two burr holes overlaying the 
binocular visual cortex at a depth of 470 µm (450 µm was used for animals at P28) 
below the cortical surface.  All four electrodes were secured using cyanoacrylate glue 
and then reinforced with dental cement.  Finally, the remaining skull was covered 
with dental cement to form a stable “head cap”.  Animals were put back to their 
home cages and kept warm with a thermal blanket to accelerate recovery and avoid 
death caused by loss of body heat.  Jellies containing 0.5 mg/kg of Buprenorphine 
were given to animals for post-operative pain relief.  Animals were monitored 
frequently for signs of discomfort or infection and allowed at least 24 hr recovery 
before proceeding to habituation and further training.  Animals showing signs of 
infection or significant weight loss after surgery would be removed from further 
experiment and humanely culled. 
 
2.8.2 Habituation and VEP recording 
Animals were allowed to habituate to the head restrain apparatus for 30 min 
at the day prior to further chronic VEP recordings.  To fit the animal into the restrain 
apparatus, its headpost was screwed tight with the apparatus and thus the head of the 
animal remained still but its body could move freely inside the holding cylinder.  The 
animal and the apparatus were then put in front of a CRT monitor at a distance of 20 
cm.  Animals remained still but alert at all times during the recording procedure.  An 
isolated room was used for the VEP recording to minimize the background noise, 




During the habituation process a grey screen was first presented to the animal 
for 100 phase reversals, followed by 300 phase reversals using 0° sine-wave gratings 
of 100% contrast.  Animals showing signs of distress (e.g., squeak, running) were 
first checked and if the distress signs continued animals were returned to their home 
cages temporarily and tested later.  Animals that successfully passed the habituation 
phase were further tested for their basal VEP response at the next day, which 
consisted of 300 phase reversals at a random orientation of 100% contrast.  For long-
term recordings, animals received one recording session per day (60 min maximum) 
for five consecutive days.  Animals showing continuous distress signs during 
recordings were removed from the experiment. 
 
2.8.3 Data acquiring and analysis 
Electrical signals were amplified (1000×) and acquired via a USB board (NI 
USB-6251, National Instruments, TX, US).  Data were first acquired and analysed 
using custom software written in LabView (National Instruments, TX, US) provided 
courtesy of the Maffei Lab (Pisa, Italy) and with the assistance of the Bear Lab (MIT, 
MA, US).  Individual traces were then re-analysed and plotted with MATLAB with 
the script provided by Dr. Aleksander Domanski. 
 The amplitude of VEP was quantified by measuring the trough – peak 
response amplitude, as described previously (Frenkel and Bear, 2004; Sawtell et al., 
2003).  In general, animals were presented around 300 – 500 phase reversals of each 




of a given contrast and orientation) varied depending on animals’ response to the 
presentation.  If VEP responses varied over 15% between trials then additional trials 
were performed until at least 3 successful trials were acquired for each animal. 
 
2.8.4 Post-mortem histological verification 
Animals were humanely culled via cervical dislocation and electrolytic 
lesions were conducted using a 9-V battery (Duracell®).  Brains were quickly 
removed and stored in ice-cold 4% PFA overnight.  Brains were sliced into 50 µm 
coronal sections and rinsed thoroughly with PBS.  Slices were then put on pre-coated 
slides and left in room temperature overnight.  Next day, slides were rinsed with 
ddH2O several times and then put into Nissl staining solution
8 for 5 – 15 min 
followed by several rinses with 70% ethanol.  Slides were then rinsed with 95% 
ethanol containing 0.1% glacial acetic acid, then dehydrated with 100% ethanol for 
10 min.  Finally, slides were rinsed with xylene and then coverslipped with DPX 
(Sigma-Aldrich).  A Leica light microscope was then used for image acquisition. 
 
2.9 Statistics 
Data were analysed with GraphPad Prism (version 6th, GraphPad Software, 
CA, USA), presented as mean ± SEM unless otherwise specified. Student’s unpaired 
                                                 




t-test, Kolmogorov-Smirnov (K-S) test, or analysis of variance (ANOVA) were used 
for statistical analysis as appropriate.  Specifically, Student’s unpaired t-test was used 
when comparing two unpaired groups.  K-S test is a non-parametric and distribution 
free (i.e., making no assumption about the distribution of data) statistical test.  It was 
used when comparing two distribution datasets (e.g., cumulative frequency).  
ANOVA was used when comparing three or more means (groups or variable) for 
statistical significance.  p values were reported and significance was set when p < 
0.05 (marked as *; ** when p < 0.01 and *** when p < 0.001, respectively).  A free 
statistical software G*Power was adopted to perform Power analysis where 





Chapter 3: White Matter Abnormalities in the 
Fmr1−/y Mice 
3.1 Introduction 
3.1.1 Evidence for a role of altered WM tracts in FXS 
Brain white matter is made up of axon tracts that connect distant structures.  
The white appearance results from the axons being coated with myelin, which is 
essential for maintaining the stability and fidelity of signal conduction in the brain.  
For example, white matter abnormalities have been linked to seizures or altered 
sensory sensitivities, as well as altered cognitive capabilities—features commonly 
associated with FXS and autism (Fields, 2008; Levy et al., 2009).  Yet, while 
numerous studies have focused on the effects of the loss of FMRP in brain grey 
matter, whether white matter abnormalities influence the fragile X pathophysiology 
remains unclear. 
Altered brain connectivity is key to the pathophysiology of ASDs/ID and 
related neurodevelopmental disorders.  Early brain imaging studies indicated white 
matter tract differences between autistic patients and age-matched normal controls.  
For example, one study using DTI showed that the FA values were reduced in 
several brain regions in young patients with autism (control group: 13.4 ± 2.8 years; 
autism group: 14.6 ± 3.4 years), including the anterior cingulate and subgenual area, 




targeting teenagers and young adults also found the volume of CC was significantly 
reduced in the autism group (Alexander et al., 2007). 
Because most people with FXS also develop ASDs, researchers looked for 
white matter abnormalities in FXS using brain imaging and post-mortem autopsy.  
The Reiss laboratory published a series of brain imaging studies targeting different 
population of individuals with FXS to examine the white matter abnormalities in 
FXS compared to unaffected individuals.  A longitudinal MRI study focusing on 
young boys (1 – 3 y/o) with FXS showed increased WMV in bilateral fronto-striatal 
and medial temporal regions, indicated an early onset white matter abnormalities in 
these areas in individuals with FXS (Hoeft et al., 2010).  Intriguingly, WMV was 
significantly increased over time in some other regions including the ventral 
prefrontal tracts and posterior temporal regions (Hoeft et al., 2010).  The increased 
WMV over time in these tracts along with the accumulating evidence showing that 
FMRP can regulate axonal development (Bureau et al., 2008; Tessier and Broadie, 
2008) and myelination (Pacey et al., 2013; Wang et al., 2004), suggested that white 
matter abnormalities in these tracts in FXS were result from an axonal pathology due 
to the loss of FMRP in these areas rather than a secondary connectional 
dysregulation between brain regions.  Meanwhile, the size of the posterior vermis 
was significantly reduced in both males and females with FXS compared to healthy 
controls (Mostofsky et al., 1998).  The posterior vermis is located in the cerebellum 
and mainly involves in motor coordination and receives information from the spinal 
cord about proprioception.  Moreover, recent studies identified the connection 




suggests a role of cerebellum in cognitive function (Middleton and Strick, 1994; Paul 
et al., 2009). 
A further study using DTI, which examined females with FXS, revealed that 
the FA values in white matter in frontostriatal pathways and parietal sensory-motor 
tracts were reduced (Barnea-Goraly et al., 2003).  Another DTI study in young males 
(range from 1 year 7 months to 3 year 10 months) indicated that the FXS patients had 
an increased relative fibre density after DTI reconstruction in the left ventral 
frontostriatal pathway, which the author claimed the greater relative fibre in this area 
was associated to lower IQ (Haas et al., 2009).  Other labs also published some 
studies to explore the white matter abnormalities in FXS.  For example, Villalon-
Reina et al. reported that FA was lower in the internal capsule, posterior thalami, and 
precentral gyrus in girls with FXS (Villalon-Reina et al., 2013).  Recently, a DTI 
study using individuals with FXS and IQ-matched controls (average IQ: 70, all FXS 
negative) showing that an increased FA and reduced radial diffusivity values were 
found in the inferior longitudinal, inferior fronto-occipital and uncinate fasciculi in 
FXS group.  There was also an increased FA in the CC in FXS group (Green et al., 
2015). 
 
3.1.2 FMRP targets mRNAs encoding WM proteins 
FMRP is an mRNA binding protein that has numerous functions, including 
transporting specific mRNAs from the nucleus to the cytoplasm as well as regulating 




example is the mRNA coding for MBP; FMRP binds MBP mRNA in its 3’ UTR and 
suppresses its translation in vitro, suggesting that loss of FMRP could lead to 
alterations in myelination (Brown et al., 1998; Wang et al., 2004).  Indeed, findings 
from several human brain imaging studies are consistent with this possibility.  For 
example, one DTI study revealed a decrease in myelination in fronto-striatal 
pathways, as well as parietal sensory-motor tracts in female teenagers diagnosed with 
FXS compared to healthy controls (Barnea-Goraly et al., 2003).  DTI showed an 
increase of white matter fibre density in left ventral fronto-striatal pathway, while the 
fractional anisotropy between individuals with FXS and control groups remained the 
same (Haas et al., 2009).  However, due to the varieties of imaging techniques and 
different subject populations, the precise mechanism of white matter abnormalities in 
FXS still remains unclear. 
 
3.1.3 Evidence for WM abnormalities in a mouse model of 
FXS 
The Fmr1−/y mice does not show gross abnormalities regarding myelination of 
the white matter tract (The Dutch-Belgian Fragile X Consortium, 1994).  Pacey et al. 
showed an early loss of MBP (up to 80%), reduced myelinated axons and thinner 
myelin sheaths in the cerebellum of the Fmr1−/y mice (Pacey et al., 2013).  Although 
these phenomena seemed only to happen in early developmental stages (P7) as they 
were later corrected by P30 through development.  The Fmr1−/y mice also showed a 




reduced myelination in early development.  However, another study suggested that 
losing FMRP did not alter the gross MBP expression in cerebral hemisphere 
homogenates from P8, P12, and P15.  MBP level in homogenates detected by 
Western blots was also not altered during active myelination period (P21) nor after 
active myelination (6 weeks, 5 months) between the Fmr1−/y and WT mice 
(Giampetruzzi et al., 2013).  Ellegood et al. demonstrated that brain white matter of 
the Fmr1−/y mice was not significantly different compared to WT mice at P30 using 
both DTI and computed tomography (Ellegood et al., 2010).  However, a decrease of 
cerebellum volume was reported by using MRI.  More specifically, the volume of the 
arbor vita of the cerebellum was significantly reduced in the Fmr1−/y mice (Ellegood 
et al., 2010). 
One consequence of abnormal white matter development could be impaired 
action potential propagation, possibly leading to alterations in the timing of synaptic 
signalling, a key regulator of spike-timing-dependent plasticity (STDP).  This may 
explain numerous studies in the Fmr1−/y mice that suggest loss of FMRP leads to 
alterations in synaptic plasticity, including abnormal STDP (Bagni and Greenough, 
2005; Comery et al., 1997; Desai et al., 2006; Harlow et al., 2010; Irwin et al., 2001; 
Meredith et al., 2007; Nimchinsky et al., 2001; Till et al., 2012). 
To determine whether loss of FMRP in mice would lead to white matter or 
axon fibre abnormalities, I used MBP immunohistochemistry to examine the general 
distribution of MBP in the CC and the IC of the Fmr1−/y mice.  CC and IC were 
chosen due to several previously mentioned imaging studies had already found 




et al., 2015; Villalon-Reina et al., 2013).  Next, serial EM images were taken to 
examine the fine microstructures of axon fibres in the CC area to provide evidence of 
any myelination or axonal differences in the mouse model of FXS.  Our data 
suggested that there was a mild but significantly increase of axon fibre diameter in 
the Fmr1−/y mice compared to WT controls.  Thus, we then used a computer 
simulation software NEURON to predict the axonal conduction and tested whether 
the increase of axonal fibre diameter we observed in the Fmr1−/y mice would lead to 
an increase in axonal conduction velocity. 
Table 3-1.  Summary of myelin sheath detection through various methods during development. 
 P3 P5 P7 P10 P14 P21 P28 





↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑↑ 


















+: indicates myelin positive 
−: indicates no signs of myelin sheaths 
↑: indicates an increased number 
LFB: Luxol fast blue stain; used to detect lipoproteins  demonstrate myelin under 
light microscopy 
OLGs: oligodendrocytes 
CC: corpus callosum 
EM: electron microscopy 






3.2 Materials and methods 
3.2.1 Animals 
The Fmr1−/y mice originally obtained from Neuromice.org (Northwestern 
University, Evanston, IL, USA) were backcrossed more than twenty generations onto 
the C57BL/6JOla background (Harlan Labs, Bicester, UK).  Fmr1−/y mice were used 
as experimental groups and WT littermates were used as controls in this Chapter.  
For the immunohistochemical staining experiments, animals at P14 – P15 and P20 – 




Mice were anesthetized with sodium pentobarbital prior to transcardial 
perfusion with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde 
(PFA) in 0.1 M phosphate buffer.  Brains were removed and post-fixed in 4% PFA 
overnight at 4°C before being sectioned.  Coronal sections were sliced at 50 µm 
using a vibrating microtome (Leica #VT1000 S) and sections containing the dorsal 
hippocampus were first washed with ice-cold PBS several times then incubated with 
blocking buffer containing 5% cold water fish gelatin and 0.5% Triton X-100 in PBS 
for 2 hr at room temperature.  Sections were then washed several times with PBS and 
treated with primary antibodies specific for MBP (1:400, rat anti-MBP, AbD Serotec 
#MCA409S) and neurofilament-heavy chain (NF-H) (1:3000, chicken anti-NF-H, 




secondary antibodies (1:200, Alexa Fluor® 488 donkey anti-rat IgG, Life 
Technologies #A21208; 1:200, goat anti-chicken IgG biotin conjugated, Millipore) in 
blocking buffer on the second day.  After several washes with PBS containing 0.1% 
Triton X-100 (PBST), sections were further treated with streptavidin-568 (1:200, 
Alexa Fluor® 568 conjugate, Life Technologies #S-11226) in blocking buffer and 
nuclei were counterstained by TO-PRO®-3 iodide (1:1000, Life Technologies 
#T3605) in PBST.  Finally, sections were mounted and coverslipped in 
VECTASHIELD® HardSet (Vector #H-1400, CA, USA) before confocal imaging.  
For long-term storage and better section preservation, sections were incubated and 
stored in VECTASHIELD® (Vector #H-1000, CA, USA) prior and after confocal 
imaging. 
 
3.2.3 Electron microscopy 
Mice were anaesthetised with sodium pentobarbital prior to transcardial 
perfusion with ice-cold PBS followed by 2% PFA and 2.5% glutaraldehyde in 0.1 M 
PB.  Brains were removed and post-fixed in 4% PFA for 2 – 4 h before being 
sectioned in the coronal plane.  All sections were post-fixed in 1% osmium tetroxide 
in 0.1 M PB for 30 min, dehydrated in an ascending series of ethanol, followed by 
propylene oxide and embedded on glass slides in Durcupan resin.  Area of interest 
(CC in this case) was cut off from each section and put on a pre-made resin block, 
secured with superglue and left it in the hood for 24 – 48 hr before use.  Ultrathin 
sections (60 nm) were cut from regions of the CC (1 × 1 mm2) where close to the 




Scientific), stained with lead citrate in a LKB-Wallac Ultrostainer (Gaithersburg, 
MD, USA) and imaged using a Philips CM120 BioTwin transmission electron 
microscope. 
 
3.2.4 NEURON simulation 
The free NEURON software was obtained through its official webpage 
(https://www.neuron.yale.edu/neuron/).  Data simulation was conducted with Dr. 
Aleksander Domanski.  Briefly, we generated a model neuron based on values 
acquired from our EM experiments, and the axonal conduction velocity and 
conduction latency were modelled by inputting axon fibre diameter and myelin 
sheath thickness into the model neuron. 
 
3.2.5 Image analysis and statistics 
NIH-ImageJ (NIH, Bethesda, USA) was used for general image analysis and 
axonal measurement.  Six parameters were measured for each myelinated axon from 
the EM images taken, these parameters were axon diameter (AD), axon outer 
diameter (OD), axon inner diameter (ID), myelin sheath thickness, g-ratio, and X-






Figure 3-1.  An example figure of how different axonal measurements were made. 
A typical myelinated axon (without gaps) is shown in (A), where axon diameter is marked as (a) and 
axon outer diameter is marked as (b).  An axon with gaps is shown in (B), where axon diameter is 






I specifically measured the “inner” and “outer” diameter of an axon (for a 
normal axon without any gaps, the inner axon diameter = 0) in order to get an 
accurate measurement for the g-ratio calculation. g-ratio of the axon was calculated 
as: 
 
However, for those axons with gaps I needed to get around of those gaps so 
the modified g-ratio for the axon in (B) would be: 
 
In order to separate this modified g-ratio I called it “X-ratio” in this thesis, for 
a normal axon without gaps the g-ratio and X-ratio would be the same.  Finally, the 
myelin sheath thickness of the axon in (A) would be calculated as: 
 
And for axon in (B), the myelin sheath thickness would be calculated as: 
 
All statistics in this Chapter were conducted by using GraphPad Prism 
(version 6th, GraphPad Software, CA, USA), unpaired Student’s t-test, K-S test, or 
ANOVA were used for statistical analysis as appropriate.  Average data were 




when p < 0.01 and *** when p < 0.001, respectively).  A free statistical software 
G*Power was adopted to perform Power analysis as where appropriate (Faul et al., 




3.3.1 Loss of FMRP did not cause gross changes in MBP 
labelled structures in the mouse CNS. 
To look at the effect of loss of FMRP on gross myelination I first compared 
the myelin basic protein (MBP) expression in the Fmr1−/y mice and its WT littermate 
controls using immunofluorescence staining at two developmental stages: juvenile 
(P14 – 15) and one week after that (P21 – 22).  MBP expression was widely used as 
a way to examine the myelination process in the brain.  In fact, the protein itself 
plays a very important role in myelination as it is a major constituent of the myelin 
sheath.  Our first aim was to see whether MBP expressed differently due to the loss 
of FMRP in the Fmr1−/y mouse.  Since MBP is the key component of myelination, 
we therefore chose two big white matter tracts in the brain to start with, in this case 
we started with the CC and the IC. 
At the two developmental stages we chose, no gross MBP expression was 
changed in the area of CC or IC (Fig. 3-2).  This agreed well with previous reports 




of white matter tract morphologies at these developmental stages (Giampetruzzi et al., 
2013; Pacey et al., 2013). 
 
Figure 3-2.  Representative MBP expression in the IC and CC area was identical between the 
Fmr1−/y mice and WT controls. 
MBP expression in the IC and CC area at P15 (A) and P21 (B) of the Fmr1−/y mice and WT controls 
are shown.  MBP was labelled in green and nuclei were counter-stained with blue TO-PRO-3 staining.  
The MBP-stained axon fibres did not show a gross difference between the two genotypes at both IC 
and CC.  Note that MBP-labelled axon fibres were not only exist in the CC but also reach out to deep 
cortical layers in the CC area (bottom figures in both (A) and (B)).  Scale bar: 200 μm. 
 
I next examined MBP expression in the cortex at the above developmental 
stages, as a previous study reported changes in the pattern of cortical axonal 
arborisation and branching in the Fmr1−/y mice (Bureau et al., 2008).  I found no 
evidence of gross changes of MBP expression in the WM beneath or within the 




(Fig. 3-3), indicating no delay in the developmental progression of myelination in the 
cortex. 
 
Figure 3-3.  Representative MBP expression in the somatosensory cortex was identical between 
Fmr1−/y and WT mice. 
MBP expression in the somatosensory cortex did not show gross changes between the Fmr1−/y mice 
and WT controls at P15 (A) and P21 (B).  MBP was labelled in green and nuclei were counter-stained 
with blue TO-PRO-3 staining.  MBP expression in the somatosensory cortex at P15 (A) showed a 
dense staining in layer VI and CC (at the bottom of the graph) and reach out to deeper layers and 
mostly stop at layer IV, no gross changes (qualitatively) were noticed between the two genotypes of 
animals. At P21 (B), the amount of MBP staining was increased and again denser staining was noticed 
in layer VI, however, MBP-stained fibres reached out to layer I in both genotypes, and occupied more 






3.3.2 Number of myelinated axons in the CC is comparable in 
the Fmr1−/y and WT mice. 
I next performed electron microscopy on CC from WT and Fmr1−/y mice and 
to determine whether losing FMRP in mice at early developmental stages (P14 – P15) 
and young adulthood (P35 – P37) would lead to changes of white matter tracts or the 
myelination status of these tracts. 
A series of EM images in the area of CC from both Fmr1−/y and WT mice 
were taken (Fig. 3-4) and the density of myelinated/unmyelinated axons and the 
myelin sheath thickness of myelinated axons were measured by using NIH-ImageJ.  
Our data showed that the density of myelinated axons were comparable between the 
two genotypes in the CC at P14 and P35 (Fig. 3-5B), however, the density of 
myelinated axons were significantly increased in both the Fmr1−/y and WT animals 





Figure 3-4.  Representative EM images of myelinated/unmyelinated axons in the CC from the 
Fmr1−/y and WT animals at different developmental ages. 
Representative EM images of axons in the CC from the Fmr1−/y and WT animals are shown here.  
Myelinated axons were surrounded with myelin sheaths (dark, ring-shape structures that surrounded 
the axons), and the number of myelinated axons were clearly more at P35 then P14 regardless of 






Figure 3-5.  Density of myelinated axons remain unaltered in the Fmr1−/y and WT mice. 
A representative EM image of myelinated axons in the CC from a WT mouse at P35 is shown here 
(A).  The density of myelinated axons in the CC from Fmr1−/y mice and WT controls at P14 – 15 and 
P35 – 37 are shown in (B).  WT: n = 4; Fmr1−/y: n = 5.  Scale bar in (A): 1 μm. 
 
No significant differences in the number of myelinated axons were found 
between the two genotypes at P14 – 15 (Fig. 3-5B, p = 0.2771, unpaired two-tailed 
Student’s t-test) nor at P35 (Fig. 3-5B, p = 0.069, unpaired two-tailed Student’s t-
test; Power = 0.46, at least 8 WT and 10 Fmr1−/y mice will be needed if aiming to 
reach 0.8 in Power).  The density of myelinated axons was significantly increased for 
animals of both genotypes at the age of P35 than P14 (Fig. 3-5B, WT P14 and P35: p 






3.3.3 The axons with “gaps” were identical between the 
Fmr1−/y mice and WT controls. 
Interestingly, a subpopulation of the myelinated axons demonstrated clear 
“gaps” adjacent to the membrane of the axon or between the axon and its myelin 
sheath (Fig. 3-6).  Thus, I first calculated the proportion of these gaps-containing 
axons to determine if there was a difference between the two genotypes.  There was 
no significant difference between the Fmr1−/y mice and WT controls when 
comparing the percentage of gaps-containing axons (Fig. 3-7, p = 0.4367, unpaired 
two-tailed Student’s t-test).  Then I measured the size of these gaps and tried to 
determine whether these gaps would affect the actual size of the axons.  I found these 
gaps were relatively consistent in size (Fig. 3-8C) and did not alter the overall 






Figure 3-6.  Representative EM images of myelinated axons (with or without gaps) in the CC 
from a WT mouse at P35. 
Axons with gaps were noticed throughout the EM images I took regardless of genotypes.  Gaps can 
happen inside an axon or sit between an axon and its myelin sheath.  Axons with gaps are indicated by 






Figure 3-7.  Percentage of axons containing gaps in the Fmr1−/y mice and WT controls. 
No difference between the Fmr1−/y and WT mice was noticed regarding the constitution of axons with 






Figure 3-8.  The gap sizes were identical between the Fmr1−/y mice and WT controls. 
Two representative EM images showing an axon without gaps (A) and an axon with gaps (B) are 
presented, respectively.  Note that these gaps can either sit inside the axon or in between the axon and 
its myelin sheath.  The proportion of these gap size is presented in (C), and the arrow indicates a 
discontinued-break in the X axis between 0.1 μm and 0.2 μm.  WT: n = 4; Fmr1−/y: n = 5. 
 
The cumulative frequency of axon diameter of both genotypes remained 
unaltered at P35 (Fig. 3-9B, p = 0.3291, K-S test).  Similarly, the cumulative 
frequency of the gap size was also unaltered between the two genotypes (Fig. 3-9D, 





Figure 3-9.  The gap size did not alter the overall distribution of the diameter of axon fibres in 
the Fmr1−/y mice and WT controls at P35. 
The distribution of axon diameter in booth genotypes at P35 is shown in (A) and the cumulative 
frequency of the diameter of axon fibres of the Fmr1−/y mice and WT controls is shown in (B).  The 
distribution of gap size in both genotypes is shown in (C) (the arrow indicates a discontinued-break in 
the X axis between 0.1 μm and 0.2 μm), and the cumulative frequency of the gap size of both 








Since the gaps located between an axon and its myelin sheath would lead to 
an “increase” of estimates of axon outer diameter, and hence skew the estimates of 
the g-ratio, I devised a second ratio, here called the “X-ratio” to generate an 
alternative measurement of the ratio of myelin sheath thickness to axon diameter.  
Considering that the gap size could have a direct impact on several measurements 
especially the axon outer diameter and g-ratio, I calculated the correlation between 
the gap size and the axon diameter, myelin sheath thickness, g-ratio, and X-ratio.  
Our results suggested that the gap size was correlated with the axon diameter in both 
genotypes (Fig. 3-10A, WT: p < 0.0001, R2 = 0.26; Fmr1−/y: p < 0.0001, R2 = 0.16), 
and was also correlated with the X-ratio in both genotypes (Fig. 3-10D, WT: p < 
0.0001, R2 = 0.26; Fmr1−/y: p < 0.0001, R2 = 0.12).  However, the gap size was not 
correlated with either the myelin sheath thickness (Fig. 3-10B, WT: p = 0.101, R2 = 
0.02; Fmr1−/y: p = 0.2364, R2 = 0.01) or the g-ratio (Fig. 3-10C, WT: p = 0.97, R2 < 





Figure 3-10.  The correlation between the gap size and the axon diameter, myelin sheath 
thickness, g-ratio, and X-ratio. 
A correlation was found between the gaps and axon diameter, and there was also a correlation 
between the gaps and the X-ratio in both genotypes.  No correlation was found between the gaps and 





3.3.4 No gross changes besides an increase in axon diameter 
in the CC of the Fmr1−/y mice at P35. 
I next asked whether loss of FMRP would affect the diameter of axon fibres 
or the extent of myelination at P35.  Animals at the age of P14 – P15 were not 
included as there were few myelinated axons at this age (Fig. 3-5B).  I quantified the 
axon diameter, axon outer diameter (including the thickness of its myelin sheath), g-
ratio, X-ratio, myelin sheath thickness, and gap size from EM images of CC from the 
Fmr1−/y and WT mice (Fig. 3-11).  Comparison of the total number of myelinated 
axons between Fmr1−/y and WT littermates did not reveal any significant effects of 
genotype (Fig. 3-5B).  Whereas axon diameter was significantly enlarged in the 
Fmr1−/y mice compared to WT controls at P35 (Fig. 3-11A, p = 0.03, unpaired two-
tailed Student’s t-test; Power = 0.68, at least 5 WT and 7 Fmr1−/y mice will be 
needed if aiming to reach 0.8 in Power), the outer diameter, myelin sheath thickness, 
and gap size of the axons remained unchanged between the two genotypes (Fig. 3-
11B, p = 0.084; Fig. 3-11E, p = 0.89; Fig. 3-11F, p = 0.396, unpaired two-tailed 
Student’s t-test).  Interestingly, the difference in axon diameter resulting from the 
loss of FMRP did not affect the g-ratio or X-ratio of the Fmr1−/y mice (Fig. 3-11C, p 
= 0.068 and Fig. 3-11D, p = 0.149, unpaired two-tailed Student’s t-test).  The 
proportion of axons with gaps were also not different between the two genotypes 
(Fig. 3-11G, p = 0.799 and Fig. 3-11H, p = 0.437, unpaired two-tailed Student’s t-
test).  Together, these findings indicate that loss of FMRP may not affect myelination 





Figure 3-11.  Different measurements of axons of the Fmr1−/y and WT mice at P35. 
Several parameters of axonal measurement were plotted with the data obtained from EM images of 
both the Fmr1−/y and WT mice at P35.  Axon diameter (A), outer diameter an axon (B), g-ratio (C), X-
ratio (D), myelin sheath thickness (E), the size of a gap (F), number of axons with gaps (G), and the 
proportion of axons with gaps of all axons (H) are presented and unpaired Student’s t-test was used 
for each individual graphs.  n = 4 for WT and n = 5 for Fmr1−/y. 
 
3.3.5 Computational models of axonal transduction suggest 
that loss of FMRP might increase the conduction 
velocity of axons. 
I then asked whether the increase in axon diameter in the Fmr1−/y mice might 




in the simulation software NEURON to the values measured in the Fmr1−/y and 
control littermates I was able to predict conduction velocity in the myelinated axons 
of a model neuron (Fig. 3-12).  This modelling predicted that the conduction latency 
in the Fmr1−/y mice would be significantly shorter than the WT animals (Fig. 3-13A, 
p = 0.04, unpaired two-tailed Student’s t-test; Power = 0.63, at least 6 WT and 8 
Fmr1−/y mice will be needed if aiming to reach 0.8 in Power), suggesting that the 
increase of axon diameter in the Fmr1−/y mice impacts axonal conduction.  However, 
the axon conduction velocity simulated from the program was not significantly 
different between the Fmr1−/y and WT mice (Fig. 3-13B, p = 0.073, unpaired two-
tailed Student’s t-test).  Since conduction latency and axon conduction velocity 
should be directly linked, I was surprised by this result as I would have predicted the 
velocity would also significantly increase in the Fmr1−/y animals compared to 
controls, although we did see that the simulated axon conduction velocity was 
increased (but not significantly) in the Fmr1−/y animals (Fig. 3-13B). 
One thing that will also affect the axon conduction velocity is g-ratio, which 
indicates the myelination status of axons.  We did not see any differences of g-ratio, 
X-ratio, and even myelin sheath thickness between the Fmr1−/y and WT animals (Fig. 
3-11C, 3-11D, and 3-11E), suggesting that the increase of axon conduction velocity 
in the Fmr1−/y animals might be due to the increase of axon diameter only rather than 





Figure 3-12.  The working environment overview of the simulation software NEURON. 
 
 
Figure 3-13.  The NEURON simulation results of conduction latency and velocity of axons from 
the Fmr1−/y and WT animals at P35. 
Simulation of axonal conduction latency from the Fmr1−/y and WT animals is shown in (A), axonal 




results of conduction velocity between the two genotypes is shown in (B), and there is no difference 
between the two genotypes.  WT: n = 4; Fmr1−/y: n = 5. 
 
3.4 Discussion 
3.4.1 No gross WM abnormalities in Fmr1−/y mice. 
Together, my current data show that the axon diameter of the Fmr1−/y mice 
was mildly but significantly larger than WT control animals at P35, which could lead 
to an increase of axonal conduction velocity as suggested by our neuron modelling.  
This suggested a potential mechanism underlying the altered spike-timing-dependent 
plasticity (STDP) in the Fmr1−/y mice reported by other labs (Desai et al., 2006; 
Meredith et al., 2007) and offers a new perspective on the cause of intellectual 
disabilities in FXS and related disorders focusing on white matter. 
From the immunohistochemical staining experiments I did not notice any 
gross changes of MBP expression in the somatosensory cortex, CC, nor IC; which 
agreed well with some previous reports suggesting that losing FMRP did not cause a 
fundamental change of white matter tract morphologies (Giampetruzzi et al., 2013; 
Pacey et al., 2013).  However, some former MRI and DTI work did show some 
interesting findings (summarised in Table 1-1) when they examined the white matter 
tracts between individuals with FXS and healthy controls (Barnea-Goraly et al., 2003; 
Green et al., 2015; Haas et al., 2009; Hoeft et al., 2010; Mostofsky et al., 1998).  




impact on the white matter tract morphologies or, more specifically, the axon fibre 
morphology of these tracts as suggested by my current findings. 
We found that there was no difference of the total number of myelinated 
axons between the Fmr1−/y and WT mice at P35 through examining the EM images 
acquired from both genotypes (Fig. 3-5B).  A previous report suggested that there 
was a delay in myelination in the cerebellum of the Fmr1−/y mice at early postnatal 
ages (P7), the Fmr1−/y mice then caught up with myelination at P15 and this delay 
between the Fmr1−/y and WT mice was no longer evident (Pacey et al., 2013).  This 
may explain the result we observed in the CC, as by P35 the myelination process is 
mostly completed in the mouse CNS (Vincze et al., 2008). 
 
3.4.2 An increase of axon diameter might lead to an increase 
of conduction velocity. 
An increase of fibre diameter can be directly related to an increase of axonal 
conduction velocity, as for a given g-ratio in a group of myelinated axons, the bigger 
the axon diameter the faster the conduction velocity for that axon.  This nearly linear 
relationship between the axon diameter and conduction velocity has been proposed 
and examined at the late 1930s by Hursh (Hursh, 1939) and later on Rushton 
(Rushton, 1951).  However, in Rushton’s work he suggests that “1 μm” is a critical 
number: for axon fibre diameter above 1 μm “myelination increases conduction 
velocity”, below this value “conduction is faster without myelination”.  This may 




are below 1 μm in diameter, therefore, there are likely other factors need to be taken 
into consideration when identifying the relationship between axon diameter and 
conduction velocity.  Taking the CC as an example, axon diameter in mice callosal 
regions varies from 0.1 – 2 μm, in rabbits from 0.05 – 1.84 μm, in cats 0 – 3.5 μm, 
and 0.1 – 6 μm for monkeys (for a comprehensive review, see Olivares et al., 2001).  
The estimated conduction velocity is relatively similar between mice and rabbits 
(mice: 1.2 m/s; rabbits: 0.85 m/s), but it is faster in cats (12 m/s) than in monkeys 
(6.86 m/s) despite the observation that the axon diameter is larger in monkeys 
(Innocenti et al., 1995; Olivares et al., 2001).  Thus, the size of axon diameter would 
not be the only factor that determines conduction velocity. 
Our current simulation predicted that the conduction latency would be 
significantly reduced in the Fmr1−/y mice compared to the WT controls, however the 
conduction velocity would not be significantly different between the two genotypes, 
although it was slightly increased in the Fmr1−/y mice.  The conduction velocity of a 
myelinated axon increases directly with the diameter of the fibre, doubling the 
diameter gives a doubling of the rate; in those unmyelinated axons, the velocity 
increases with the square root of the axon diameter (i.e., the rate would only be 
doubled if the axon is four times larger) (Hildebrand et al., 1993).  However, 
numerous factors should be taken into account when calculating the conduction 
velocity besides axon diameter and myelination.  The intermodal distance, g-ratio, 
and nodal properties will also affect the conduction velocity, however not as 
dramatically as the previous two parameters (Waxman, 1980).  One thing might also 




sampling (Aboitiz and Montiel, 2003; Olivares et al., 2001).  Interestingly, axons 
connecting to higher order brain regions such as the prefrontal and frontal areas tend 
to be smaller in size, poorly myelinated and with a slow conduction speed and are 
mainly concentrated in the genu part of the CC (i.e., anterior pole of the CC); on the 
contrary, axons with larger calibre, highly myelinated and with a fast conduction 
speed are concentrated in the body part of the cerebellum, which is consisted of 
fibres that connect visual and somatosensory cortices (Aboitiz and Montiel, 2003; 
Aboitiz et al., 1992).  These regional differences in the CC are best characterised in 
primates.  In rodents, no gross changes of fibre calibre of the CC was noticed, at least 
not in the posterior part of the CC (Olivares et al., 2001).  All the tissues we sampled 
for EM were acquired from the CC close to the midline margin with a size of 1 × 1 
mm2.  In this case we would expect most of the axons we measured would be 
originated from the same region of the CC. 
 
3.4.3 The gaps were unlikely to be artefacts, but more likely 
to be some yet-unknown microstructures. 
The gaps we observed in many myelinated axons were unusual and have not 
been reported previously (Fig. 3-6).  These gaps are unlikely to be an artefact during 
our EM preparation or the imaging process for mainly two reasons: 1) 50% of the 
tissues were handled and processed by me, and one senior EM technician assisted me 
with the rest.  We were both blind to the genotypes and these gap-containing axons 




in this field, unfortunately none of them could give us a clue about these gaps, but 
they all agreed these were not artefacts.  Finally, if these gaps were artefacts, we 
would expect they expressed evenly in the same batch of samples; however, our data 
showed that only some of the images contained these gap-containing axons, again 
suggested that these gaps were not artefacts. 
The fact that these gaps spread either inside the axon or sit between the axon 
and its myelin sheath makes it hard to interpret what is their function and 
physiological role, especially when it is not mentioned in literatures previously.  Our 
best assumption of this gap-like structure is the Schmidt-Lanterman clefts (also 
known as myelin incisures or Schmidt-Lanterman incisures) as the morphology looks 
similar and the fact that it forms a connection between the cell cytoplasm internal 
and external to the myelin sheath.  However, the Schmidt-Lanterman clefts only 
persists in the PNS (for a detailed review, see Ghabriel and Allt, 1981).  We have no 
clue whether the gaps we observed are the counterparts of the Schmidt-Lanterman 
clefts in the CNS.  And the physiological roles of these gaps and the developmental 
distributions of them remains unclear.  Despite of our lack of understanding of the 
gaps, the increase of axon diameter in the Fmr1−/y mice was independent of the gaps 
as we found no significant differences of myelin sheath thickness, g-ratio, and the X-
ratio between the two genotypes (Fig. 3-11).  And the gap-containing axons were no 
difference between the Fmr1−/y and WT mice, suggesting that these gaps were some 
yet-unknown structures during normal white matter development in the CNS. 
In summary, we found no gross changes of myelination and the number of 




well with previous findings that losing FMRP did not alter myelination in the brain.  
Further analysis revealed an increase of axon diameter in the Fmr1−/y mice, and our 
simulation model suggested that the magnitude of the increase could lead to a higher 
conduction velocity in the Fmr1−/y mice.  These current findings offered a new 
insight into how STDP was altered in the loss of FMRP, possibly through an 
alteration of the axon diameter and eventually resulted in a disrupted conduction 
velocity in certain brain regions such as the CC.  In the near future, I plan to measure 
the latency between stimulation and the elicited afferent fibre volley, and with a 
known distance between the stimulation site and recording site (marked with 
biocytin) I will be able to estimate the conduction velocity of the CC in the Fmr1−/y 
mice in vitro.
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Chapter 4: The Effects of Lovastatin on 
Dendritic Spine Abnormalities in FXS 
4.1 Introduction 
4.1.1 Dendritic spine abnormalities in FXS 
Fragile X syndrome was first described by Martin and Bell in 1943 (Martin 
and Bell, 1943).  Seventy years of clinical research has described several key FXS 
phenotypes which are commonly expressed among most of the affected individuals, 
such as an elongated face, macroorchidism, intellectual disability, epilepsy, and 
autistic behaviours (Bowen et al., 1978; Hatton et al., 2006; Kooy, 2003; Musumeci 
et al., 1991; Penagarikano et al., 2007; Turner et al., 1975).  Post-mortem 
examination of FXS patients did not reveal any gross changes in the brain compared 
to healthy individuals (Reyniers et al., 1999).  Several human post-mortem studies 
indicated that there was an increase of immature long/thin dendritic spines in the 
individuals with FXS (Hinton et al., 1991; Irwin et al., 2001, 2000; Rudelli et al., 
1985; Wisniewski et al., 1991).  However, the small sample size in some studies and 
various developmental stages and brain areas of sampling made the results hard to 
interpret. 
The FXS mouse model recapitulates most of these phenotypes (Comery et al., 
1997; Irwin et al., 2002; Nimchinsky et al., 2001; The Dutch-Belgian Fragile X 
Consortium, 1994), which offers a great opportunity for researchers to explore the 
pathological symptoms and the underlying mechanisms of FXS.  Early reports 
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revealed an excessively long and immature dendritic spine morphology appeared in 
the Fmr1−/y mice compared to WT controls (Comery et al., 1997; Irwin et al., 2002; 
Nimchinsky et al., 2001).  Increased spine density across different neocortical layers 
in various brain regions have also been reported in the Fmr1−/y mice (Dölen et al., 
2007; Hayashi et al., 2007; Liu et al., 2011).  However, most of these studies used 
the Golgi method for spine visualisation, which was a method known to have poor 
morphological information of spines and easy to get random and unpredictable 
staining, therefore might yield inconsistent results between different labs (Buell, 
1982; Mancuso et al., 2013; Rosoklija et al., 2003).  Thus, I chose to use the 
intracellular fluorescent dye-filling technique as the method of spine visualisation, 
which can give a better morphological information and less distortion of the spine 
morphology (Trommald et al., 1995). 
 
4.1.2 The development and function of spines 
Dendritic spines are where the excitatory synapses going to form, and thus 
these “protrusions” alongside the dendritic tree play a crucial role in regulating the 
excitability of a given cell.  Dendritic spines are dynamic, formation of a spine only 
takes several minutes (Bhatt et al., 2009; Yuste and Bonhoeffer, 2004; Ziv and Smith, 
1996); while some spines are forming, other spines are being eliminated, a process 
called “spine pruning”.  This dynamic process of spine formation has been proposed 
as one of the important potential mechanisms of learning and memory (Knafo et al., 
2004; Maletic-Savatic et al., 1999; Moser et al., 1994; Segal, 2005; Yuste and 
Bonhoeffer, 2001).  Dendritic spines can also be classified as either “mature” or 
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“immature” based on their morphology (Harris et al., 1992).  However, due to the 
variety of cell composition in different brain areas, some spines considered “mature” 
in a designated brain region may become less mature or “immature” in another brain 
area.  Spine morphology is also highly regulated by development (Wijetunge et al., 
2014).  The current well-accepted concept of spine formation is that neurons will 
generate spines in excess during development which is followed by a period of 
“pruning”.  Eventually a dynamic equilibrium will be achieved where the loss and 
gain of spine formation is balanced (Segal, 2005). 
 
4.1.3 The mGluR theory of FXS 
Since the paper proposing the “mGluR theory of FXS” came out in 2004 
(Bear et al., 2004), FXS became one of the very first developmental brain disorders 
where therapies were being developed to treat “core deficits” (as opposed to 
symptoms) based on a rational hypothesis.  The mGluR theory is based on the 
observation that the symptoms/phenotypes of losing FMRP in patients/mouse models 
are very similar as a result of exaggerated mGluR signalling.  For example, mGluR 
hypersensitivity specifically in the CA1 region of the hippocampus leads to an 
enhanced LTD (mGluR-LTD), one of the most consistent phenotypes reported in the 
Fmr1−/y mice (Bhattacharya et al., 2012; Huber et al., 2002).  Thus, to 
physiologically reduce the activity of mGluR-signalling seems to be a promising 
route to alleviate the symptoms of FXS.  Several attempts have been made, including 
large-scale clinical trials and animal studies (Berry-Kravis et al., 2009; Gantois et al., 
2013; Pop et al., 2014).  However, Novartis and Roche announced earlier last year 
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that their mGluR antagonists AFQ056 and RG7090 (RO4917523) failed to show 
beneficial therapeutic effects in their clinical trials.  The results were disappointing to 
the whole FXS community, and the withdrawal of these pharmaceutical companies 
may imply that the mGluR theory is no longer a favourable target in treating FXS.  
Despite the unsuccessful attempts from these trials, we may want to ask ourselves 
whether these trials were actually “testing” the mGluR theory or not, before we jump 
to the conclusions that mGluR antagonists were ineffective.  First of all, both trials 
used the Autism Behaviour Checklist (ABC) and IQ as their primary and secondary 
outcome measures, respectively.  However, none of them could be used to measure 
“synaptic plasticity” in those individuals with FXS, therefore it was hard to interpret 
the effect of these drugs when the improvement of synaptic plasticity was a major 
outcome in animal studies (Dölen et al., 2007; Michalon et al., 2012; Pop et al., 
2014).  More importantly, it was the caregivers or parents who scored the ABC for 
those participants but not clinicians, and this would only add more variability for the 
outcome measure. 
Second, most of the core symptoms of FXS can be found in early 
development (i.e., 3 – 5 y/o) and we can easily focus on such an early stage of 
development to examine the effects of drugs in animal models, but not humans.  In 
both clinical trials, the age of the participants were mostly teenagers and adults, 
which had already passed the developmental stage when mGluR antagonists showed 
positive effects in animal studies.  Third, the required dosage for these drugs to 
effectively target the mGluR signalling in humans still remains unclear.  And 
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whether the 3-month trials were long enough to observe the positive outcome was 
also hard to know. 
While attempts were made targeting the mGluR-signalling, other studies 
targeted the upstream or downstream targets of mGluR5 activation/signalling, 
including inhibitory control (i.e., the GABA signalling) in both FXS patients and 
mouse models were also conducted and the results looked promising (Berry-Kravis 
et al., 2012; Henderson et al., 2012). 
 
4.1.4 Disrupted Ras-ERK signalling in FXS and the potential 
therapeutic effect of lovastatin 
An excessive protein synthesis downstream of the mGluR pathway has been 
reported in the Fmr1−/y mice (Osterweil et al., 2010; Qin et al., 2005).  The Ras-ERK 
pathway is one of the downstream signalling of mGluR that involves protein 
translation, and inhibiting this pathway has rescued the excessive protein synthesis in 
the mouse model of FXS (Osterweil et al., 2013, 2010).  Like FXS, another single-
gene neurodevelopmental disorder called neurofibromatosis type 1 (NF1), for which 
an increase of Ras activity has been proposed as its main underlying pathological 
mechanism (Basu et al., 1992; DeClue et al., 1992) might shed a light on the FXS 
treatment.  Li et al. published a paper in 2005 suggesting the HMG-CoA reductase 
inhibitor lovastatin is able to reduce certain cognitive and behavioural deficits in the 
mouse model of NF1 (Li et al., 2005).  Followed by that, Osterweil et al. published a 
study in 2013 using lovastatin as a mGluR-signalling modulator and they 
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successfully rescued several key phenotypes of the Fmr1−/y mice, including excessive 
protein synthesis, mGluR-induced epileptogenesis, hyperexcitability in the visual 
cortex, and reduced the susceptibility to audio-genic seizures (Osterweil et al., 2013).  
Lovastatin itself is a natural compound which can be found in food such as oyster 
mushrooms and red yeast rice, and was initially used as a treatment for 
hyperlipidemia as it acts as an inhibitor of the HMG-CoA reductase, which is a key 
enzyme of cholesterol synthesis.  Lovastatin is well-tolerated and can be prescribed 
to young children and elderly people (Descamps et al., 2011; Tobert, 1988), making 
it an ideal drug for FXS as most patients develop their symptoms in their childhood 
(Bailey et al., 2009) 
In this Chapter, I tested whether lovastatin would rescue the altered dendritic 
spine density and morphology in Fmr1−/y mice.  Statins are known to suppress the 
expression of chondroitin sulfate proteoglycans (CSPGs) (Holmberg et al., 2008).  
CSPGs are extracellular matrix molecules that are essential in glial scar formation 
and neural development.  Previous reports also point out the importance of CSPGs in 
inhibiting axon regeneration (for review, see Yiu and He, 2006).  CSPGs down-
regulate spine formation by dephosphorylating tropomyosin receptor kinase B 
(TrkB), the receptor of brain-derived neurotrophic factor (BDNF) (Kurihara and 
Yamashita, 2012).  Hence, lovastatin treatment is likely to rescue the dendritic spine 
abnormalities in Fmr1−/y mice. 
A treatment-oriented, oral route of administering lovastatin was used in the 
current study, by supplying animals the rodent chows that pre-mixed with lovastatin.  
Fmr1−/y mice and WT controls were randomly assigned to either lovastatin-
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containing chows (lovachows, LOV), or control chows (CON) treatment for 10 days 
during early development (P25) and detailed spine analysis was conducted 
afterwards.  This age was chosen as spine turnover rate decreased and the overall 
circuit towards maturation around this time point (Holtmaat et al., 2005).  Spine 
density and morphology was assessed using confocal microscopy with a resolution of 
approximately 180 nm. 
 
4.2 Materials and methods 
4.2.1 Animals 
All animals were obtained from the animal unit located in the Hugh Robson 
Building (BRR-HRB, The University of Edinburgh) in accordance with the United 
Kingdom Animals (Scientific Procedures) Act 1986 under the authority of Project 
Licences (PPL 60/3631 and PPL 60/4290).  Animals were housed under a 12 hr/12 hr 
light/dark cycle.  The Fmr1−/y mice used in this Chapter were originally purchased 
from the Jackson Labs and then backcrossed and maintained onto the C57BL/6J 
substrain purchased from Charles River UK.  Male Fmr1−/y mice and their WT 
littermates were first weighted and then assigned randomly to receive either 
lovastatin-containing chows or control chows as their source of food.  All mice have 
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4.2.2 Lovastatin treatment 
LOV and CON were purchased from Bio-Serv (Flemington, NJ, USA).  LOV 
were regular rodent chows pre-mixed with 0.01 % (w/w) lovastatin, which was a 
dose equivalent to 10 – 25 mg/kg daily (Osterweil et al., 2013; Yamada et al., 2000).  
All experimental mice were first weighted at P25 and then randomly assigned to 
either the LOV group or the CON group.  The drug treatment lasted for 10 days and 
the weights of all mice were monitored daily for the first 3 days then every 3 days 
afterwards.  All mice were sacrificed at the age between P35 and P37 through 
transcardial perfusion and their brains were removed and stored overnight at 4°C for 
future experiments. 
 
4.2.3 Stick and stain 
Mice were sacrificed through transcardial perfusion with ice-cold PBS then 
followed by 4% PFA.  The volume and concentration of PFA needed to be carefully 
monitored as this would affect the dye-filling process dramatically.  For filling cells 
in the hippocampal CA1 and V1 in the visual cortex, I used 6 – 7 ml of 4% PFA for 
perfusion and then post-fixed with 2% PFA overnight at 4°C.  Brains were then 
rinsed with ice-cold PBS several times next morning, and quickly sliced into 200 µm 
coronal sections with a vibratome.  Sections containing CA1 or V1 were used in this 
experiment. 
Coronal sections containing either CA1 or V1 were placed in a chamber on a 
membranous filter (Millipore #HAWG04700, MA, USA), a “C” shaped weight was 
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then put on top to ensure the section remain in position during dye-filling.  The 
chamber was filled with ice-cold PBS and was put into a holding stage of the upright 
microscope.  The section was imaged using a 20X water immersion objective in 
PBS.  Microinjection pipettes were pulled from thin walled glass capillaries (1.5 mm 
O.D. × 1.17 mm I.D., Harvard Apparatus, MA, USA) and filled with fluorescent dye 
(Alexa Fluor® 568 Hydrazide, 10 mM made up in ddH2O, Life Technologies #A-
10437).  They were subsequently backfilled with a conducting solution (0.1 M KCl, 
pH 7.4).  An AgCl2 wire which connected to a pulse generator (Isolated Pulse 
Stimulator, A-M Systems Model 2100, WA, USA) was inserted in the electrode.  An 
earth wire connecting the solution and the pulse generator was used to close the 
circuit.  The electrode was checked to see if regular puffs of dye were emitted under 
fluorescence, then inserted carefully into a cell body without penetrating it.  I focused 
on pyramidal cells located in the CA1 and layer II/III of the visual cortex.  A given 
cell might require 15 – 20 min to fill depending on its size and fixation using a 
continuous square pulse at 1 Hz.  Generally 3 – 5 cells were filled for each region 
(i.e., CA1 and V1) from a single animal.  Cells after filling were post-fixed with 4% 
PFA for 1 hr then rinsed with PBS and stored in mounting medium 
(VECTASHIELD® antifade mounting medium, Vector # H-1000, CA, USA) at 4°C 
before imaging. 
Before imaging, sections were rinsed with PBS and counterstained with TO-
PRO®-3 iodide (1:1000, Life Technologies #T3605) then mounted with 
VECTASHIELD® HardSet (Vector # H-1400, CA, USA).  An inverted laser-
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scanning confocal microscope (Zeiss Axiovert LSM510, Germany) was used to 
acquire images of filled cells.  All images were acquired by Nyquist sampling. 
 
4.2.4 Image analysis 
Confocal image Z-stacks (0.14 µm per stack) were first deconvolved by using 
the deconvolution software (Huygens Essential, The Netherlands) prior image 
analysis.  NIH ImageJ was used to analyse dendritic spine density and characterise 
spine morphology.  For more detailed spine measurement such as spine head 
diameter and spine length, a commercial image analysis software IMARIS® with 
FilamentTracer plugin (Bitplane, Zurich, Switzerland) was used in order to perform a 
more detailed dendritic structure reconstruction (Fig. 4-1 – 4-3). 
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Figure 4-1.  A representative figure showing the dendritic structure reconstruction process 
using IMARIS. 
To reconstruct a dendrite, I first set-up “seeds” along the dendrites of interest to tell IMARIS which 
dendrite needed to be reconstructed.  For most of the situations IMARIS would mark more than one 
dendrite which, in our case, was not ideal as I only wanted one dendrite to be reconstructed at a time 
to prevent oversampling from certain neurons over the others.  Those excess dendrites were trimmed 
manually.  I only analysed one of the secondary apical dendrites (apical obliques) and one of the 
secondary basal dendrites for each neuron for the dendritic spine analysis. 
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Figure 4-2.  A representative image showing the dendrite reconstruction process using IMARIS 
is presented here. 
Here in (A) a dendrite of interest was selected and reconstructed in (B) and (C), however almost every 
other dendrite in the same region was also reconstructed at the same time.  Manually trimming was 
done at this stage to delete those dendrites that were out of focus. 
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Figure 4-3.  A representative figure showing a fully reconstructed dendrite and its dendritic 
spines. 
After removing those unwanted dendrites in the image, the dendritic spines on the dendrite of interest 
were reconstructed by IMARIS at this stage.  Manual trimming may still be required at this stage to 
remove any spines that were out of focus.  Since the Z plane resolution (about 200 nm) of our 
confocal set-up is far worse than the X-Y plane, spines grew toward the Z planes were only used for 
density analysis and were excluded from further morphology characterisation. 
 
4.2.5 Western blotting 
Animals were sacrificed via neck dislocation, brains were then quickly 
removed and the region of interest (hippocampus and visual cortex) were dissected 
out from both hemispheres.  All procedures were performed in a dissecting dish on 
ice and filled with ice-cold PBS with 10% sucrose.  Dissected tissues were quickly 
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put into 1.5 ml Eppendorf tubes which were pre-cooled with dry ice to “snap-freeze” 
before stored in a −80°C freezer. 
Tissues were homogenised with lysis buffer containing protease and 
phosphatase inhibitors (RIPA buffer: 50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-
100, 0.5% sodium deoxylcholate, 0.1% SDS, 1 mM EDTA, pH 7.4; protease 
inhibitor (EDTA free), Roche #11836170001; phosphatase inhibitor cocktail, 
Calbiochem #524625 (II) and #524628 (IV)).  Protein concentration of homogenised 
tissues were checked by using a protein assay kit (PierceTM BCA Protein Assay Kit, 
Thermo #23225, 23227) before running the Western blot.  Briefly, for a microplate 
(96 wells), pipette 10 µl of each standard or unknown sample replicate into each 
well, and then add 200 µl of the BCA working reagent into each well.  The 
microplate was then put on a plate shaker to mix thoroughly for 30 seconds.  Plate 
was then covered with tin foil and left in 37°C for 30 min for incubation.  Finally, the 
microplate was allowed to cool to room temperature prior plate reading.  Several 
loading stocks were made based on the plate reading results of protein concentration 
of each sample.  A 50 µl loading stock with a protein concentration of 0.5 µg/µl 
(containing 25 µl of 2X Laemmli buffer) was made for each sample and all loading 
stocks were stored in a −80°C freezer prior gel running.  Details of buffers used and 
buffers recipes can be found in the Appendix section (Chapter 8) at the end of the 
thesis. 
Pre-cast gels (Mini-PROTEAN® TGX gels, Bio-Rad #456-1046; 12%) were 
used for all Western blotting experiments in this Chapter.  Those pre-made loading 
stocks were heated to 95°C on a heat plate for 5 min, and 2 pre-cast gels were put 
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into one cassette and then the cassette was put into a tank filled with running buffer.  
The first and last lane of each gel were loaded with 5 µl of 2X Laemmli buffer only, 
and one lane was loaded with 5 µl of protein ladder (PageRuler® Plus Prestained 
Protein Ladder, 10 to 250 kDa, Thermo #26619) of each gel.  The remaining lanes 
was then loaded with 10 µl loading stock to make the final protein concentration of 
each lane equal to 5 µg.  Gels were running for about 100 min with 100 V before 
transferring to nitrocellulose membranes.  All components were equilibrated in 
transfer buffer to reduce the risk of air bubbles which would impede protein transfer. 
The gels were transferred to nitrocellulose membranes for 1 hr with 100 mA, 
then membranes were washed thoroughly with PBS followed by incubating in the 
blocking buffer (Odyssey® blocking buffer, Li-COR #927-40000, Cambridge, UK) 
for 45 min at room temperature.  Primary antibodies against ERK1/2 (or pERK1/2) 
and beta-actin were then added into the blocking buffer (with 0.1% Tween-20) at the 
desired concentration (ERK1/2: 1:2000, mouse anti-ERK1/2, Cell Signalling #4696S; 
pERK1/2: 1:2000, mouse anti-pERK1/2, Cell Signalling #9106S; β-actin: 1:2000, 
rabbit anti-β-actin, abcam #ab8227) and gels were incubated at 4°C overnight.  
Membranes were washed thoroughly with PBS the next day and incubated with 
secondary antibodies (goat anti-mouse Alexa Fluor® 680, Life Technologies #A-
21057, 1:5000; goat anti-rabbit IRDye® 800, Li-COR #926-32211, 1:5000) for 1 hr 
at room temperature in a light-tight box to prevent fading.  Membranes were then 
washed again with PBS for several times and were imaged with an Odyssey Infrared 
Imaging System (Li-COR Odyssey 9120, Cambridge, UK).  Images of Western 
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results were then quantified with a freeware provided by Li-COR (Image StudioTM 
Lite, Li-COR). 
Some membranes were blotted several times with different antibodies, in this 
case membranes were incubated in 1X stripping buffer (ReBlot Plus stripping 
solution (10X), Millipore #2504) for 10 – 15 min at room temperature and rinsed 
thoroughly with PBS.  After incubating in blocking buffer for 1 hr, a new primary 
antibody can then be introduced to the membrane following the above process. 
For Western blot results, images gathered via Li-COR Odyssey were 
processed and quantified by using their own software Image StudioTM Lite.  Two 
channels were analysed separately.  For each channel, multiple size-fixed user-
defined region of interests (ROIs) were put on top of each individual lane where 
proteins were shown.  Along that, a small area surrounding each ROI was used as the 
background noise value for further readout adjustment.  An absolute value was then 
shown for each ROI after subtracting its own background noise value.  The value of 
β-actin was used as a loading control and all values presented are shown as a ratio of 
protein : β-actin. 
 
4.2.6 Statistics 
Data were analysed with GraphPad Prism (version 6th, GraphPad Software, 
CA, USA), presented as mean ± SEM unless otherwise specified.  Student’s unpaired 
t-test, K-S test, or ANOVA were used for statistical analysis as appropriate.  p values 
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were reported and significance was set when p < 0.05 (marked as *; ** when p < 
0.01 and *** when p < 0.001, respectively. 
 
4.3 Results 
4.3.1 Dendritic spine density was unaltered between the 
Fmr1−/y and WT mice in CA1 and V1 after LOV treatment. 
In this Chapter, I tested whether LOV treatment would affect dendritic spine 
density or morphology in the Fmr1−/y mice.  Mice from both genotypes were given 
CON or LOV treatment for 10 days and dendritic spines from dye-filled neurons in 
the CA1 and V1 were analysed (Fig. 4-4 – 4-6). 
 
Figure 4-4.  A diagram showing the general experimental design of this Chapter. 
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Both the Fmr1−/y mice and WT controls were assigned randomly to receive either CON or LOV 
treatment for 10 days from P25.  At P35, all mice were sacrificed via transcardial perfusion and then I 
performed “stick and stain” on selected coronal sections containing the CA1 or V1 region.  Dye-filled 
neurons were then imaged by a laser scanning confocal set-up in the IMPACT centre at HRB. 
 
 
Figure 4-5.  Representative figures of dye-filled neurons in the CA1 and V1 region. 
A CA1 pyramidal cell is shown in (A), the apical and basal dendrites used for spine density and 
morphology analysis are marked in yellow.  Two neurons from the V1 region are shown in (B). 
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Figure 4-6.  Representative figures of an apical dendrite from the CA1 region are shown to 
illustrate using colour-coding to assist image analysis. 
An apical dendrite from the CA1 region is shown in (A), and the same dendrite was colour-coded in 
(B) using ImageJ to assist spine visualisation and analysis.  A 300X zoomed-in spine section (the 
yellow box in the bottom right corner) was highlighted in (B).  Dendritic spine samples were marked 
with the yellow arrow heads in both graphs.  Scale bar: 10 µm. 
 
I first looked into the overall dendritic spine density of the Fmr1−/y and WT 
mice and see if there were any changes after the lovastatin treatment.  There was no 
interaction between genotypes and treatments across all regions examined (Fig. 4-
7A, F(1, 13) = 0.1701, p = 0.6867; Fig. 4-7B, F(1, 14) = 0.1151, p = 0.7394; Fig. 4-7C, 
F(1, 18) = 1.515, p = 0.2342; Fig. 4-7D, F(1, 17) = 0.08411, p = 0.7753, Two-way 
ANOVA).  Drug treatment did not have an effect on spine density in CA1 and V1 
dendrites (Fig. 4-7A, F(1, 13) = 0.2166, p = 0.6493; Fig. 4-7B, F(1, 14) = 0.4587, p = 
0.5093; Fig. 4-7C, F(1, 18) = 2.605, p = 0.1239; Fig. 4-7D, F(1, 17) = 0.03133, p = 
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0.8616, Two-way ANOVA).  A genotype effect on spine density was only found in 
the V1 apical dendrites (Fig. 4-7A, F(1, 13) = 6.523, p = 0.0240, Two-way ANOVA), 
and no effect was found on the rest of the regions examined (Fig. 4-7B, F(1, 14) = 
2.727, p = 0.1209; Fig. 4-7C, F(1, 18) = 0.09648, p = 0.7597; Fig. 4-7D, F(1, 17) = 
0.2972, p = 0.5927, Two-way ANOVA). 
However, a significant increase of spine density was noticed in the V1 apical 
dendrites of the Fmr1−/y mice compared to the WT mice (Fig. 4-7A, p = 0.0315, 
unpaired two-tailed Student’s t-test; Power = 0.65, at least 7 WT and 5 Fmr1−/y mice 
will be needed if aiming to reach 0.8 in Power), when both of them receiving CON 
treatment (i.e., under normal condition).  This increase of spine density in V1 of the 
Fmr1−/y mice was diminished after 10 days of LOV treatment compared to the WT 
controls (Fig. 4-7A, LOV WT vs. LOV Fmr1−/y, p = 0.2607, unpaired two-tailed 
Student’s t-test).  However, this was likely due to the slight increase of spine density 
in the WT animals after LOV treatment (Fig. 4-7A, CON WT vs. LOV WT, p = 
0.5860, unpaired two-tailed Student’s t-test; mean of CON WT = 12.06 ± 0.97, mean 
of LOV WT = 13.15 ± 1.79), as spine density of the Fmr1−/y mice did not alter after 
LOV treatment (Fig. 4-7A, CON Fmr1−/y vs. LOV Fmr1−/y, p = 0.9668, unpaired 
two-tailed Student’s t-test; mean of CON Fmr1−/y = 15.76 ± 0.94, mean of LOV 
Fmr1−/y = 15.82 ± 1.20).  Meanwhile, the spine density in the LOV Fmr1−/y group 
was still significantly increased compared to the CON WT group (Fig. 4-7A, p = 
0.0427, unpaired two-tailed Student’s t-test). 
No differences in spine density were found in the CA1 region (both apical 
and basal dendrites) and basal dendrites in the V1 region.  A slight but not significant 
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increase of spine density of the apical dendrites in the CA1 region was noticed in the 
Fmr1−/y mice after 10 days of lovastatin treatment (Fig. 4-7C, CON Fmr1−/y vs. LOV 
Fmr1−/y, p = 0.0630, unpaired two-tailed Student’s t-test). 
 
Figure 4-7.  The effect of lovastatin treatment on dendritic spine density of the Fmr1−/y and WT 
mice are presented. 
Dendritic spine density of the Fmr1−/y and WT mice from CA1 and V1 are shown before and after 10 
days of CON/LOV treatment.  Mean spine density per 10 µm along the dendrites from left to right in 
(A): 12.06, 13.15, 15.76, 15.82; (B): 13.75, 14.08, 15.03, 16.03; (C): 18.88, 19.31, 17.84, 21.05; (D) 
15.13, 15.28, 16.27, 15.63.  n = 5 in each group besides the LOV-Fmr1−/y group, where n = 7. 
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4.3.2 Dendritic spine morphologies were largely unaltered 
between the Fmr1−/y and WT mice before and after LOV 
treatment. 
As a first attempt to identify differences in spine morphologies between 
genotypes, I attempted to categorise dendritic spines (long/thin, stubby, mushroom, 
etc.) based on their prominent features (e.g., neck length, head width) as previously 
reported (Arellano et al., 2007; Galvez and Greenough, 2005; Harris et al., 1992; 
Hering and Sheng, 2001).  A detailed diagram of how spines were grouped is shown 
in Fig. 4-8 and different spine morphologies are shown in Fig. 4-9. 
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Figure 4-8.  A detailed diagram showing how spines were grouped into different categories. 
This diagram was drawn by Dr. Lasani Wijetunge based on a lab meeting about spine morphology 
characterisation.  We first excluded all spines that did not have a clear attachment to the dendritic 
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shaft, as in this case we cannot conclude they are spines or some random artefacts.  We next excluded 
those spines located on the Z plane, as the Z resolution of the confocal microscope was poor compared 
to the X-Y plane.  The remaining spines were then categorised first by its uniformity, more precisely, 
with or without a clear spine “neck”.  Spines that are without a clear neck and are short were called 
“stubby” spines; short and thin spines were therefore categorised as “short & thin”; longer spines and 
without a prominent head were then named as “filopodia”, which was consistent with previous 
literatures.  Spines with a clear neck and a prominent head were then classified as “mushroom” spines, 




Figure 4-9.  A representative figure showing spines with different morphologies. 
Several dendritic spines along a dendrite are shown in (A).  Two mushroom spines are shown in (B), 
one pearly spine (C), one stubby spine (D), one bifurcated spine (E), and one filopodia spine (F) is 
shown in the right panel of the figure, respectively.  Scale bar: 1 µm. 
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Based on this categorisation procedure, I did not find any significant 
differences between the Fmr1−/y and WT mice on spine morphologies, and 80% of all 
the spines I have measured were mushroom-like spines (Fig. 4-10 and Fig. 4-11). 
 
Figure 4-10.  Dendritic spines with different morphologies from the CA1 region of the Fmr1−/y 
and WT mice are presented (apical dendrites). 
Stubby, filopodia/short and thin, and mushroom spines were characterised from the apical dendrites in 
the CA1 region.  The proportion of spines with different morphologies are shown here.  WT animals 
treated with CON or LOV are shown in (A).  Fmr1−/y mice treated with CON or LOV are shown in 
(B).  In (C) and (D), WT and Fmr1−/y mice treated with either CON or LOV are shown, respectively.  
n equals number of animals. 
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There were no gross changes between the two genotypes (Fig. 4-10A and Fig. 
4-10B), nor between the two different treatments (Fig. 4-10C and Fig. 4-10D) in 
spine morphology.  Unpaired two-tailed Student’s t-test was used to examine the 
difference between groups.  Results in Fig. 4-10A: stubby: p = 0.8991, filopodia: p = 
0.7501, mushroom: p = 0.6212; Fig. 4-10B: stubby: p = 0.9376, filopodia: p = 
0.1529, mushroom: p = 0.6104; Fig. 4-10C: stubby: p = 0.8621, filopodia: p = 
0.7598, mushroom: p = 0.6884; Fig. 4-10D: stubby: p = 0.8419, filopodia: p = 
0.3563, mushroom: p = 0.5394.  The statistical Power in this experiment was 0.28, at 
least 6 animals under the CON treatment and 12 animals for the LOV group will be 
needed if aiming to reach 0.8 in Power. 
 




Figure 4-11.  Dendritic spines with different morphologies from the CA1 region of the Fmr1−/y 
and WT mice are presented (basal dendrites). 
Stubby, filopodia/short and thin, and mushroom spines were characterised from the basal dendrites in 
the CA1 region.  The proportion of spines with different morphologies are shown here.  WT animals 
treated with CON or LOV are shown in (A).  Fmr1−/y mice treated with CON or LOV are shown in 
(B).  In (C) and (D), WT and Fmr1−/y mice treated with either CON or LOV are shown, respectively.  
n equals number of animals. 
 
There were no gross changes between the two genotypes (Fig. 4-11A and Fig. 
4-11B), nor between the two different treatments (Fig. 4-11C and Fig. 4-11D).  
Unpaired two-tailed Student’s t-test was used to examine the difference between 
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groups.  Results in Fig. 4-11A: stubby: p = 0.4355, filopodia: p = 0.6981, mushroom: 
p = 0.075; Fig. 4-11B: stubby: p = 0.4273, filopodia: p = 0.4726, mushroom: p = 
0.8178; Fig. 4-11C: stubby: p = 0.446, filopodia: p = 0.9409, mushroom: p = 0.9793; 
Fig. 4-11D: stubby: p = 0.5495, filopodia: p = 0.0818, mushroom: p = 0.1525.  The 
statistical Power in this experiment was 0.13, at least 15 animals under the CON 
treatment and 31 animals for the LOV group will be needed if aiming to reach 0.8 in 
Power.  These preliminary results indicated that the “morphological categorisation” 
approach was not effective and might not be able to detect the differences between 
the two genotypes (if there were any).  Hence, I took another approach to examine 
spine morphology and it will be discussed in the following section. 
 
4.3.3 Detailed spine morphology measurements indicated 
that the spine head diameter was increased in the 
Fmr1−/y mice. 
It has recently been shown that dendritic spine categorisation is artificial and 
instead, spine morphology is a continuum (Tønnesen et al., 2014; Wijetunge et al., 
2014).  Hence, to get a more accurate estimate of spine morphology, I analysed spine 
head width and length with the commercial software IMARIS® alongside with a 
specific plugin called “FilamentTracer” (Bitplane, Zurich, Switzerland).  I started 
with measuring the spine head diameter as an increased spine head diameter in the 
Fmr1−/y mice was reported previously (Wijetunge et al., 2014).  Consistent with these 
previous studies, I found a significant increase in spine head diameter from CA1 
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apical dendrites in the Fmr1−/y mice compared to the WT controls (Fig. 4-12A).  I 
also found a consistent increase of spine head diameter in the apical dendrites of the 
CA1 region and both apical and basal dendrites in the V1 region when the WT mice 
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Figure 4-12.  LOV treatment rescued the increased spine head diameter of CA1 apical dendrites 
in the Fmr1−/y mice. 
For all four figures, the left panel showed the cumulative frequency distribution of spine head 
diameter and the mean for each individual animal was plotted in the right panel.  Control chow treated 
animals are shown in (A), where Fmr1−/y mice and WT mice are marked with red and black, 
respectively.  LOV treated animals are shown in (B), where Fmr1−/y mice and WT mice are marked 
with red and black, respectively.  In (C), WT animals treated with CON or LOV are shown in black or 
red, respectively.  In (D), Fmr1−/y animals treated with CON or LOV are shown in black or red, 
respectively.  The dots in the right small panel represent each individual animal.  CON-WT: n = 5; 
LOV-WT: n = 7; CON-Fmr1−/y: n = 5; LOV-Fmr1−/y: n = 6.   
 
 
   123 
 
 Spine head diameter of CA1 apical dendrites was significantly increased in 
the Fmr1−/y mice compared to WT controls under CON treatment (Fig. 4-12A, 
cumulative frequency was tested with K-S test, p < 0.0001; overall mean difference 
was tested via unpaired two-tailed Student’s t-test, p = 0.0057; Power = 0.90).  The 
increased spine head diameter in the Fmr1−/y mice was diminished after 10 days of 
LOV treatment (Fig. 4-12B, cumulative frequency was tested with K-S test, p < 
0.0001; overall mean difference was tested via unpaired two-tailed Student’s t-test, p 
= 0.258).  The difference of spine head diameter on WT animals between two 
treatments was shown in Fig. 4-12C, where animals receiving LOV treatment for 10 
days had bigger spine head compared to the animals under CON treatment 
(cumulative frequency was tested with K-S test, p < 0.0001; overall mean difference 
was tested via unpaired two-tailed Student’s t-test, p = 0.003; Power = 0.97).  There 
was no difference in spine head diameter between the two treatment groups of the 
Fmr1−/y mice (Fig. 4-12D, cumulative frequency was tested with K-S test, p = 
0.2370; overall mean difference was tested via unpaired two-tailed Student’s t-test, p 
= 0.6939). 
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Figure 4-13.  Mean spine head diameter of basal dendrites in the CA1 region were not altered. 
Statistics and figure compositions are the same as shown in Fig. 4-12.  Control chow treated animals 
are shown in (A), where Fmr1−/y mice and WT mice are marked with red and black, respectively.  
LOV treated animals are shown in (B), where Fmr1−/y mice and WT mice are marked with red and 
black, respectively.  In (C), WT animals treated with CON or LOV are shown in black or red, 
respectively.  In (D), Fmr1−/y animals treated with CON or LOV are shown in black or red, 
respectively.  The dots in the right small panel represent each individual animal.  CON-WT: n = 5; 
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 The mean spine head diameter of CA1 basal dendrites were not altered 
between the two genotypes or between the two treatments in both regions examined.  
In Fig. 4-13A, the overall cumulative distribution of spine head diameter of the 
Fmr1−/y mice was significantly smaller than the WT mice (p < 0.0001, K-S test).  But 
the mean spine head diameter remained unaltered (p = 0.0788, unpaired two-tailed 
Student’s t-test).  LOV treatment did not have a significant effect on overall mean 
spine head diameter of the two genotypes (Fig. 4-13B, p = 0.4279, unpaired two-
tailed Student’s t-test).  However, the cumulative frequency distribution suggested 
that after LOV treatment, the WT animals’ spine head diameter was increased 
compared to the Fmr1−/y mice (Fig. 4-13B, p < 0.0001, K-S test).  The spine head 
diameter of WT animals receiving either the LOV or the CON treatment are shown 
in Fig. 4-13C.  The overall mean was not altered (Fig. 4-13C, p = 0.4568, unpaired 
two-tailed Student’s t-test), but the cumulative distribution of the spine head 
diameter in the LOV treated mice was significantly increased compared to the CON 
group (Fig. 4-13C, p < 0.0001, K-S test).  A similar pattern was also noticed in Fig. 
4-13D, while no gross changes were noticed when comparing the overall mean of the 
spine head diameter between the Fmr1−/y and WT mice (Fig. 4-13D, p = 0.3448, 
unpaired two-tailed Student’s t-test).  A significant increase of the cumulative 
distribution of spine diameter was noticed in the LOV group compared to the CON 
group (Fig 4-13D, p < 0.0001, K-S test). 
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Figure 4-14.  LOV treatment increased the spine head diameter of the apical dendrites from the 
V1 region of the WT animals. 
Statistics and figure compositions are the same as shown in Fig. 4-12.  Control chow treated animals 
are shown in (A), where Fmr1−/y mice and WT mice are marked with red and black, respectively.  
LOV treated animals are shown in (B), where Fmr1−/y mice and WT mice are marked with red and 
black, respectively.  In (C), WT animals treated with CON or LOV are shown in black or red, 
respectively.  In (D), Fmr1−/y animals treated with CON or LOV are shown in black or red, 
respectively.  The dots in the right small panel represent each individual animal.  CON-WT: n = 5; 
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The mean spine head diameter of V1 apical dendrites were not altered 
between the two genotypes.  However, WT animals treated with LOV showed an 
increased spine head diameter compared with the Fmr1−/y mice (Fig. 4-14C).  In Fig. 
4-14A, the overall cumulative distribution of spine head diameter of the Fmr1−/y mice 
was significantly larger than the WT mice (p < 0.0001, K-S test).  But the mean spine 
head diameter remained unaltered (p = 0.7519, unpaired two-tailed Student’s t-test).  
LOV treatment did not have a significant effect on overall mean spine head diameter 
of the two genotypes (Fig. 4-14B, p = 0.2424, unpaired two-tailed Student’s t-test).  
However, the cumulative frequency distribution suggested that after LOV treatment, 
the WT animals’ spine head diameter was increased compared to the Fmr1−/y mice 
(Fig 4-14B, p < 0.0001, K-S test).  The spine head diameter of WT animals receiving 
either the LOV or the CON treatment were shown in Fig. 4-14C.  The overall mean 
was increased in the LOV group (Fig. 4-14C, p = 0.0394, unpaired two-tailed 
Student’s t-test; Power = 0.58, at least 8 animals per group will be needed if aiming 
to reach 0.8 in Power), and the cumulative distribution of the spine head diameter in 
the LOV treated mice was significantly increased compared to the CON group (Fig. 
4-14C, p < 0.0001, K-S test).  A similar pattern was also noticed in Fig. 4-14D, while 
no gross changes were noticed when comparing the overall mean of the spine head 
diameter between the Fmr1−/y and WT mice (Fig. 4-14D, p = 0.1977, unpaired two-
tailed Student’s t-test).  A significant increase of the cumulative distribution of spine 
diameter was noticed in the LOV group compared to the CON group (Fig. 4-14D, p 
< 0.0001, K-S test). 
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Figure 4-15.  Mean spine head diameter of the V1 basal dendrites were significantly increased in 
the WT mice after LOV treatment. 
Statistics and figure compositions are the same as shown in Fig. 4-12.  Control chow treated animals 
are shown in (A), where Fmr1−/y mice and WT mice are marked with red and black, respectively.  
LOV treated animals are shown in (B), where Fmr1−/y mice and WT mice are marked with red and 
black, respectively.  In (C), WT animals treated with CON or LOV are shown in black or red, 
respectively.  In (D), Fmr1−/y animals treated with CON or LOV are shown in black or red, 
respectively.  The dots in the right small panel represent each individual animal.  CON-WT: n = 5; 
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The overall mean spine head diameter of V1 basal dendrites were not altered 
between the two genotypes as shown in Fig. 4-15A (p = 0.2861, unpaired two-tailed 
Student’s t-test).  But the cumulative distribution indicated that WT animals had 
significantly larger spine heads compared to the Fmr1−/y mice (Fig. 4-15A, p < 
0.0001, K-S test).  The LOV treatment boosted the mean spine head diameter even 
further in WT mice (Fig. 4-15B, p = 0.2861, unpaired two-tailed Student’s t-test; 
Power = 0.94).  The same effect was also noticed when analysing the overall 
cumulative frequency distribution from the same animals (Fig. 4-15B, p < 0.0001, K-
S test).  An increase of spine head diameter was noticed in WT mice when LOV 
treatment was given for 10 days (Fig. 4-15C, p = 0.0027, unpaired two-tailed 
Student’s t-test; p < 0.0001, K-S test; Power = 0.96).  A similar trend of increasing 
spine head diameter was also shown in the Fmr1−/y mice after 10 days of LOV 
treatment, however only indicated in the cumulative frequency distribution (Fig. 4-
15D, p = 0.0785, unpaired two-tailed Student’s t-test; p < 0.0001, K-S test). 
I next asked whether the spine length was altered between the Fmr1−/y mice 
and WT controls before and after the LOV treatment.  A similar analysis was then 
performed on the same mice I used for the spine head diameter analysis (Fig. 4-16 – 
19). 
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Figure 4-16.  Dendritic spine length did not alter when sampling from the CA1 apical dendrites 
from the Fmr1−/y mice and WT controls. 
Statistics and figure compositions are the same as shown in Fig. 4-12.  Control chow treated animals 
are shown in (A), where Fmr1−/y mice and WT mice are marked with red and black, respectively.  
LOV treated animals are shown in (B), where Fmr1−/y mice and WT mice are marked with red and 
black, respectively.  In (C), WT animals treated with CON or LOV are shown in black or red, 
respectively.  In (D), Fmr1−/y animals treated with CON or LOV are shown in black or red, 
respectively.  The dots in the right small panel represent each individual animal.  CON-WT: n = 5; 
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No gross spine length changes were noticed in the CA1 apical dendrites from 
both genotypes before nor after LOV treatment.  Detailed cumulative frequency 
analysis showed an increased spine length in the Fmr1−/y mice compared to the WT 
controls under CON treatment (Fig. 4-16A, p = 0.02, K-S test; p = 0.1780, unpaired 
two-tailed Student’s t-test).  This difference between the two genotypes was 
diminished after 10 days of LOV treatment (Fig. 4-16B, p = 0.12, K-S test; p = 
0.2393, unpaired two-tailed Student’s t-test).  LOV treatment induced a significant 
increase of spine length in the WT controls (Fig. 4-16C, p < 0.0001, K-S test; p = 
0.0869, unpaired two-tailed Student’s t-test), but caused an opposite effect when 
applied to the Fmr1−/y mice (Fig. 4-16D, p = 0.0078, K-S test; p = 0.2901, unpaired 
two-tailed Student’s t-test). 
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Figure 4-17.  No gross changes of spine length were noticed in the CA1 basal dendrites from the 
two genotypes before or after LOV treatment. 
Statistics and figure compositions are the same as shown in Fig. 4-12.  Control chow treated animals 
are shown in (A), where Fmr1−/y mice and WT mice are marked with red and black, respectively.  
LOV treated animals are shown in (B), where Fmr1−/y mice and WT mice are marked with red and 
black, respectively.  In (C), WT animals treated with CON or LOV are shown in black or red, 
respectively.  In (D), Fmr1−/y animals treated with CON or LOV are shown in black or red, 
respectively.  The dots in the right small panel represent each individual animal.  CON-WT: n = 5; 
LOV-WT: n = 7; CON-Fmr1−/y: n = 5; LOV-Fmr1−/y: n = 6. 
 
There were no overall mean spine length changes in the CA1 basal dendrites 
throughout the experiment.  Under normal conditions (i.e., animals receiving CON 
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treatment), the spine length in the Fmr1−/y mice was significantly increased compared 
to the WT controls when looking at the cumulative frequency distributions (Fig. 4-
17A, p = 0.007, K-S test; p = 0.8107, unpaired two-tailed Student’s t-test).  The 
increase of spine length in the Fmr1−/y mice persisted after 10 days of LOV treatment 
(Fig. 4-17B, p = 0.04, K-S test; p = 0.7243, unpaired two-tailed Student’s t-test).  
LOV treatment induced a subtle but significant increase in spine length in both 
genotypes, although the overall mean spine length remained unaltered (Fig. 4-17C, p 
= 0.0024, K-S test, p = 0.7731, unpaired two-tailed Student’s t-test; Fig. 4-17D, p = 
0.0054, K-S test; p = 0.7737, unpaired two-tailed Student’s t-test). 
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Figure 4-18.  A significant increase of spine length in the V1 apical dendrites of the WT mice 
was noticed compared to the Fmr1−/y mice after 10 days of LOV treatment. 
Statistics and figure compositions are the same as shown in Fig. 4-12.  Control chow treated animals 
are shown in (A), where Fmr1−/y mice and WT mice are marked with red and black, respectively.  
LOV treated animals are shown in (B), where Fmr1−/y mice and WT mice are marked with red and 
black, respectively.  In (C), WT animals treated with CON or LOV are shown in black or red, 
respectively.  In (D), Fmr1−/y animals treated with CON or LOV are shown in black or red, 
respectively.  The dots in the right small panel represent each individual animal.  CON-WT: n = 5; 
LOV-WT: n = 5; CON-Fmr1−/y: n = 5; LOV-Fmr1−/y: n = 5. 
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The dendritic spine length in the V1 apical dendrites was significantly 
reduced in the Fmr1−/y mice under both CON and LOV treatment when comparing to 
their WT littermates (Fig. 4-18A, p < 0.0001, K-S test; p = 0.0510, unpaired two-
tailed Student’s t-test; Power = 0.53, at least 9 animals per group will be needed if 
aiming to reach 0.8 in Power; Fig. 4-18B, p < 0.0001, K-S test; p = 0.0058, unpaired 
two-tailed Student’s t-test; Power = 0.90).  Unlike CA1 apical dendrites, LOV 
treatment did not cause any gross changes on spine length of the V1 apical dendrites 
of the WT mice (Fig. 4-18C, p = 0.13, K-S test; p = 0.9704, unpaired two-tailed 
Student’s t-test).  However, LOV treatment caused a mild but significant increase in 
spine length in the V1 apical dendrites of the Fmr1−/y mice (Fig. 4-18D, p < 0.0001, 
K-S test; p = 0.8702, unpaired two-tailed Student’s t-test). 
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Figure 4-19.  The spine length of the V1 basal dendrites was significantly reduced in the Fmr1−/y 
mice. 
Statistics and figure compositions are the same as shown in Fig. 4-12.  Control chow treated animals 
are shown in (A), where Fmr1−/y mice and WT mice are marked with red and black, respectively.  
LOV treated animals are shown in (B), where Fmr1−/y mice and WT mice are marked with red and 
black, respectively.  In (C), WT animals treated with CON or LOV are shown in black or red, 
respectively.  In (D), Fmr1−/y animals treated with CON or LOV are shown in black or red, 
respectively.  The dots in the right small panel represent each individual animal.  CON-WT: n = 5; 
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The spine length of the V1 basal dendrites was significantly reduced in the 
Fmr1−/y mice under either CON or LOV treatment when comparing to the WT 
controls (Fig. 4-19A, p < 0.0001, K-S test; p = 0.1174, unpaired two-tailed Student’s 
t-test; Fig. 4-19B, p < 0.0001, K-S test; p = 0.3053, unpaired two-tailed Student’s t-
test).  LOV treatment for 10 days induced a slightly increased spine length in the V1 
basal dendrites in both genotypes (Fig. 4-19C, p = 0.0003, K-S test; p = 0.2644, 
unpaired two-tailed Student’s t-test; Fig. 4-19D, p < 0.0001, K-S test; p = 0.2203, 
unpaired two-tailed Student’s t-test). 
In summary, my quantitative analysis of spine morphology suggests that 1) 
dendritic spine head size was increased in CA1 apical dendrites of the Fmr1−/y mice 
compared to WT controls (Fig. 4-12A); 2) LOV treatment increased spine head 
diameter of the CA1 apical dendrites of the WT mice to a similar size found in the 
Fmr1−/y mice (Fig. 4-12B and 4-12C).  A similar effect was found for V1 apical and 
basal dendrites, where an increase of spine head diameter in the LOV treated WT 
animals were noticed (Fig. 4-14C and 4-15C).  3) LOV treatment did not 
significantly alter the size of dendritic spines in the Fmr1−/y mice (Fig. 4-12D, 4-13D, 
4-14D, and 4-15D).  4) Dendritic spine length was largely unaffected by genotype 
and treatment; an increase of spine length was noticed in the CA1 apical dendrites of 
the Fmr1−/y mice compared to the WT controls under CON treatment (Fig. 4-16A).  
However, an opposite effect was also noticed when sampling from the V1 apical 
dendrites, where the WT controls had longer spines than the Fmr1−/y mice (Fig. 4-
18A and 4-18B). 
 
 
   138 
 
4.3.4 LOV treatment did not alter the basal protein expression 
of ERK and pERK in WT and Fmr1−/y mice. 
A similar study published by Osterweil et al. found that the LOV treatment 
reduced the excessive protein synthesis in the Fmr1−/y mice to WT levels (Osterweil 
et al., 2013).  This was specifically due to the inhibition of the Ras-ERK pathway, as 
both lovastatin and a Ras antagonist farnesylthiosalicylic acid (FTS) reduced the 
excessive protein synthesis in the Fmr1−/y mice (Osterweil et al., 2013).  Meanwhile, 
Osterweil et al. also reported that no difference was found in basal levels of Ras, 
ERK1/2, and pERK1/2 in hippocampal slices from the Fmr1−/y mice.  Acute 
application of lovastatin significantly reduced ERK1/2 activation in both WT and 
Fmr1−/y slices (Osterweil et al., 2013).  Thus, I examined ERK1/2 and pERK1/2 
levels under the current LOV treatment by Western blotting.  Hippocampi and visual 
cortices from both hemispheres were used for Western blotting in regard to where 
dendritic spines were analysed previously.  No interactions were found between the 
genotype and treatment among all groups (Fig. 4-20A, F(1, 14) = 0.2557, p = 0.6210; 
Fig. 4-20B, F(1, 14) = 0.4690, p = 0.5046; Fig. 4-20C, F(1, 12) = 0.5622, p = 0.4678; Fig. 
4-20D, F(1, 12) = 1.110, p = 0.3128).  LOV treatment did not affect the ERK1/2 and 
pERK1/2 expression among all regions examined (Fig. 4-20A, F(1, 14) = 0.5442, p = 
0.4729; Fig. 4-20B, F(1, 14) = 0.08089, p = 0.7803; Fig. 4-20C, F(1, 12) = 0.0005485, p 
= 0.9817; Fig. 4-20D, F(1, 12) = 1.139, p = 0.3068).  Similarly, genotype did not cause 
an effect on both the ERK1/2 and pERK1/2 expression in CA1 and V1 (Fig. 4-20A, 
F(1, 14) = 0.2043, p = 0.6582; Fig. 4-20B, F(1, 14) = 0.01990, p = 0.8898; Fig. 4-20C, 
F(1, 12) = 0.1564, p = 0.6994; Fig. 4-20D, F(1, 12) = 0.4403, p = 0.5195). 
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My results suggest that no difference in basal levels of ERK1/2 and pERK1/2 
are found between the Fmr1−/y mice and WT controls, which agreed well with 
previous findings.  Moreover, 10 days of lovastatin treatment does not alter the 
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Figure 4-20.  Downstream protein markers were unaltered after LOV treatment in both 
genotypes. 
Two protein markers downstream the mGluR-signalling were analysed by Western blotting.  
Representative Western blot images are shown on top and their relative quantification are shown at 
the bottom of each figure.  ERK1/2 and pERK1/2 protein levels remains unaltered before and after the 
LOV treatment for 10 days.  Data were analysed by using Two-way ANOVA.  Number of dots of 
each bar represents the number of animals used.  WT-C: n = 3; WT-L: n = 5; Fmr1−/y-C: n = 4; 
Fmr1−/y-L: n = 4. 
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4.4 Discussion 
My findings suggest that LOV treatment for 10 days did not alter the 
dendritic spine density in CA1 and layer II/III of the visual cortex from both of the 
Fmr1−/y mice and WT controls.  Instead, an elevation of spine density was noticed in 
layer II/III apical dendrites of the visual cortex of the Fmr1−/y mice under the basal 
condition, which agreed with previous findings in the same region (Dölen et al., 
2007).  In contrast, a profound effect of lovastatin on spine morphology is noticed.  
Specifically, the spine head diameter was significantly enlarged in CA1 apical 
dendrites and both apical and basal dendrites in V1 of the WT animals treated with 
lovastatin.  The Fmr1−/y mice exhibited an increase of spine head diameter in CA1 
apical dendrites compared to WT animals under the basal condition (i.e., CON 
treatment), and LOV treatment failed to restore the enlarged spines of the Fmr1−/y 
mice to the WT level.  Intriguingly, LOV treatment increases the spine head diameter 
of the CA1 apical dendrites of the WT mice to a similar size found in the Fmr1−/y 
mice, without altering the size of spine in the Fmr1−/y mice. 
Dendritic spine length remains largely unaltered between the Fmr1−/y mice 
and WT animals.  An increase of spine length is noticed in the CA1 apical dendrite 
of the Fmr1−/y mice.  On the contrary, a decrease in spine length is noticed in both 
apical and basal dendrites in the V1 of the Fmr1−/y mice.  Unlike the profound effect 
of increasing spine head diameter of the WT mice, spine length remains largely 
unaltered with regard to LOV treatment in both the Fmr1−/y mice and WT controls.  
Finally, ERK1/2 and pERK1/2 expression are not altered between the Fmr1−/y mice 
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and WT controls under basal conditions, and LOV treatment does not alter either 
protein expression as examined with Western blotting. 
 
4.4.1 How does lovastatin regulate the Ras-ERK pathway? 
As one of the members of the statin family, lovastatin was originally used as 
an antihyperlipidemic drug back in 1980s, which successfully reduced LDL 
cholesterol in healthy volunteers without any severe side effects (Tobert et al., 1982a, 
1982b).  Similar to other members of the statin family, lovastatin reduces cholesterol 
synthesis by inhibiting its key enzyme HMG-CoA reductase, causing a reduction of 
mevalonate, which is a precursor for cholesterol (Endo et al., 1977; Maron et al., 
2000).  However, two isoprenoid intermediates are also reduced during this process; 
the geranylgeranyl pyrophosphate (GGPP) and the farnesyl pyrophosphate (FPP) 
(Edwards, 1999).  These two pyrophosphates not only participate in the cholesterol 
synthesis pathway but also are essential in the post-translational modification of 
proteins.  Certain G-proteins such as Ras will only be activated after associating to 
the cell membrane, and this requires addition of lipid moieties by either farnesylation 
or geranylgeranylation (Higgins and Casey, 1996; Whyte et al., 1997). 
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Figure 4-21.  A simplified diagram of the cholesterol synthesise pathway. 
HMG-CoA is the precursor of cholesterol synthesis.  HMG-CoA reductase catalyses the production of 
mevalonate from HMG-CoA and acts as a rate-limiting enzyme for cholesterol synthesis.  Statins 
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occupy the active site of HMG-CoA reductase, hence prevent HMG-CoA from binding to HMG-CoA 
reductase (Istvan and Deisenhofer, 2001).  Mevalonate is then metabolised to farnesyl-PP by a series 
of enzymes along with some intermediates, including the mevalonate-5-PP, isopentenyl-5-PP, and 
geranyl-PP. 
 
4.4.2 The possible therapeutic effects of lovastatin beyond 
lowering blood cholesterol. 
An approach of using statins as a treatment for certain types of cancer has 
emerged in the early ’90s.  Among that, Li et al. also started to use lovastatin as a 
treatment of NF1 (Li et al., 2005).  The underlying mechanism of NF1 is an 
exaggerated Ras activity and eventually leads to an impairment of LTP, causing 
hyperactivity, learning disability and cognitive impairment in human patients and 
animal models (Costa et al., 2002; Koth et al., 2000; Ozonoff, 1999).  More recently, 
another study was reported using lovastatin to successfully rescue some key 
phenotypes of the Fmr1−/y mice (Osterweil et al., 2013).  However, the dendritic 
spine abnormalities found in the Fmr1−/y mice were not addressed in that study.  Thus, 
in the current study I focused on the effect of lovastatin on rescuing dendritic spine 
abnormalities in Fmr1−/y mice. 
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Figure 4-22.  A simplified diagram showing how lovastatin reduces the activity of Ras-MAPK 
pathway. 
Lovastatin reduces Ras activation through reducing intracellular levels of farnesyl-pyrophosphate (F) 
and geranylgeranyl- pyrophosphate (GG), which are both required for Ras anchoring to the plasma 
membrane in order to initiate its downstream signalling.  The presence of lovastatin switches Ras 
from an active GTP-binding state to an inactive GDP-binding state through reducing the levels of F 
and GG, hence inhibits Ras-MAPK signalling.  The Ras-MAPK signalling initiates when active Ras 
activates RAF, RAF then activates MEK, which in turn phorsphorylates and activates ERK.  RSK is 
then activated by ERK, and in turn activates S6 which regulates mRNA translation and protein 
synthesis in an mTOR independent manner (Dhillon et al., 2007; Roux et al., 2007).  Abbreviations: 
GDP: guanosine diphosphate; GTP: guanosine-5’-triphosphate; MAPK: mitogen-activated protein 
kinase; MEK: MAPK kinase; mTOR: mammalian target of rapamycin; RAF: rapidly accelerated 
fibrosarcoma; RSK: p90 ribosomal S6 kinase; S6: ribosomal protein S6 
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Table 4-1.  A summary of dendritic spine abnormalities in different cortical layers and the 
hippocampus reported previously in Fmr1−/y mice. 
 Age Methods Strains Regions Notes 
Layer II/III 
1 P7 – P21 2P, in vivo C57BL/6 Barrel Cx 
D: normal 
L: normal 
High turnover at P10 – P12 
Immature ↑ 
2 P14 2P, acute slices C57 PFC 
D: normal 
L: longer 
3 P30 Golgi, fixed C57 Visual Cx D: higher 









6 P7, P14 Golgi, fixed C57 Barrel Cx D: normal 
Layer V 
7 P7 – P21 2P, fixed FVB Barrel Cx 
D: higher at P7; normal at 
P14 & P30 
L: longer at P7 & P14; 
normal at P30 
8 
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Motility: normal 




10 Adult Golgi, fixed FVB Visual Cx 
D: normal 
Immature ↑ 
11 Adult Golgi, fixed C57 Visual Cx 
D: higher 
Immature ↑ 
12 Adult Golgi, fixed C57 Visual Cx 
D: normal 
Filopodia ↑; mushroom ↓ 
13 P25; Adult Golgi, fixed C57 Barrel Cx 
D: higher in adults; normal 
at P25 





P0 + 7 
DIV or 21 
DIV 





















L: longer at P7 
Immature ↑ 
17 




C57  D: normal 
18 
E18 + 21 
DIV 
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19 P60 – P90 Golgi, fixed C57 CA1 
D: higher 
Immature ↑ 
Cx: cortex; D: spine density; DIV: days in vitro; EM: electron microscopy; FITC: fluorescein 
isothiocyanate; GFP: green fluorescent protein; L: spine length.  Adopted from (Portera-Cailliau, 
2012).  Ref. 1): (Cruz-Martín et al., 2010); 2): (Meredith et al., 2007); 3): (Dölen et al., 2007); 4): 
(Hayashi et al., 2007); 5): (Liu et al., 2011); 6): (Harlow et al., 2010); 7) & 8): (Nimchinsky et al., 
2001); 9): (Comery et al., 1997); 10): (Irwin et al., 2002); 11): (McKinney et al., 2005); 12): (Restivo 
et al., 2005); 13): (Galvez and Greenough, 2005); 14): (Braun and Segal, 2000; Segal et al., 2003); 
15): (Antar et al., 2006); 16): (Bilousova et al., 2009); 17): (Pfeiffer and Huber, 2007); 18): (de Vrij et 
al., 2008); 19): (Grossman et al., 2006) 
 
4.4.3 Dendritic spine abnormalities in Fmr1−/y mice. 
The current findings regarding the changes of spine density and morphology 
in the Fmr1−/y mice are controversial (Table 4-1).  Depending on different brain 
regions and various cortical layers composition, loss of FMRP can lead to very 
different outcomes.  The results may also vary depending on how the tissues were 
sampled (i.e., fixed or unfixed), methodologies used (e.g., Golgi staining, fluorescent 
labelling), and the developmental stages chosen. 
Consistent with some previous findings, the dendritic spine density in the 
apical dendrites of the visual cortex was significantly increased in the Fmr1−/y mice 
compared to the WT littermates (Comery et al., 1997; Dölen et al., 2007; McKinney 
et al., 2005).  LOV treatments failed to rescue this phenotype; however, through 
increasing the spine density in the WT by about 12% with changing only 1% in the 
Fmr1−/y mice, the increased spine density in the Fmr1−/y mice was diminished. 
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I noticed a significant increase of spine head diameter in the CA1 apical 
dendrites of the Fmr1−/y mice compared to WT controls under CON treatment, and 
this difference was diminished when both groups were treated with lovastatin.  
Meanwhile, LOV treatment showed a dramatic impact on increasing spine head 
diameter in the WT mice in various regions, including the CA1 apical, V1 apical, and 
V1 basal dendrites.  On the contrary, LOV treatment did not show significant 
changes of the mean spine head diameter in the Fmr1−/y mice in the same regions 
where significant changes were shown in the WT mice. 
 
4.4.4 The possible mechanism of how lovastatin regulates 
spine morphology in mice. 
The fact that LOV treatment seems to have a profound effect on spine 
morphology is surprising; however, this effect is limited to the WT animals only and 
no gross alterations have been found in the Fmr1−/y mice treated with lovastatin.  One 
possible explanation of how lovastatin regulates dendritic spine morphology is that 
statins are known to suppress the expression of CSPGs (Holmberg et al., 2008), 
which suppress spine formation in cortical neurons (Kurihara and Yamashita, 2012).  
This might explain the slight increase of spine density in the V1 apical dendrites of 
the WT mice after LOV treatment, but why spine density remained unaltered after 
LOV treatment in the Fmr1−/y mice is still unclear.  The relationship between CSPGs 
and FXS is poorly understood, and further evidence will be needed to elucidate the 
different response to LOV treatment in the Fmr1−/y mice and WT controls. 
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4.4.5 The relationship between spine morphology and 
synapse compartmentalisation. 
As spine morphology is closely related to synapse compartmentalisation 
(Svoboda et al., 1996; Wijetunge et al., 2014; Yuste, 2013), the morphological 
changes of spines after LOV treatment may imply an overall change in local signal 
propagation in the designated brain regions. 
 In a detailed review by Rafael Yuste in 2013, he described spine 
compartmentalisation as follows:  
“…spines can behave as separate electrical compartments, by demonstrating 
that the somatic amplitude of the potentials generated by activating a spine was 
inversely proportional to the length of its spine neck (Araya et al., 2006).  Thus, 
whereas spines with short necks generated larger somatic potentials, those with long 
necks generated smaller, or even undetectable, depolarisations” (Yuste, 2013). 
However, due to the limit of resolution of the confocal microscopy (roughly 
180 nm in the X-Y plane), I do not have a precise measurement of the dendritic spine 
neck width, which is the most crucial factor regarding compartmentalisation 
(Tønnesen et al., 2014).  In addition, spine neck length has also been proved to be 
essential to electrical compartmentalisation.  A reverse linear relationship of spine 
neck length and the amplitude of uncaging potentials at the soma has been reported, 
and it is independent of the size of the spine head (Araya et al., 2006).  Thus, the 
reduced spine length in the visual cortex of the Fmr1−/y mice may suggest an increase 
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in electrical compartmentalisation compared to the WT mice.  Given the fact that the 
size of spine head in the visual cortex was not significantly altered between the two 
genotypes, the increased spine length was likely to be attributed mainly to the neck 
length.  To elucidate our speculation on spine neck changes after LOV treatment, a 
higher power microscopy such as STED will be needed in the future. 
One possibility that LOV treatment had a more profound impact on the WT 
mice might be that the dosage of lovastatin given was not sufficient to cause any 
effects in the Fmr1−/y mice.  However, the dose of lovastatin we chose was consistent 
with previous literature and it has been shown that this dosage can rescue audio-
genic seizure after only 48 hr of oral administration (Osterweil et al., 2013).  To 
further verify the effectiveness of the LOV treatment, I performed several Western 
blot experiments to examine specifically the MAPK activity in the Fmr1−/y and WT 
mice.  Unlike previous in vitro findings, where lovastatin treatment reduces the 
MAPK activity in the WT mice by about 15% and causes a 20% reduction in the 
Fmr1−/y mice (Osterweil et al., 2013), my data suggested that LOV treatment did not 
show a profound reduction of MAPK activity in vivo.  Similar experimental design 
using the NF1+/− mice suggested that consecutive administration of lovastatin (10 
mg/kg, SC) for four days can reduce MAPK activity to the WT level.  And oral 
administration of lovastatin (0.15 mg lovastatin into 200 mg pellets) can rescue the 
cognitive deficits of the NF1+/− mice when assessed with the lateralized reaction-time 
task (Li et al., 2005).  However, despite the difference of lovastatin dosages used 
across studies, none of these experiments have examined the MAPK activity after 
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lovastatin administration “orally”, suggesting that the reduction of MAPK activity 
might not be easily observable when lovastatin was administered orally. 
Another possibility why the current LOV treatment did not alter the MAPK 
activity was that I used a 10-day consecutive treatment, instead of a short-term drug 
administration.  I chose to use a chronic lovastatin treatment as this mimicked the 
actual drug usage in humans.  It would be beneficial to re-examine the MAPK 
activity after an acute oral administration of lovastatin for 48 hr, as this can provide 





Chapter 5: The Intrinsic Inhibitory Network 
Difference in Two C57BL/6 Substrains of Mice 
5.1 Introduction 
Animal models are valuable for scientific research.  Various animals ranging 
from Drosophila to chimpanzees contribute to the understanding of human diseases 
and facilitate our knowledge of the underlying mechanisms of the diseases.  Mice are 
one of the most widely used animal models for studying human diseases for several 
reasons: highly reproductive, short life span, genetic manipulations are well-
established, and as mammals they share many common anatomical and physiological 
traits with humans.  More importantly, some of the symptoms we observed in human 
patients are reproducible in mouse models of the same disease, both behaviourally 
and physiologically. 
The first inbred mouse strain was developed by a Harvard biologist Clarence 
Cook Little in 1909.  This strain was known as DBA, which stands for the coat 
colour alleles dilute (D), brown (B), and non-agouti (A).  Since then many mouse 
strains have been developed to suit specific research interests, such that there are 
currently more than 450 mouse strains available worldwide (Beck et al., 2000).  Most 
of the mice used in scientific research are inbred (at least over 20 generations) to 
ensure they are genetically identical, thus each mouse from the same strain can be 
treated as an identical “replicate”.  Despite the fact that the diversity of mouse strains 




between strains should be carefully considered before starting the experiment.  For 
example, the C3H mouse strain suffers from retinal degeneration around P28 and 
therefore is not suitable for any experiments that requires vision-related tasks (Dunn, 
1954; Sidman and Green, 1965).  Thus, it is critical that researchers are aware of the 
phenotypical characteristics of the mouse strain that is used for their experiments, to 
avoid drawing any incorrect conclusions from their findings. 
 
5.1.1 The origin of the two C57BL/6 substrains used in this 
Chapter 
The C57BL/6 strain is considered as one of the most widely used inbred 
mouse strains in scientific research (Crawley et al., 1997).  I focused on two popular 
substrains, the C57BL/6JOla and the C57BL/6J, to study their in vivo responses 
toward a specific visual stimulus.  The C57BL/6JOla substrain mentioned in this 
thesis was originated from the Jackson Labs in 1948, later imported into UK by 
OLAC in 1974 and then acquired by Harlan Labs in 1985.  Both OLAC and Harlan 
Labs kept this line inbred since it first separated from the Jackson Labs.  Forty years 
of inbred breeding have led to some genetic deletions in this substrain, notably the 
gene encoding α-synuclein (Scna) (Specht and Schoepfer, 2001) and the gene 
encoding multimerin 1 (Mmrn1) (Reheman et al., 2010; Specht and Schoepfer, 2004).  
On the other hand, the C57BL/6J substrain has been distributed by Charles River UK 
since 1981, and they continually replenished their stock mice with the Jackson Labs.  




encoding for the nicotinamide nucleotide transhydrogenase (Nnt) was found missing 
in mice originated from the Jackson Labs (Mekada et al., 2009).  A detailed timeline 
of how the C57BL/6 substrains were distributed and maintained is listed below (Fig. 
5-1). 
 
Figure 5-1.  The origin of the two C57BL/6 substrains I used in this thesis. 
This figure summarises the timeline and origin of the commonly used C57BL/6 substrains.  The 
C57BL/6JOla (C57BL/6JOlaHsd as shown in the figure) and C57BL/6J substrains are marked with 
red boxes as they were used to study the stimulus-selective visual potentiation in this Chapter.  Figure 






5.1.2 The loss of α-Synuclein in the C57BL/6JOla substrain 
The work published by Ranson et al. indicated that the C57BL/6JOla mice 
lacked the open-eye potentiation response after being monocularly deprived for 5 – 6 
days during the critical period, a phenomenon that can be seen in the C57BL/6J 
(Ranson et al., 2012).  A lack of homeostatic plasticity in the C57BL/6JOla was then 
been proposed, while the intrinsic signal response and retinotopic map remained 
unaltered (Ranson et al., 2012).  Thus, it is intriguing that the subtle background 
substrain difference can lead to such a distinct physiological response difference.  In 
the work of Specht and Schoepfer they indicated that both the mRNA and the protein 
product of α-synuclein were not found in the C57BL/6JOla mice throughout their 
lifespan.  Thus, a chromosomal deletion of the α-synuclein gene locus (Scna) was 
then suggested.  Interestingly, the amount of another form of synuclein (β-synuclein) 
which is also abundant in the brain did not seem to compensate the loss of α-
synuclein, as the authors did not find any alterations of its protein level through 
postnatal development (Specht and Schoepfer, 2001). 
α-Synuclein is a protein initially recognised as a precursor for the non-β 
amyloid component of Alzheimer’s disease (AD) amyloid plaques (Polymeropoulos 
et al., 1997; Uéda et al., 1993).  It is mostly found located in the presynaptic 
terminals and while its precise function is still unknown, it is thought to facilitate 
amyloid plaques formation and aggregation and therefore accelerate the progression 
of AD (Han et al., 1995; Iwai et al., 1995; Jensen et al., 1997).  α-Synuclein then was 




disease (PD).  A mutation within the α-synuclein gene was found in one large Italian 
kindred and three other independent Greek origin families with autosomal dominant 
inheritance for the PD phenotype (Polymeropoulos et al., 1997).  Despite the fact that 
α-synuclein is involved in neurodegenerative disorders such as AD and PD, complete 
removal of either the mRNA or the protein product of α-synuclein gene in mouse 
does not show gross anatomical or physiological alterations (Abeliovich et al., 2000), 
which might be due to the compensation effect from another brain-rich isoform, β-
synuclein, although the precise compensatory mechanism remains unclear. 
It is intriguing that α-synuclein knockout C57BL/6JOla mice did not show 
homeostatic plasticity.  Interestingly the loss of α-synuclein did not cause the loss of 
homeostatic plasticity as α-synuclein knock-out mice showed normal homeostatic 
plasticity after monocular deprivation (MD) (Ranson et al., 2012).  To further our 
understanding of the differences in C57BL/6 substrains, I examined whether the 
C57BL/6JOla substrain has defects in another form of experience-dependent 
potentiation, namely stimulus-selective response potentiation (SRP).  SRP is an 
experience-dependent visual plasticity that according to Frenkel et al. it is based on 
NMDA and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors trafficking (Frenkel et al., 2006).  This may not only uncover some 
unknown substrain characteristics of the C57BL/6JOla mice, but also help to shed 
some light on the underlying mechanism of the absence of homeostatic plasticity in 
this substrain. 
In this Chapter, I examined the physiological responses within the primary 




mice; C57BL/6J, C57BL/6JOla, and a mixture of these two substrains by crossing 
them for more than three generations (C57BL/6JaxOla).  I focused on the C57BL/6J 
and the C57BL/6JOla substrains as these are the two most prevalent substrains used 
in the USA and Europe, respectively, and these strains have been the most commonly 
used models for neurodevelopmental disorders, including FXS.  Furthermore, 
Syngap+/− mice will not breed on the C57BL/6J background but will breed 
effectively on the C57BL/6JOla background.  Therefore prior to examining SRP in 
our models of FXS (on the C57BL/6J background) and SYNGAP1 haploinsufficiency 
(on the C57BL/6JOla background), it was first necessary to characterise SRP on 
these two backgrounds to allow comparison between models of neurodevelopmental 
disorders. 
 
5.2 Materials and methods 
5.2.1 Animals 
Two different backgrounds of C57BL/6 mice were used, C57BL/6JOla mice 
were purchased from Harlan Labs (Bicester, UK) and C57BL/6J were purchased 
from Charles River (Charles River UK, Ltd.).  All mice were then backcrossed at 
least for 20 generations before use.  A mixed background of these two substrains 
were created by crossing them for three generations.  To be specific, F1 hybrid mice 
(i.e., the mixed background) were produced by crossing mice of these two different 
inbred strains (i.e., the C57BL/6J and the C57BL/6JOla).  F1 males and females were 




crossing F2 littermates.  All mice have ad libitum access to food and water at all 
times through the experiment.  Animals were kept in the animal unit located in the 
Hugh Robson Building (BRR-HRB, The University of Edinburgh) and kept under a 
12 hr/12 hr light/dark cycle. 
 
5.2.2 Stereotaxic surgery and electrode implantation 
Mice were anesthetized by inhalation of isoflurane (1.5 – 2% in pure O2).  
Depth of anaesthesia was carefully monitored throughout the whole surgery 
procedure via monitoring the respiration rate and hind-limb pinch withdrawal.  A 
heating plate connected to a thermometer was used at all times during surgery to 
maintain the animal’s body temperature.  A subcutaneous injection of Buprenorphine 
(Vetergesic®; 0.05 mg/kg) was given prior to surgery.  Surgical area was first cleaned 
with iodine and 70% ethanol, then the skull was exposed by removing the hair and 
skin above.  For future head restraint purposes, a steel headpost was affixed to the 
skull at a position anterior to bregma with cyanoacrylate glue.  Two small burr holes 
were drilled in the skull just anterior to bregma and overlaying the prefrontal cortex, 
and another two burr holes were drilled overlaying the binocular visual cortex (3.2 
mm lateral of lambda; 3 mm was used for animals at P28).  Two reference electrodes 
were implanted into the two burr holes anterior to bregma.  Each one of the reference 
electrodes was custom made by soldering a silver wire with a gold wire contact (FST 
#19003-00).  Two tungsten recording electrodes (FHC Tungsten Microelectrode, 
UEWSECSEBN1C, Ext. 2 mm/Epoxy 2 mm/7 mm Exp. w/ male pin, impedance 




binocular visual cortex at a depth of 470 µm (450 µm was used for animals at P28) 
below the cortical surface.  All four electrodes were secured using cyanoacrylate glue 
and then reinforced with dental cement.  Finally, the remaining skull was covered 
with dental cement to form a stable “head cap”.  Animals were put back in their 
home cages and kept warm with a thermal blanket to accelerate recovery and avoid 
death caused by loss of body heat.  Jellies containing 0.5 mg/kg of Buprenorphine 
were given to animals for post-operative pain relief.  Animals were monitored 
frequently for signs of discomfort or infection and allowed at least 24 hr recovery 
before proceeding habituation and further training.  Animals showing signs of 
infection or significant weight loss after surgery would be removed from further 
experiment and humanely culled. 
 
5.2.3 VEP recording 
5.2.3.1 Visual stimulus 
All visual stimuli were generated by a ViSaGe stimulus generator (ViSaGe 
MKII, Cambridge Research Systems, Kent, UK).  Stimuli used in this experiment 
were full-field sine-wave gratings of 100% contrast (for the grey screen contrast was 
set to 0%), square reversing at 1 Hz and with a spatial frequency set at 0.05 
cycles/degree.  The display CRT monitor was positioned 20 cm in front of the mouse 





5.2.3.2 SRP recording procedure 
Animals were allowed to habituate to the head restraint apparatus for 30 min 
on the day prior to further chronic VEP recordings.  To fit the animal into the 
restraint apparatus, its headpost was screwed tight with the apparatus and thus the 
head of the animal remained still but its body could move freely inside the holding 
cylinder (3.7 cm in diameter, close to the size of a toilet paper roll).  The animal and 
the apparatus were then put in front of a CRT monitor at a distance of 20 cm.  
Animals remained still but alert at all times during the recording procedure.  An 
isolated room was used for the VEP recording to minimize the background noise, 
and all room lights were turned off during recording. 
During the habituation process a grey screen was first presented to the animal 
for 100 phase reversals, followed by 300 phase reversals using 0° sine-wave gratings 
of 100% contrast.  Animals showing signs of distress (e.g., squeak, running) were 
first checked and if the distress signs continued animals were returned to their home 
cages temporarily and tested later.  The next day, animals received 300 phase 
reversals at a random orientation of 100% contrast.  Animals were then presented 
with the same stimuli for another four days.  At Day 5, animals were first presented 
with the same stimuli then a novel orientation (orthogonal to the familiar stimulus 
used for previous recordings) was introduced to each animal six hours after the first 
session (D5N).  According to the literature, SRP can induce robust and long-lasting 
VEP responses for the familiar stimulus after 5 days of training.  Introducing a novel 




which indicates that SRP is stimulus-specific and mice are capable of discriminating 
different visual stimuli (Cooke and Bear, 2012; Frenkel et al., 2006). 
 
Figure 5-2.  A representative diagram of experimental design and timeline for chronic VEP 
recording in mice. 
The top panel of this diagram indicates the experimental timeline for this experiment.  Young adult 
mice at the age around P40 – P60 were implanted with recording electrodes and then returned to their 
home cages.  Animals were then habituated to the head restraint apparatus and a series of VEP 
recordings were performed once daily for 5 consecutive days.  At Day 5, a novel orientation was 
introduced to each animal and the VEP responses were recorded accordingly. 
 
5.2.4 Data acquisition and analysis 
Electrical signals were amplified (1000×) and acquired via a USB board (NI 
USB-6251, National Instruments, TX, US).  Data were first acquired and analysed 




provided courtesy of the Maffei Lab (Pisa, Italy) and with the assistance of the Bear 
Lab (MIT, MA, US).  Individual traces were then re-analysed and plotted with 
MATLAB with a script provided by Dr. Aleksander Domanski. 
 The amplitude of VEP was quantified by measuring the trough – peak 
response amplitude, as described previously (Frenkel and Bear, 2004; Sawtell et al., 
2003).  In general, animals were presented around 300 – 500 phase reversals of each 
oriented stimulus per day.  The number of trials (1 trial contained 100 phase reversals 
of a given contrast and orientation) varied depending on animals’ response to the 
presentation.  If VEP responses varied over 15% between trials then additional trials 
were performed until at least 3 successful trials were acquired for each animal. 
 
5.2.5 Histology 
In order to mark the recording sites, animals were humanely culled via 
cervical dislocation followed by electrolytic lesions near the implantation sites.  
Electrolytic lesions were then conducted using a 9-V battery (MN1604, Duracell®, 
2.1A) for roughly 1 – 2 sec.  Brains were quickly removed and stored in ice-cold 4% 
PFA overnight.  Brains were sliced into 50 µm coronal sections and rinsed 
thoroughly with PBS.  Slices were then put on pre-coated slides and left in room 
temperature overnight.  Next day, slides were rinsed with ddH2O several times and 
then put into Nissl staining solution for 5 – 15 min followed by several rinses with 
70% ethanol.  Slides were then rinsed with 95% ethanol containing 0.1% glacial 




rinsed with xylene and then coverslipped with DPX (Sigma-Aldrich).  A Leica 
upright microscope (DM5500 Capture) with an image acquisition software (AF6000 
E) was then used for image acquisition. 
 
5.3 Results 
5.3.1 SRP was only inducible on the C57BL/6J substrain. 
After electrode implantation, three groups of mice with different background 
substrains were chronically recorded for five days using the SRP protocol.  As 
previously mentioned, the SRP protocol contained five consecutive recordings using 
the same visual stimulus over five days, and on Day 5 a novel stimulus was 
introduced around six hours after the previous recording session (D5N).  The 
summarised results are shown in Fig. 5-3, where only mice on the C57BL/6J 
background showed a significantly potentiated VEP response through chronic 
recordings over five days (Fig. 5-3A, D1 vs. D5, p = 0.0003, unpaired two-tailed 
Student’s t-test) and both the C57BL/6JOla group and the mix group were failed (Fig. 
5-3B, D1 vs. D5, p = 0.1554; and Fig. 5-3C, D1 vs. D5, p = 0.1314, unpaired two-
tailed Student’s t-test).  The potentiated response of the C57BL/6J mice was then 
diminished when animals were presented with a novel stimulus (D5N), which then 
drove the VEP response back to baseline (Fig. 5-3A, D5 vs. D5N, p = 0.0018; D1 vs 
D5N, p = 0.0647, unpaired two-tailed Student’s t-test).  This phenomenon is well 
established and recognised as the feature of SRP, which suggests the potentiated 




animals chronically.  I failed to induce SRP in the C57BL/6JOla substrain, and 
surprisingly, the mixed background also failed to show SRP after 3 generations of 
crossing (i.e., F3 animals). 
 
Figure 5-3.  SRP cannot be established in the C57BL/6JOla or the mixed background mice. 
Three different background substrains of mice were chronically recorded for 5 days using the SRP 
protocol.  The C57BL/6J mice (A) showed clear SRP as the VEP amplitude gradually increased from 
Day 1 to Day 5.  And then the VEP amplitude dropped back to baseline when a novel stimulus was 
presented on Day 5 six hours after the previous session (D5N).  In contrast, only one C57BL/6JOla 
mouse showed SRP while all the remaining C57BL/6JOla (B) and mixed background mice (C) failed 
to show SRP after five days of training.  VEP responses were first normalised to baseline (D1) and 






5.3.2 A distinct LFP power peak in the frequency ranges 
between 60 – 80 Hz was noticed in the C57BL/6JOla 
mice. 
The failure to induce SRP in the C57BL/6JOla substrain along with the lack 
of homeostatic plasticity reported previously by Ranson et al. made me wonder if the 
basal cortical response of this substrain was different from the C57BL/6J substrain 
(Ranson et al., 2012).  To characterise the cortical response to visual stimuli, I next 
examined the local field potential (LFP) and frequency power spectrum during the 
SRP protocols.  By converting the raw VEP data with a customised MATLAB script 
(using multi-taper Fast Fourier Transform), I was able to analyse the LFP power and 
frequency of these animals.  An example of transformed VEP data is presented in 
Figure 5-4, where the LFP power over frequency is shown combined with the 
original VEP amplitude distribution, to provide a better overview of the in vivo 





Figure 5-4.  Representative figures of VEP power density estimate and amplitude distribution. 
In (A), VEP responses were analysed as LFP and presented as its estimated power against its 
frequency.  Total VEP amplitude distribution from the same trial is presented in (B).  Black line and 
bars are VEP responses during the cue “on-set” phase, and cue “off-set” phase is indicated in red.  
“On-set” and “off-set” was used to indicate the phase reversal of the given visual stimuli. 
 
Surprisingly while the general profile was very similar between the two 
substrains, there was a significant increase of LFP power in the gamma frequency of 
the C57BL/6JOla mice compared to the C57BL/6J mice.  An example is shown in 
Figure 5-5, where an obvious elevation of LFP power in the gamma frequency was 





Figure 5-5.  An example of the mean gamma power distribution between two substrains of the 
C57BL/6 mice. 
The C57BL/6JOla mice showed a clear increased in LFP power near the frequency of 70 Hz with a 
noticeable peak at 72 – 74 Hz, which was inside the gamma range.  On the contrary, the C57BL/6J 
mice did not show any peak in LFP power in the gamma range. The blue boxes indicate the frequency 
range between 60 – 80 Hz.  VEP responses during the cue “on-set” phase and cue “off-set” phase are 
indicated in black and red, respectively. 
 
With the data transformation tool my next goal was to compare the 
differences between the two C57BL/6 substrains.  I therefore listed all experimental 
animals’ data first to examine the individual difference then the group differences 
between the two substrains.  All mice on the C57BL/6JOla background are shown in 
Figure 5-6, and a distinct LFP power peak was noticed during recordings from D1 of 
the SRP recording across all animals in the frequency range between 60 – 80 Hz (Fig. 




the C57BL/6J background (Fig. 5-7).  A substrain phenotype was clearly noticed, 
thus we wanted to examine if the same phenomenon still existed if we crossed the 
substrains.  Strikingly, after three generations of crossing the C57BL/6J and the 
C57BL/6JOla mice, the C57BL/6JaxOla mice showed a “reduced” LFP power peak 





Figure 5-6.  The gamma power distribution recorded from six C57BL/6JOla animals. 
VEP amplitudes and LFP power recorded from six C57BL/6JOla mice of their first day of SRP are 
presented here (A – F).  Mean gamma power recorded during cue on-set and off-set is shown in black 




presented in the bottom left corner of each individual animal.  The blue boxes indicate the frequency 









Figure 5-7.  The gamma power distribution recorded from eight C57BL/6J animals. 
Mean gamma power of SRP D1 recording session from eight C57BL/6J mice are presented here (A – 
H).  Mean gamma power recorded during cue on-set and off-set is shown in black and red, 
respectively.  The overall VEP amplitudes for each animal during that session is also presented in the 
bottom left corner of each individual animal.  A lack of the LFP power peak in the high gamma 








Figure 5-8.  The gamma power distribution recorded from four C57BL/6JaxOla animals. 
Similar to the findings reported previously in the C57BL/6J mice, four mice with the mix 
backgrounds are shown here and no obvious LFP power in the gamma frequency is noticed (A – D).  
Mean gamma power recorded during cue on-set and off-set is shown in black and red, respectively.  
The overall VEP amplitudes for each animal during that session is also presented in the bottom left 





5.3.3 Five days of SRP reduced the LFP power peak within 
the high gamma frequency range especially in the 
C57BL/6JOla mice. 
I then examined the LFP power peak after 5 days of SRP experiment.  
Intriguingly, the power peak of the C57BL/6JOla mice was dramatically reduced 
compared to SRP D1 (Fig. 5-9 and 5-13).  For the C57BL/6J and the C57BL/6JaxOla 
mice, due to their initial LFP power peaks being small they did not show any 
significant changes after 5 days of SRP (Fig. 5-10, 5-11, and 5-13).  LFP power 
spectrum and VEP amplitudes of each individual animal are presented in Fig. 5-9 – 






Figure 5-9.  The gamma power distribution recorded from the same C57BL/6JOla animals after 




The LFP power peak in the gamma frequency was greatly reduced compared to the recordings done 
on D1.  For better comparison, (A – E) represents the same animals presented in Fig. 5-6A to 5-6E, 
respectively.  The animal presented in Fig. 5-6F is removed from the current figure as its headpost 
was detached during recordings.  Mean gamma power recorded during cue on-set and off-set is shown 
in black and red, respectively.  The overall VEP amplitudes for each animal during that session is also 








Figure 5-10.  The gamma power distribution recorded from the same C57BL/6J animals after 5 
days of SRP. 
As shown previously, LFP power spectrum and VEP amplitudes from the same batch of C57BL/6J 
mice presented in Fig. 5-7A to 5-7H are presented here with their recordings on D5 of the SRP 
protocol (A, B, G, and H).  Mean gamma power recorded during cue on-set and off-set is shown in 
black and red, respectively.  The overall VEP amplitudes for each animal during that session is also 
presented in the bottom left corner of each individual animal.  Two animals (C and F) suffered from 
headpost detachment thus were excluded from the current experiment; another two animals (D and E) 
were excluded due to showing stress signs (e.g., squeak, running) during recordings and therefore I 






Figure 5-11.  The gamma power distribution of four C57BL/6JaxOla animals after SRP. 
Same animals with the mix backgrounds presented in Fig. 5-8A to 5-8D are shown here (A – D).  Five 
days of SRP did not cause a profound effect on gamma power, most likely due to the lack of LFP 
power peak in the gamma frequency in the first place as presented in Fig. 5-8.  Mean gamma power 
recorded during cue on-set and off-set is shown in black and red, respectively.  The overall VEP 






To statistically quantify the LFP peak in the gamma range, I first analysed the 
overall LFP power distribution of the C57BL/6JOla mice.  The overall LFP power 
peak fell in the frequency range between 70 – 76 Hz for the six C57BL/6JOla mice 
(Fig. 5-12).  Thus, all mice were re-analysed and the LFP power peaks in the 
frequency range between 70 – 76 Hz were isolated and plotted in Fig. 5-13.  A 
significant reduction of the LFP power after 5 days of SRP was noted in the 
C57BL/6JOla (Fig. 5-13A, D1 vs. D5, p = 0.013; Fig. 5-13B, p = 0.0118, unpaired 
two-tailed Student’s t-test).  The novel stimulus introduced in the D5N session did 
not induce a significant LFP power change in the C57BL/6JOla mice compared with 
their response at D5 (Fig. 5-13A, D5 vs. D5N, p = 0.2442; Fig. 5-13B, p = 0.4165).  
No changes in LFP power after 5 days of SRP was seen in either the C57BL/6J mice 
(Fig. 5-13A, D1 vs. D5, p = 0.9915; Fig. 5-13B, p = 0.8403) or the C57BL/6JaxOla 





Figure 5-12.  LFP power frequency distribution of six C57BL/6JOla mice. 
Each individual trace represents one C57BL/6JOla mouse, and the overall mean of these six mice is 
presented in red.  The overall mean peak of the LFP power spectrum fell between 70 – 76 Hz and 






Figure 5-13.  The LFP power peak in the gamma range was reduced after 5 days of SRP in the 
C57BL/6JOla mice. 
The LFP power in the gamma range (70 – 76 Hz) from three different background substrains are 
presented here.  A significant reduction of the LFP power after 5 days of SRP was noted in the 
C57BL/6JOla mice during both cue on-set (A) and cue off-set (B) conditions.  However, the 
C57BL/6J and the C57BL/6JaxOla mice did not show any significant differences of the LFP power in 
the designated frequency range either before or after SRP.  Substrains are simplified as follows: Jax = 
C57BL/6J; Ola = C57BL/6JOla; JaxOla = C57BL/6JaxOla; D1 and D5 represented the day of SRP, 
where D5N represented a novel stimulus was introduced on D5 after SRP. 
 
5.3.4 The LFP power peak in the gamma range was 
significantly reduced when animals were recorded 
during the critical period. 
A critical period of visual plasticity is well defined in the mice, and it is 




1996).  The LFP power peak in the gamma range in adult C57BL/6JOla mice was 
reduced after 5 days of SRP training suggested it can be regulated through repeated 
exposure to a familiar stimulus chronically.  Beyond this, whether the increased LFP 
power would affect homeostatic plasticity within the visual cortex is unknown.  
Moreover, it is not clear if the increased gamma power in the C57BL/6JOla substrain 
exists during the critical period.  Thus, mice from the two different C57BL/6 
substrains were recorded at postnatal day 28 (P28) to examine the LFP power during 
the critical period.  I first listed all the individual animal’s LFP power spectrum and 
VEP amplitudes for a clear comparison between groups.  Juvenile mice on the 
C57BL/6JOla background and the C57BL/6J background are presented in Figure 5-
14 and 5-15, respectively.  A prominent reduction of LFP power peak in the gamma 
frequency was noticed in the C57BL/6JOla mice when comparing to adult animals 
on the same background (Fig. 5-14).  On the contrary, the LFP power spectrum in the 
juvenile C57BL/6J mice was almost identical to adult mice on the same background 
(Fig. 5-15).  A summarised figure highlighting the difference between adult and 
juvenile animals on both backgrounds is presented for better comparison (Fig. 5-16). 
I noticed that in some animals there was a clear power peak around the 50 Hz 
range which is often considered as a result of contamination, usually known as the 
power-line noise which come from the equipment used in the recording environment.  
These noises might dampen the LFP power spectrum in the gamma range, as 3 out of 
7 C57BL/6JOla mice that showed the 50 Hz noise also failed to show a clear gamma 
power peak (Fig. 5-14C, 5-14D, and 5-14F).  Meanwhile, the remaining 4 




peaks were smaller than in adult mice on the same background (Fig. 5-14A, 5-14B, 








Figure 5-14.  The gamma power peaks recorded from seven C57BL/6JOla animals during the 
critical period (P28) were decreased compared to adulthood. 
Seven juvenile C57BL/6JOla mice are presented here along with their LFP power spectrum and VEP 
amplitudes (A – G).  Mean gamma power recorded during cue on-set and off-set is shown in black 
and red, respectively.  The overall VEP amplitudes for each animal during that session is also 






Figure 5-15.  The gamma power distribution recorded from six C57BL/6J animals during the 




Six juvenile C57BL/6J mice are presented here along with their LFP power spectrum and VEP 
amplitudes (A – F).  Mean gamma power recorded during cue on-set and off-set is shown in black and 
red, respectively.  The overall VEP amplitudes for each animal during that session is also presented in 









Figure 5-16.  A representative figure shows the gamma power difference between adult and 
juvenile mice on both backgrounds.   
Adult and juvenile animals on either the C57BL/6JOla or the C57BL/6J backgrounds are compared in 
this figure.  One representative animal is chosen for each condition.  Adult and juvenile (P28) 
C57BL/6JOla mice are shown in (A) and (B), respectively.  Similarly, adult and juvenile (P28) mice 
on the C57BL/6J background are shown in (C) and (D), respectively.  Mean gamma power recorded 
during cue on-set and off-set is shown in black and red, respectively.  The overall VEP amplitudes for 
each animal during that session is also presented in the bottom left corner of each individual animal. 
 
A significant reduction of the LFP power in the frequency range of 70 – 76 




the same substrain (Fig. 5-17A, Ola vs. Ola 28, p = 0.0214; Power = 0.71, at least 7 
adult animals and 9 juvenile mice will be needed if aiming to reach 0.8 in Power; 
Fig. 5-17B, p = 0.0332, unpaired two-tailed Student’s t-test; Power = 0.63, at least 9 
adult animals and 11 juvenile mice will be needed if aiming to reach 0.8 in Power).  
Meanwhile, the significant difference of LFP power in the gamma range between the 
C57BL/6JOla and C57BL/6J substrains (Fig. 5-17A, Jax vs. Ola, p = 0.0005; Fig. 5-
17B, p = 0.001; Power = 0.99 in both experiments) was diminished when both were 
examined during the critical period (Fig. 5-17A, Jax 28 vs. Ola 28, p = 0.0855; Fig. 
5-17B, p = 0.0685).  Crossing the two substrains for more than three generations 
reduced the LFP power in the gamma range significantly (Fig. 5-17A, Ola vs. 
JaxOla, p = 0.0178; Power = 0.76, at least 7 Ola animals and 5 JaxOla animals will 
be needed if aiming to reach 0.8 in Power; Fig. 5-17B: p = 0.0249; Power = 0.68, at 
least 8 Ola mice and 6 JaxOla mice will be needed if aiming to reach 0.8 in Power; 
Fig. 5-17A, Jax vs. JaxOla, p = 0.1269; Fig. 5-17B, p = 0.1632). 
To summarise, I found a distinct intrinsic feature of the C57BL/6JOla 
substrain that was present in both during the critical period and adulthood that was 
regulated by visual experience (Fig. 5-16).  The increased LFP power peak within the 
gamma range was only present in the C57BL/6JOla substrain but not the C57BL/6J, 
and crossing the two substrains for three generations significantly reduced this 





Figure 5-17.  The mean gamma power change between the C57BL/6J and C57BL/6JOla mice 
during VEP recordings. 
The mean gamma power in the frequency ranges between 70 – 76 Hz of each group is presented in 
this figure.  Mean gamma power recorded at different developmental stages during the cue-onset and 
cue-offset phase is presented in (A) and (B), respectively.  Mena gamma power recorded at different 
time points along the SRP protocol during the cue-onset and cue-offset phase is presented in (C) and 
(D), respectively.  Animals from either the C57BL/6J (Jax) or the C57BL/6JOla (Ola) substrains were 
used and VEP recorded at P28 are presented as Jax P28 and Ola P28, respectively.  An additional 
group of animals generated by crossing the C57BL/6J and C57BL/6JOla was also presented as the 
“JaxOla” group.  SRP data are presented in the sequence of Day 1 (D1), Day 5 (D5), and Day 5 with a 




groups.  Number of animals used is marked upon each group as dots.  Jax P28: n = 6; Ola P28: n = 7; 
Jax: n = 8; Ola: n = 6; JaxOla: n = 6; Jax D1: n = 8; Jax D5: n = 4; Jax D5N: n = 3; Ola D1: n = 6; Ola 
D5: n = 5; Ola D5N: n = 3; JaxOla D1: n = 4; JaxOla D5: n = 3; JaxOla D5N: n = 3. 
 
5.4 Discussion 
In this Chapter, I found a distinct LFP feature in the C57BL/6JOla mice 
substrain, which was a peak of LFP power isolated in the gamma frequency range 
between 60 – 80 Hz (more precisely, 70 – 76 Hz).  This increased gamma power may 
be related to the apparent absence of SRP in this particular substrain, as SRP was 
normal in the commonly used C57BL/6J substrain.  Crossing the two substrains 
together for three generations appeared to “rescue” this LFP power peak by reducing 
roughly 25% of the gamma power.  Interestingly, this relative increase of gamma 
power in the C57BL/6JOla mice was less pronounced at P28, indicating an age-
dependency to this substrain difference.  Finally, the increased gamma power in the 
C57BL/6JOla mice reduced significantly when mice received a same visual stimulus 
daily chronically for 5 days, a protocol based on the experience-dependent learning 
(SRP).  These findings suggest that an innate feature of increased cortical inhibition 
is found in the C57BL/6JOla mice, and this increased inhibition might underlie the 







5.4.1 The origin of LFP power in the gamma frequency. 
The increased LFP power peak in the gamma range might serve as one of the 
possible mechanisms of the failure of SRP induction in the C57BL/6JOla mice.  In 
1924, when Hens Berger first successfully recorded the brain wave activities from 
humans using EEG (Haas, 2003), scientists began to use such an approach to 
understand the relationship between these brain waves and our consciousness.  One 
well known example is the different brain wave composition between awake and 
sleep, which in awake state tends to be more low-amplitude, high-frequency rhythms; 
on the contrary, large-amplitude but slow oscillations become the dominant wave 
form during sleep (Steriade and Deschenes, 1984; Steriade et al., 1993).  Neuronal 
oscillations caught neuroscientists’ attention as these oscillations with distinct 
features might serve as a fundamental mechanism of brain synchronisation (Buzsáki 
and Draguhn, 2004; Engel et al., 2001; Kahana et al., 2001; Llinás and Ribary, 1993; 
Varela et al., 2001; Whittington et al., 1995).  Among them, gamma oscillations are 
defined between the frequency ranges of 30 – 80 Hz, typically at 40 Hz (Fries, 2009; 
Fries et al., 2007; Hermes et al., 2015; Jia and Kohn, 2011).  Although the detailed 
mechanisms of how and where these oscillations originate remain elusive, current 
understanding suggest they are mainly originated from the fast-spiking, parvalbumin-
positive (PV+) GABAergic interneurons (Buzsáki and Wang, 2012; Freund, 2003; 
Fries, 2009; Sohal et al., 2009). 
In the mammalian brain, about 80% of the neurons are excitatory 
(glutamatergic principal neurons), and GABAergic inhibitory interneurons constitute 




GABAergic interneurons constitutes about 11% of all neurons in the CA1 region of 
the hippocampus.  Among them, only 24% are PV+.  In other words, PV+ 
interneurons only constitutes about 3% of all neurons in the brain (Bezaire and 
Soltesz, 2013).  However, despite the relatively low concentration, GABAergic 
interneurons are essential in regulating the overall “balance” of the brain network.  
Losing the inhibitory control provided by these interneurons will render the whole 
system into a “hyperactive” state, and this imbalance of excitatory-inhibitory control 
will eventually lead to neurological diseases such as seizure (Kumar and Buckmaster, 
2006). 
LFP, by definition, is an electrical signal that sums the electric currents from 
all nearby neurons within a small volume of nervous tissue.  It is mechanistically 
identical to the EEG and the electrocorticogram (ECoG), where EEG is recorded 
from the scalp and ECoG is recorded from the cortical surface, the LFP however, is 
recorded deep in the brain through a small metal/glass electrode (for review, see 
Buzsáki et al., 2012).  Thus, LFP will capture all the excitable membrane (e.g., spine, 
dendrite, axon) or transmembrane currents that contribute to the extracellular field, 
disregarding the source of the signals (Buzsáki et al., 2012).  The LFP signals (i.e., 
the VEPs) I recorded were gathered from the electrodes implanted in layer IV of the 
binocular region of the primary visual cortex, and according to Porciatti et al. and 
Frenkel et al.’s reports, recording at this depth can yield the maximum VEP 
responses (Frenkel et al., 2006; Porciatti et al., 1999). 
In a detailed review written by Buzsáki and Wang at 2012, the cellular 




2012).  The “cell assembly” theory offers a plausible explanation of how a group of 
neurons integrate their spiking synchronously.  The functional role of this 
hypothesised assembly is described as “to bring together sufficient numbers of peer 
neurons so that their collective spiking can discharge the postsynaptic neuron”, as 
described by Buzsáki and Wang (Buzsáki and Wang, 2012; Harris et al., 2003).  
Hence, a precise time window that allows these peer neurons to fire simultaneously 
is therefore essential.  For pyramidal neurons in the CA1 region, this time window is 
about 10 – 30 ms, which falls within a gamma cycle (Harris et al., 2003).  Gamma 
oscillations have been seen in many regions of the brain, including the neocortex 
(Cardin et al., 2009; Siegle et al., 2014; Sohal et al., 2009), amygdala (Popescu et al., 
2009), hippocampus (Mann et al., 2005; Whittington et al., 1995), striatum (Berke et 
al., 2004; Tort et al., 2008), and the visual cortex (Brunet et al., 2015; Hermes et al., 
2014; Nase et al., 2003). 
The first evidence of the involvement of fast-spiking interneurons in gamma 
oscillations was published in 1983.  In that study, a correlation between spikes 
generated from fast-spiking interneurons and LFP gamma oscillations was found in 
the hippocampus of free-behaving rats (Buzsáki et al., 1983).  Fast-spiking 
interneurons are considered as one of the most essential sources of gamma 
oscillations for several reasons.  To begin with, the nature of how interneurons 
interact with surrounding pyramidal cells sets up a good model for generating 
neuronal oscillations.  A typical basket cell can make contact to a large number of its 
neighbouring pyramidal cells (within ~100 µm), and those pyramidal cells in turn 




large population of local neurons is emerged (Isaacson and Scanziani, 2011).  
Furthermore, inhibition of fast-spiking PV+ interneurons suppresses gamma power in 
vivo (Sohal et al., 2009), and reversely, stimulating fast-spiking PV+ interneurons can 
elicit gamma oscillations in downstream pyramidal cells (Cardin et al., 2009; Sohal 
et al., 2009).  All these features of fast-spiking PV+ interneurons make them an ideal 
candidate as the origin of gamma oscillations in the brain.  To determine whether the 
increased gamma power in the C57BL/6JOla mice was due to a different profile of 
PV+ interneurons in these two substrains, I therefore plan to first characterise the 
expression of PV+ interneurons in animals on the C57BL/6J and the C57BL/6JOla 
background.  It would also be very interesting to determine the profile of PV+ 
interneurons in the C57BL/6JaxOla mice, as this could further elucidate the 
contribution of PV+ interneurons toward the increased gamma power in the 
C57BL/6JOla mice. 
 
5.4.2 A stimulus-specific gamma power in the C57BL/6J 
substrain was previously reported. 
Neurons in the mouse visual cortex have been reported to fire synchronously 
at the gamma frequency in response to visual stimulation (Nase et al., 2003).  In 
Nase et al.’s report, they found a stimulus-induced LFP power in the gamma 
frequency (~40 Hz) in the C57BL/6J substrain.  Nevertheless, I did not notice a 
distinct LFP power peak in the gamma range in this substrain.  One major difference 




animals were alert and no anaesthesia was used during my recordings; where all 
recordings were done under mild general anaesthesia (~1% isoflurane or halothane) 
in their report (Nase et al., 2003).  The use of isoflurane has been reported to reduce 
the optimal amplitudes of cortical neurons to a given visual stimulus, and it is even 
stronger than halothane under the same equipotent concentration (Villeneuve and 
Casanova, 2003). 
 
5.4.3 What are the physiological consequences of increasing 
gamma power in the primary visual cortex? 
As gamma oscillation is one of the dominant brain waves during arousal and 
alert state (Hasenstaub et al., 2005; Steriade et al., 1993), the increased gamma 
power in the visual cortex might imply an increase of attention and alertness.  
Several in vivo studies demonstrated that gamma oscillations in the visual cortex 
could increase up to tenfold in power when certain visual stimuli (but not noise) are 
presented (Henrie and Shapley, 2005; Hermes et al., 2015, 2014).  Furthermore, the 
fact that gamma oscillations may largely originate from the PV+ interneurons 
suggests that such an increase of gamma power might result in an elevated inhibitory 
network in the C57BL/6JOla mice.  One hypothesis of the function of gamma 
oscillations in the brain (especially in the visual cortex) is to enhance the signal-to-
noise ratio through suppressing the “noisy” inputs (Pritchett et al., 2015).  I wonder 
whether the increased gamma power observed in the C57BL/6JOla substrain was too 




then the reason behind the failure of eliciting SRP in the C57BL/6JOla mice would 
simply due to the animals cannot distinguish or recognise the visual stimulus 
presented every day during the SRP protocol. 
 
Figure 5-18.  An example of the VEP responses and LFP power spectrum recorded from one 
C57BL/6JOla mouse during background (grey screen) and visual stimulus. 
The C57BL/6JOla mouse showed a clear increased LFP power near the frequency around 70 Hz with 
a noticeable peak at 72 – 74 Hz, which was inside the gamma range (A).  On the contrary, the same 
mouse did not show a clear peak LFP power in the gamma range when a grey screen was presented 
(B).  Furthermore, the VEP amplitudes during the grey screen session was reduced compared to the 
stimulus session as indicated in the bar-chart at the bottom left corner of each figure.  These data 
indicate that the increased gamma power does not affect the ability to discriminate a visual stimulus 
from the background in the C57BL/6JOla mice.  The blue boxes indicate the frequency range between 
60 – 80 Hz.  VEP amplitudes and LFP power spectrum during the cue on-set and off-set phase is 





However, the gamma power was clearly different between the visual stimulus 
session and grey screen session as the figure shown above (Fig. 5-18), thus the 
C57BL/6JOla mice still can distinguish the visual stimulus from the background.  
This also suggest that the increased gamma power we noticed in these mice are 
stimulus-specific, as reported previously by other groups (Henrie and Shapley, 2005; 
Nase et al., 2003).  It is intriguing that when a given visual stimulus which can 
stimulate strong VEP responses is presented to the C57BL/6JOla mice, a distinct 
gamma power with the frequency within 60 – 80 Hz is seen; however, a grey screen 
which failed to elicit strong VEP responses also failed to stimulate the gamma power 
in this substrain.  A mutual compensatory mechanism between the cortical inhibitory 
and excitatory network might underlie this phenomenon. 
 
5.4.4 Stimulus-selective response potentiation. 
SRP is an experience-dependent visual plasticity that according to Frenkel et 
al. it is based on NMDA and AMPA receptors trafficking (Frenkel et al., 2006).  LTP 
plays an essential role in regulating synaptic plasticity (Bear and Malenka, 1994; 
Malenka, 1994; Malinow et al., 2000), and can be induced either in vivo or in vitro.  
Similar to the findings that long-term stimulation of dorsal lateral geniculate nucleus 
(dLGN) induces LTP in the primary visual cortex in rats in vivo (Heynen and Bear, 
2001), and the fact that LTP is responsible for adult open-eye potentiation after MD 
(Sawtell et al., 2003).  LTP has also been validated that it is required to establish SRP 
in mice (Frenkel et al., 2006).  Chemical blockade of the NMDA receptors by 




phosphonic acid (CPP) abolishes SRP induction in mice (Frenkel et al., 2006).  
Similar results are also noted when the NR1 subunit of the NMDA receptor is 
genetically removed in layers II – IV of the mice visual cortex (Sawtell et al., 2003, 
unpublished data). 
Moreover, the increase of AMPA receptors onto the “silent” synapses is 
known to be one of the consequences after LTP induction (see Malinow et al., 2000 
for a complete review), and this is believed to be mediated through an interaction 
between AMPA receptor and the carboxy-tail of its GluR1 subunit (Hayashi et al., 
2000).  Blockade of new AMPA receptors insertion during LTP induction through 
viral transfection of the GluR1 subunit’s C-terminal domain (GluR1-CT) has been 
shown to be effective either in vitro (Shi et al., 2001) or in vivo (Takahashi et al., 
2003).  Thus, SRP would likely be abolished if GluR1-CT vector is locally injected 
in the primary visual cortex, and this was proved by Frenkel et al. in his original SRP 
study (Frenkel et al., 2006).  Therefore, one possible explanation that SRP was 
diminished in the C57BL/6JOla mice might be due to defect of LTP, through the 
malfunctioning of either NMDA or AMPA receptors, or both.  However, none of 
these have been reported previously, making it difficult to interpret the deficit in SRP 







5.4.5 Loss of homeostatic plasticity in the C57BL/6JOla 
substrain. 
Ranson and his colleagues’ work in 2012 indicated that there was a deficit of 
homeostatic plasticity in the C57BL/6JOla mice (Ranson et al., 2012).  In this 
particular substrain, no open-eye potentiation was noticed after 5 – 6 days of MD 
during the critical period; synaptic scaling after dark exposure was also diminished 
during that period in this substrain.  Strikingly, the open-eye potentiation in adult 
C57BL/6JOla mice after 7 days of MD was identical to the C57BL/6J mice.  These 
data suggest that juvenile and adult open-eye potentiation after MD may be regulated 
via different mechanisms. 
Homeostatic plasticity is essential in regulating cellular and network activity, 
as it maintains the activity at a set point level (Feldman, 2009; Turrigiano and Nelson, 
2004).  Monocular deprivation in juvenile mice (specifically during the critical 
period) for 3 days induced a rapid reduction of visual responses of the deprived eye, 
longer deprivation (4 – 5 days) would then lead to a slower potentiation of responses 
of the opened eye accompanied with the recovery of responses of the deprived eye 
(Kaneko et al., 2008; Mrsic-Flogel et al., 2007; Sato and Stryker, 2008).  A similar 
phenomenon was noticed when the same experiment was conducted in adulthood.  A 
longer deprivation (7 days) period was necessary for adult mice to show any ocular 
dominance shift.  Although adult mice showed a weaker reduction of responses 
following MD compared to juvenile mice, a potentiated response of the non-deprived 
eye after MD was still seen in adult mice (Frenkel et al., 2006; Sato and Stryker, 




were based on a homeostatic mechanism (Kaneko et al., 2008; Mrsic-Flogel et al., 
2007).  Moreover, Kaneko et al. dissociated these into two distinct processes, where 
the potentiation of responses after MD (specifically during the critical period) was a 
homeostatic increase of responses mediated via the tumour necrosis factor-α (TNFα) 
signalling (Kaneko et al., 2008).  However, adult open-eye potentiation seems to be 
independent of TNFα signalling, as adult TNFα knockout mice showed normal open-
eye potentiation after MD (Ranson et al., 2012).  Meanwhile, Ca2+/calmodulin-
dependent protein kinase IIα (αCaMKII) was shown to be essential in LTP induction 
and maintenance (for review, see Lisman et al., 2012).  A clear deficit of LTP in the 
visual cortex was reported in adult αCaMKII mutant mice, and this phenomenon was 
age-dependent as an absence of adult-LTP was reported while synaptic potentiation 
can still be observed in the juvenile mutant animals (Kirkwood et al., 1997).  
Moreover, open-eye potentiation after 7 days of MD was completely abolished in 
adult αCaMKII mutant mice (Ranson et al., 2012), suggesting that adult open-eye 
potentiation was LTP-dependent while a homeostatic increase of responses was 
responsible for juvenile open-eye potentiation. 
 
5.4.6 The loss of α-synuclein in the C57BL/6JOla mice. 
Previous studies of the C57BL/6JOla mice did not reveal any significant 
differences compared to other substrains despite the fact that α-synuclein was absent 
in this substrain (Specht and Schoepfer, 2001).  Nevertheless, the absence of α-
synuclein did not account for the lack of homeostatic plasticity in the C57BL/6JOla 




animals after MD (Ranson et al., 2012).  Since SRP is mostly, if not all, based upon 
on LTP mechanism, the role of α-synuclein in LTP is therefore essential to elucidate.  
α-Synuclein is a protein that mainly expresses in neurons and is heavily involves in 
some neurodegenerative disorders such as PD and AD.  The precise physiological 
role of α-synuclein in these diseases remains elusive, however, it is generally 
believed that α-synuclein aggravates these diseases’ progression.  Loss of α-
synuclein in the C57BL/6JOla substrain did not cause major physiological 
abnormalities, and its spatial learning and memory performance tested with the water 
maze remained unaffected (Chen et al., 2002).  α-Synuclein is a protein that known 
to form dimers, oligomers, and fibrillar structures under certain conditions (Conway 
et al., 2000).  Among that, oligomeric forms was suggested to impair LTP and 
increase basal synaptic transmission in a NMDA receptor mediated fashion 
(Diogenes et al., 2012).  A further experiment to test whether SRP is inducible in the 
α-synuclein knock-out mice could give us a better understanding of whether the loss 
of α-synuclein dampens the SRP induction in the C57BL/6JOla mice. 
 
5.4.7 Age-dependent gamma power profile in the 
C57BL/6JOla mice. 
Intriguingly, the lack of homeostatic plasticity after short-term MD in the 
C57BL/6JOla mice during the critical period was diminished with aging.  As adult 
C57BL/6JOla mice showed normal open-eye potentiation after MD (Ranson et al., 




visual plasticity in this substrain.  We did not test if SRP was inducible in the 
juvenile C57BL/6JOla mice, but the increased LFP power peak within the gamma 
range was reduced in the juvenile mice compared to adults.  If the visual cortical 
responsiveness remained largely unaltered after puberty, a greater chance of inducing 
SRP in the juvenile C57BL/6JOla mice is therefore expected as the gamma power is 
greatly reduced at this period.  Hence, despite the current preliminary findings, future 
works focusing on eliciting SRP in the juvenile C57BL/6JOla mice would shed some 
light on the dynamic equilibrium in visual plasticity. 
My findings that the mix background mice showed a “reduced” gamma 
power comparing to the C57BL/6JOla substrain indicated that there could be a 
potential genetic “dose-response” relationship between gamma power and the 
C57BL/6JOla background.  A 66% increase of gamma power was noticed in the 
C57BL/6JOla background compared to the C57BL/6Jax mice, and after only 3 
crossings the mixed background mice showed a roughly 20% reduction in gamma 
power compared to the C57BL/6JOla mice (Fig. 5-17A and 5-17B).  It would be 
very interesting to re-examine the result if I backcross the F1 hybrid from the mixed 
background mice with the C57BL/6Jax mice, rather than using the F1 × F1 from the 
mixed background mice to acquire the F2 and F3.  In the former case, F1b (F1 
backcrossing) litters will have 75% genetic traits of the C57BL/6Jax mice; however, 
in the latter case I will continuously get litters that have 50% genetic traits of the 
C57BL/6Jax mice for my F2 and F3 crossing.  A F1b crossing could therefore 





One possibility that the gamma power was decreased in the juvenile 
C57BL/6JOla mice might be the fact that some of our animals did not show stable 
VEP recordings during that time, as most of the VEP amplitudes were below 100 µV.  
This could be a result from inaccurate electrodes implantation or electrodes 
dislocation during recording.  However, apart from two animals excluded from the 
experiment due to the detachment of headposts, my post hoc histological 
examination did not reveal any significant differences between animals and the sites 
of implantation were located around layer IV of the primary visual cortex (Fig. 5-19). 
 
Figure 5-19.  Post-mortem histological examination of the electrode implantation sites. 
Post-mortem electrolytic lesions were made right after the final recording session of each animal.  
Brain sections were stained with Nissl solution for better visualisation of different cortical layers as 
presented in (A).  To better distinguish different cortical layers in order to verify the site of electrode 
implantation, a 5X zoom-in image of (A) is presented in (B).  Cortical layers are indicated using 
Roman numerals.  The “hole” located around layer IV indicates the site of electrode implantation.  






Figure 5-20.  Precision of the implantation sites were verified using a mouse brain atlas. 
To verify the sites of electrode implantation, I used the Allen Mouse Brain Atlas to further confirm the 
implantation sites were located in layer IV of the primary visual cortex.  The primary visual cortex is 
marked with the red box, and individual cortical layers are indicated in Roman numerals.  Image 
credit: Allen Institute for Brain Science.  Primary publication: (Lein et al., 2007).  Website: © 2015 





In summary, we identified a novel mechanism that may explain the failure of 
SRP induction in the C57BL/6JOla mice via an exaggerated LFP power peak in the 
gamma range.  We found that through experience-based learning, the increased 
gamma power in the C57BL/6JOla mice was significantly reduced to the level 
present in the C57BL/6J substrain.  However, once a novel stimulus was presented 




that the failure of SRP induction was not caused by the deficit of visual 
discrimination.  This robust increase of gamma power was only noticed in the adult 









Chapter 6: Conclusions & Future Perspectives 
FXS is the leading inherited cause of human intellectual disability.  Moreover, 
among 30% of male FXS patients will meet the diagnosis criteria for autism in their 
later lives.  The cause of FXS is an expansion of the CGG trinucleotide repeat in the 
5’ UTR region of the FMR1 gene, causing hypermethylation of the gene and 
eventually lead to a reduction or absence of the protein product FMRP. 
 Previous findings suggested that no gross pathological abnormalities were 
found in the brains of individuals with FXS and the Fmr1−/y mice (Ellegood et al., 
2010; Reyniers et al., 1999; The Dutch-Belgian Fragile X Consortium, 1994).  
However, some minute differences between the FXS individuals and healthy controls 
were reported using MRI and DTI, including the CC (Villalon-Reina et al., 2013).  
Therefore, I looked into the white matter abnormalities of the CC by using EM.  
Among all parameters I have examined there were no significant differences between 
the Fmr1−/y mice and WT controls, consistent with previous literatures.  The only 
difference I found was an increased axon diameter of the Fmr1−/y mice, which agreed 
well with previous studies that no gross white matter abnormalities were identified in 
the Fmr1−/y mice.  Based on this finding I speculated that the conduction velocity and 
the latency of conduction might also be altered in the Fmr1−/y mice.  We then found 
that the conduction latency was significantly reduced and a trend of increased 





One of the best interpretations of Hebbian theory is that “cells that fire 
together, wire together”—from Carla J Shatz (Shatz, 1992).  The precise “timing” of 
cell firing has been recognised as a crucial factor of how neuronal network being 
propagated.  In other words, the temporal order of cell firing was essential for 
information processing in the neuronal network.  This idea first came out in the mid-
1990s and was soon recognised as a novel form of neuronal plasticity—STDP 
(Gerstner et al., 1996; Markram et al., 1997).  As STDP can be down to a millisecond 
precision, the shortened conduction latency we observed in the Fmr1−/y mice could 
impact information processing dramatically.  As a matter of fact, defects in STDP of 
the Fmr1−/y mice have already been reported in previous studies (Desai et al., 2006; 
Meredith et al., 2007).  Our data suggested that an increased axon diameter in the 
Fmr1−/y mice might offer a new insight in how STDP was disrupted by the loss of 
FMRP.  To better understand the effect of an increased axon diameter in axonal 
conduction velocity, I propose to perform some in vitro electrophysiological 
recordings focusing on the CC region in the near future.  Our goal will be to measure 
the latency between the stimulation and the elicited afferent fibre volley, and with the 
known distance between the stimulation site and recording site (marked with 
biocytin) we would be able to estimate the conduction velocity of the CC in the 
Fmr1−/y mice. 
The abnormalities of dendritic spines were reported in early post-mortem 
findings of individuals with FXS, including an increase of spine density in certain 
areas and excessive long/thin immature spines (Hinton et al., 1991; Irwin et al., 2001; 




some studies and various developmental stages and brain areas of sampling made the 
results hard to interpret.  Animal studies initially showed similar findings as 
previously found in individuals with FXS, an excessively long and immature 
dendritic spine morphology appeared in the Fmr1−/y mice compared to WT controls 
(Comery et al., 1997; Irwin et al., 2002; Nimchinsky et al., 2001).  Increased spine 
density across different neocortical layers in a various brain regions have also been 
reported in the Fmr1−/y mice (Dölen et al., 2007; Hayashi et al., 2007; Liu et al., 
2011).  However, recent studies using the state-of-the-art microscopy techniques 
often failed to replicate these findings in the Fmr1−/y mice (for review, see He and 
Portera-Cailliau, 2013).  At least two discrepancies were noticed between the earlier 
and more recent studies; previous studies often focused on adult stages and used the 
Golgi method as a way of staining, whereas more and more recent studies tend to 
focus on early developmental stages and used 2-photon microscopy or super-
resolution microscopy such as stimulated emission depletion microscopy (STED) 
(Cruz-Martín et al., 2010; Meredith et al., 2007; Wijetunge et al., 2014). 
Dendritic spines development is a dynamic process.  In mice, new spines are 
formed rapidly during early development, and then a dramatic “pruning” of spines 
happened around P16 to P25, causing a net loss of spines (Holtmaat et al., 2005).  
Survival spines also help stabilise the dendritic branches and eventually the majority 
of spines (66%) are stable when entering adulthood (P80 – P120).  We chose to start 
the lovastatin treatment right after weaning, and examined the spine morphology and 
density at a time when most of the spines were stable and overall network 




the vast majority of spines of the Fmr1−/y mice remained unaltered regarding their 
morphology.  In addition, we found that the spine density was elevated in layer II/III 
of the visual cortex of the Fmr1−/y mice, which was consistent with previous findings 
(Dölen et al., 2007).  Our results showed no gross abnormalities in spine morphology 
between the Fmr1−/y mice and WT controls, however, an increase of spine head 
diameter was noticed in the CA1 apical dendrites of the Fmr1−/y mice compared to 
WT controls.  This agreed well with our previous findings using STED microscopy 
at the same developmental stage, suggesting an increase of immature spine 
population in the Fmr1−/y mice (Wijetunge et al., 2014).  The lovastatin treatment 
failed to rescue the increased spine head diameter in the Fmr1−/y mice.  Surprisingly, 
all our data suggested that lovastatin treatment had a profound effect on spine 
morphology (specifically on spine head diameter), but only limited to the WT mice.  
As our data indicated that the LOV-WT group showed a significant increase of spine 
head diameter over the CON-WT in both CA1 and V1.  Details of how lovastatin 
treatment altered spine morphology in the WT mice remain unknown.  However, the 
fact that lovastatin treatment successfully rescued some key phenotypes in the 
Fmr1−/y mice (Osterweil et al., 2013) but not the spine morphology might indicate 
that different underlying mechanisms were involved in the loss of FMRP; and some 
of them could be rescued by lovastatin while others did not. 
Since ASDs/ID are developmental disorders that result from both genetic and 
environmental influences, I next studied the mechanism by which genetic 
predisposition affects experience-dependent brain development.  I compared two 




responses to visual stimuli in vivo.  My results suggest that the C57BL/6JOla 
substrain has a significant stronger overall inhibitory network activity in the visual 
cortex than the C57BL/6J substrain.  This is in good agreement with previous 
findings showing a lack of open-eye potentiation to MD in this substrain (Ranson et 
al., 2012), and highlights the need for appropriate choice of mouse strains when 
studying neurodevelopmental models.  They also give valuable insight into the 
genetic mechanisms that permit experience-dependent developmental plasticity. 
Gamma oscillations have been described in many brain regions including the 
visual cortex (Fries et al., 2001; Gray et al., 1989).  We speculated that the increase 
of LFP power in the gamma range was closely related to the alterations of PV+, fast-
spiking basket cells as these cells were essential in generating gamma oscillations 
(Cardin et al., 2009; Sohal et al., 2009).  Therefore, we are keen on examining the 
inhibitory network in the visual cortex by two strategies: first to understand the 
composition of the subpopulation of PV+ interneurons within this region through 
immunohistochemistry, follow by sophisticated single-cell patching to understand 
the electrophysiological profiles of the PV+ interneurons in the C57BL/6JOla mice. 
In summary, I discovered some fine structure abnormalities in the Fmr1−/y 
mice compared to WT controls.  However, my data also suggested that these 
differences were minute and no gross alterations were found in the loss of FMRP.  I 
believe that instead of an abrupt change, the axon and spine abnormalities were 
largely remained unaltered with only some deviations in the Fmr1−/y mice.  
Moreover, these differences would be tightly regulated by development.  Re-




Finally, my data also suggested that an innate feature of stronger inhibitory network 
was noticed in one of the commonly used C57BL/6 substrains, and therefore 
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100 mM Tris, pH 8.5 
200 mM NaCl 
0.2% SDS 
5 mM EDTA 
  




Solution A: 1 g thionin in 100 ml ddH2O 
Solution B: 6 ml glacial acetic acid (98 – 100%) with 994 ml 
ddH2O 
Solution C: 0.1 M sodium acetate solution (NaC2H3O2-3H2O) 
Nissl solution: mix 90 ml B with 10 ml C and 2.5 ml A 
Abbreviations: EDTA: ethylenediaminetetraacetic acid; ddH2O: double-distilled 







8.2 Thermocycling conditions for genotyping 
 Cycling Conditions 
Step Fmr1 
 Temperature Duration 
1 94°C 3 min 
2 94°C 30 sec 
3 63°C 30 sec 
4 72°C 1 min 
5  Go to step 2, 35 times 
6 72°C 2 min 
7 10°C 5 min 
8  












8.3 Materials for Western blotting 
Materials Ingredients/Source Concentration 
RIPA buffer 
50 mM Tris-HCl, pH 7.4 
150 mM NaCl 
1% Triton X-100 
0.5% sodium deoxylcholate 
0.1% SDS 
1 mM EDTA 
 
Laemmli buffer (2X) Bio-Rad #161-0737  
protease inhibitor (EDTA 
free) 
Roche #11836170001 
1 tablet in 10 
ml lysis buffer 
phosphatase inhibitor 
cocktail 
Calbiochem #524625 (II), #524628 
(IV) 
1:100 
PierceTM BCA protein 
assay kit 
Thermo #23225, #23227  
Mini-PROTEAN® 
TGXTM gels 
Bio-Rad #456-1046  
pERK1/2 1˚Ab 
Cell Signaling #9106S (from 
mouse) 
Cell Signaling #4370 (from rabbit) 
1:2000 
ERK1/2 1˚Ab 
Cell Signaling #4696 (from mouse) 




abcam #ab8226 (from mouse) 
abcam #ab8227 (from rabbit) 
1:2000 
IRDye® 800CW Goat 
anti-Rabbit 2˚Ab 
Li-COR #926-32211 1:5000 
Alexa Fluor 680® Goat 





Odyssey blocking buffer Li-COR #927-40000  
ReBlot Plus stripping 
solution (10X) 
Millipore #2504 dilute to 1X 
running buffer 
25 mM Tris 
190 mM glycine 
0.1% SDS 
adjust pH to 8.3 
 
transfer buffer 
25 mM Tris 
190 mM glycine 
0.1% SDS (for proteins larger than 
80 kDa) 
20% methanol 
adjust pH to 8.3 
 
nitrocellulose membrane Bio-Rad #162-0112  
PageRuler Plus 
prestained protein ladder, 
10 to 250 kDa 
Thermo #26619  
Abbreviations: 1˚Ab: primary antibody; 2˚Ab: secondary antibody; kDa: kilo Dalton; 
RIPA: radio-immunoprecipitation assay; SDS: sodium dodecyl sulfate;  
